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ABSTRACT 
Cardiovascular disorders are the leading cause of death in the United States. Members 
of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) 
class of lipid-lowering drugs are used worldwide for the prevention and treatment of 
cardiovascular disorders. Cardiovascular disorders are the primary cause of morbidity 
and mortality in patients with diabetes mellitus and obesity as well as renal and liver 
transplantation. The rising global burden of these chronic disorders has resulted in 
long-term use of statins to prevent and treat cardiovascular disorders in diverse patient 
populations. Several statins are commercially available; however, atorvastatin calcium 
(Lipitor
®, Pfizer Pharmaceuticals, NY) is the world’s top selling medication of all 
time; whereas, rosuvastatin calcium (Crestor
®
, AstraZeneca, DE) is the most 
efficacious member of statin family.   
Although, statins are well-tolerated, approximately 7% of patients on statin therapy 
experience myotoxicity, which is ranging from a mild condition called myalgia to a 
rare but potentially fatal rhabdomyolysis requiring hospitalization. A meta analysis 
study reported by the United States FDA indicated three times higher incidence of 
rhabdomyolysis in patients with diabetes mellitus. Previously published in vitro and 
clinical studies identified the role of lactone metabolites in myopathy. Our group 
found significantly elevated plasma concentrations of atorvastatin lactone metabolites 
in the stable kidney transplant recipients with diabetes mellitus. Our study indicated 
that reduced clearance of lactone could be attributed to decreased activity of 
cytochrome P450 (CYP) 3A4, which is the main drug metabolizing enzyme. Prior 
  
studies assessed the effect of genetic polymorphism in drug metabolizing enzymes and 
transporters on pharmacokinetics and toxicological properties of parent drug and 
lactone metabolite in healthy Finish and Korean populations. 
Currently, limited information is available on the effect of concurrent diseases and 
genetic polymorphisms of drug metabolizing enzymes and transporters on 
pharmacokinetics of acid and lactone forms of atorvastatin. Altered pharmacokinetics 
of atorvastatin acid or lactone in concomitant diseases possibly influences the clinical 
outcome, resulting in unfavorable benefit/risk ratio. In this study, we have assessed the 
impact of inherent demographic characteristics in conjunction with coexisting diseases 
and genetic polymorphisms using a population pharmacokinetic analysis utilizing a 
nonlinear mixed effect model to identify potential covariates that explain the 
variability in pharmacokinetic properties of acid and lactone forms of atorvastatin. 
A physiologically-based pharmacokinetic modeling approach was used for the 
prediction of pharmacokinetics of orally administered atorvastatin acid and 
rosuvastatin acid along with their major metabolites from in vitro data allowing 
mechanistic characterization of the observed concentration-time profile. A mechanistic 
modeling is needed to provide insights into the interplay of various phenomena 
involved in oral absorption and metabolism of drugs. Additionally, simulations 
through virtual patients using physiologically-based pharmacokinetic modeling will 
allow to design a population pharmacokinetic study and to determine significant 
covariates. 
  
Manuscript I of this dissertation provides detailed information of pharmacokinetic 
and pharmacological properties of atorvastatin and rosuvastatin acid. Moreover, it 
describes the effect of various factors such as age, gender, race, food, liver and kidney 
diseases, time of drug administration, and genetic polymorphism of drug 
metabolizing enzymes and transporters on the pharmacokinetic properties of both 
statins. Atorvastatin acid is significantly metabolized by CYP3A4, and it is more 
likely to cause clinically important drug-drug interaction. Previously reported drug-
drug interactions of atorvastatin are discussed in this manuscript. This manuscript will 
be submitted for publication to “Clinical Pharmacokinetics” as a review article.  
Due to lack of simple and sensitive methods for simultaneous quantification of 
atorvastatin and its five metabolites in human plasma, a liquid chromatography 
tandem-mass spectrometry (LC-MS/MS) bioanalytical method was developed. 
Manuscript II explains in detail about the development and validation of a sensitive, 
selective and simple LC-MS/MS assay for simultaneous quantitative determination of 
parent drug and its five metabolites (published in Anal Bioanal Chem. 2011 
Apr;400(2):423-33).  
Esterase activity is a key reason of instability of ester-containing drugs in biological 
matrices. The effect of several anticoagulants on lactone to acid interconversion was 
investigated by comparing different types of plasma (sodium heparin, K2EDTA and 
sodium fluoride/potassium oxalate) and serum. No, statistically significant difference 
was found between serum and plasma with various anticoagulants; however, sodium 
fluoride (esterase inhibitor) plasma was preferred to ensure stability of lactone upon 
  
long-term storage of clinical study samples. Comprehensive stability studies were 
conducted prior to the method validation to establish stability conditions for unstable 
lactone analytes during the extraction steps as well as storage duration of clinical 
samples. The method was validated according to recent FDA guidelines. The post-
column infusion test was performed to assess matrix effect. Ortho- and para-hydroxy 
analytes have similar precursor ion-product ion transitions. Additionally, the acid form 
could possibly undergo in-source fragmentation and, following the loss of water, the 
resulting product would interfere with their respective lactone forms. For these 
combined reasons, chromatographic conditions that would assure baseline 
chromatographic separation of the respective analytes were determined. This goal was 
achieved using a narrow-bore Zorbax-SB phenyl column. Because this column 
provided excellent peak focusing a high S/N was obtained that enabled us to use a 
simple protein precipitation extraction procedure without performing pre-
concentration steps for sample clean up. The extraction method contained a simple 
protein precipitation step requiring only 50 μL of plasma and achieved a lower limit of 
quantification of 50 pg/mL for all six analytes. 
To the best of our knowledge, no published bioanalytical method has described a fully 
validated LC-MS/MS assay for the quantification of rosuvastatin lactone metabolite in 
human plasma. A sensitive and simple LC-MS/MS assay was developed for the 
simultaneous quantification of parent drug and its two metabolites in human plasma. 
Manuscript III describes the development and validation of an LC-MS/MS method 
for the simultaneous quantification of rosuvastatin acid and its two metabolites; N-
  
desmethyl rosuvastatin and rosuvastatin lactone (published in Anal Bioanal Chem. 
2012 Jan; 402(3):1217-27).  
Like atorvastatin lactone, rosuvastatin lactone is also very unstable. Stability of all the 
three analytes was tested in various conditions such as non-buffered human plasma 
and buffered human plasma (human plasma diluted 1:1 with 0.1 M, pH 4.0 sodium 
acetate buffer). For the proposed assay, plasma was diluted 1:1 with 0.1 M, pH 4.0 
sodium acetate buffer due to prevent the loss of lactone form (25%) that occurred in 
non-buffered plasma after 1 month storage at -80 °C. Furthermore, to ensure stability 
of rosuvastatin lactone metabolite during extraction of samples, 0.1% v/v glacial acetic 
acid in methanol was used as precipitating agent to minimize the interconversion of 
lactone to acid and vice versa. With the use of narrow-bore Zorbax-SB Phenyl 
column, lower limit of quantification of 0.1 ng/mL for acid and lactone forms of 
rosuvastatin, and 0.5 ng/mL for N-desmethyl rosuvastatin acid were achieved using 50 
µL of buffered human plasma.  
The impact of concurrent chronic disorders and polymorphisms in genes coding for 
drug metabolizing enzymes and transporters involved in the parent drug and the major 
metabolite elimination were investigated through a population pharmacokinetic 
modeling approach using NONMEM software (Manuscript IV). The plasma 
concentrations of parent drug and metabolite of one hundred and thirty two, male 
(n=77) or female (n=55) non-transplant (diabetic, n=46; non-diabetic, n=53) or the 
stable kidney transplant (diabetic, n=22; non-diabetic, n=11) recipients receiving a 
single oral dose or multiple oral doses of Lipitor (atorvastatin calcium) were included 
  
in the study. The study samples were analyzed using an LC-MS/MS method described 
in Manuscript II. 
A complex parent-metabolite combined population pharmacokinetic model was 
developed by analyzing a total of 639 concentrations including both acid (n=322) and 
lactone (n=317) forms of atorvastatin through a nonlinear mixed-effects modeling 
approach to identify and interpret the genetic, demographic, physiological and 
pathological factors that significantly affect the pharmacokinetic properties of 
atorvastatin acid and its major metabolite. Concentration-time profiles of atorvastatin 
acid and lactone metabolite were adequately described respectively, using a two-
compartment model with first-order oral absorption and a one-compartment model 
with linear elimination, with some degree of interconversion between the two forms. 
Covariate model building was conducted to investigate and determine sources of 
variability (covariates) that elucidate differences in pharmacokinetic parameters 
between patients, through univariate analysis followed by stepwise forward addition 
and backward elimination. Covariate analysis identified the kidney transplantation 
status and lactate dehydrogenase (liver enzyme) as significant covariates affecting the 
apparent clearance of atorvastatin lactone metabolite. Renal transplant recipients had 
50% lower metabolite clearance than non-transplant patients. However, 
polymorphisms in genes coding for enzymes and transporters as well as biomarkers of 
diabetes such as HbA1c and serum glucose levels did not significantly affect the 
pharmacokinetics of either parent drug or metabolite. The final model was validated 
using a visual predictive check method and nonparametric bootstrap analysis, which 
guaranteed robustness of the present population pharmacokinetic model. The finding 
  
of the study indicated the need of careful monitoring while prescribing atorvastatin 
treatment to the kidney transplant population. This manuscript will be submitted for 
publication to “Clinical Pharmacology and Therapeutics” as a research article. 
Manuscript V (to be submitted to “Molecular Pharmaceutics”) presents a whole-body 
physiologically-based pharmacokinetic (PBPK) model for atorvastatin and 
rosuvastatin acid with their respective metabolites allowing a mechanistic 
characterization of observed plasma concentration-time profiles of parent drug and its 
metabolites. Plasma samples obtained from the stable kidney transplant recipients with 
diabetes mellitus were analyzed using LC-MS/MS methods described in Manuscripts 
II and III. 
The GastroPlus (Simulations Plus, Inc., USA) advanced compartmental absorption 
and transit (ACAT) model, generic PBPK module and population estimates for age-
related physiology feature were used to predict systemic exposure of both statins 
following an oral administration in stable kidney transplant recipients with diabetes 
mellitus. The required number of input parameters was obtained experimentally, in 
silico and from the literature. Atorvastatin acid undergoes extensive gut and hepatic 
metabolism mainly by CYP3A4. In vitro Km and Vmax values of metabolic clearance of 
atorvastatin acid previously determined in our laboratory using diabetic human liver 
microsomal fractions were implemented in the model. The model used a built-in utility 
for conversion of in vitro Km and Vmax values to in vivo values. To predict observed 
large volume of distribution of both statins, the Berezhkovskiy algorithm was utilized 
to determine tissue distribution of perfusion-limited tissues. The observed mean 
  
plasma concentration-time curves for both statins and their metabolites were 
adequately described by the proposed PBPK model. A parameter sensitivity analysis 
identified that systemic exposure of both statins is significantly affected by changes in 
intestinal transit time. Part of the validation process included virtual trial simulations, 
which allowed incorporation of inter-subject variability. The virtual trial simulation 
results showed that the observed mean plasma concentration-time curves of both 
statins lay between 90% confidence interval of simulated concentrations of ten virtual 
patients. The present whole-body PBPK model demonstrated that in vitro metabolic 
clearance data generated from a specific disease tissue were superior for adequate 
prediction of systemic exposure of an extensively metabolized drug that might have 
modified due to altered activity of drug metabolizing enzyme in a specific disease 
state 
In summary, the work presented in this dissertation evaluate the effect of preexisting 
disease states including diabetes mellitus and renal transplant as well as genetic 
polymorphisms in drug metabolizing enzymes and transporters that predominantly 
contribute to overall disposition of atorvastatin acid and its lactone metabolite. The 
study indicated that the clearance of lactone, a myotoxic metabolite of atorvastatin 
acid, is significantly decreased by 50% in the stable kidney transplant recipients. 
However, the unbalanced sample size in this study restricts to delineate the individual 
influence of renal transplant and diabetes mellitus on clearance of parent drug and its 
metabolite. In addition, for the first time the disposition of atorvastatin acid and 
rosuvastatin acid as well as their respective metabolites was characterized using a 
mechanistic modeling approach, to predict observed plasma concentration-time 
  
profiles in the kidney transplant recipients with diabetes mellitus. The PBPK model 
that integrated in vitro kinetic parameters for metabolic clearance of atorvastatin acid 
measured in human liver microsomal fractions of diabetic livers were superior for the 
prediction of observed plasma concentration-time curve of atorvastatin acid. 
Overall, this study demonstrated a significant reduction of clearance of atorvastatin 
lactone metabolite in patients with the kidney transplant and thus they might be at 
higher risk of developing myotoxicity. This finding indicated the need of careful 
monitoring of atorvastatin acid therapy in the kidney transplant recipients who are on 
multiple medications and also have lifetime co-morbidities. Moreover, mechanistic 
modeling suggested that the systemic exposure of both statins is very sensitive to 
change in intestinal transit time. It would be beneficial to study the activity of 
intestinal drug metabolizing enzymes and transporters in diabetes mellitus and its 
impact on pharmacokinetics of statins. 
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PREFACE 
This dissertation was prepared according to the University of Rhode Island 
‘Guidelines for the Format of Theses and Dissertations’ standards for Manuscript 
format. This dissertation consists of five manuscripts that have been combined to 
satisfy the requirements of the department of Biomedical and Pharmaceutical 
Sciences, College of Pharmacy, University of Rhode Island. 
MANUSCRIPT I: Clinical Pharmacokinetics of Atorvastatin and Rosuvastatin  
This manuscript has been prepared for publication and will be submitted to “Clinical 
Pharmacokinetics” as a review article. 
MANUSCRIPT II: Development and Validation of a Sensitive, Simple and Rapid 
Method for Simultaneous Quantitation of Atorvastatin and its Acid and Lactone 
Metabolites by Liquid Chromatography-Tandem Mass Spectrometry (LC-
MS/MS) 
This manuscript has been published in a peer-reviewed journal “Analytical and 
Bioanalytical Chemistry”, April 2011. 
MANUSCRIPT III: A Simple Assay for Simultaneous Determination of 
Rosuvastatin acid, Rosuvastatin-5s-lactone and N-desmethyl rosuvastatin in 
Human Plasma using Liquid Chromatography-Tandem Mass Spectrometry (LC-
MS/MS) 
This manuscript has been published in a peer-reviewed journal “Analytical and 
Bioanalytical Chemistry”, January 2012. 
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MANUSCRIPT IV: Development of a Combined Parent-Metabolite Population 
Pharmacokinetic Model for Atorvastatin Acid and its Lactone Metabolite: 
Implication of Renal Transplantation  
This manuscript has been prepared for publication and will be submitted to “Clinical 
Pharmacokinetics” as a research article. 
MANUSCRIPT V: Development of Physiologically-Based Pharmacokinetic 
Model for Atorvastatin Acid and Rosuvastatin Acid with their Metabolites: In 
vitro and in vivo studies 
This manuscript has been prepared for publication and will be submitted to 
“Molecular Pharmaceutics” as a research article. 
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Abstract 
 
Dyslipidemia is the main risk factor for the development of atherosclerosis and coronary 
artery diseases. Cardiovascular disorders are the first leading cause of death in the Unites 
States and a major cause of morbidity and mortality in patients with diabetes mellitus, 
obesity, renal or liver transplantation. 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitors (statins) class of lipid-lowering drugs are the first choice for 
prevention and treatment of cardiovascular diseases. The increasing global burden of 
heart diseases resulted in extensive use of statin therapy in a diverse patient population. 
Statin-associated skeletal muscle toxicity is the most common side effect with statin 
therapy that sometimes results in life threatening rhabdomyolysis.   
Among commercially available statins, worldwide, atorvastatin acid is the top-selling 
prescribed medication; however, rosuvastatin acid is considered the most efficacious 
statin. The present, review article summarizes the clinical pharmacokinetics properties of 
two widely prescribed antihyperlipidemic agents, atorvastatin and rosuvastatin acid. 
Atorvastatin acid is a biopharmaceutics classification system (BCS) and 
biopharmaceutical drug disposition classification system (BDDCS) class II drug and, 
therefore, it is highly soluble and permeable and exhibits complete absorption following 
an oral dosing. It is >98% bound to plasma proteins and display extensive peripheral 
tissue distribution. Significant metabolism, both in the gut and liver, primarily by 
cytochrome P450 (CYP) 3A4, plays a key role in the first-pass effect that explains its 
remarkably low oral bioavailability (14%). It is also biotransformed into glucuronide 
metabolites mediated by uridinediphosphoglucuronyl-transferase (UGT) enzymes and 
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undergoes lactonization. The parent drug and its metabolites are mainly excreted into 
bile. The drug is a substrate of several hepatic uptake transporters of organic anion-
transporting polypeptide family. Moreover, it is believed to be a substrate of efflux 
transporters including p-glycoprotein (MDR1) and breast cancer resistant protein 
(BCRP),  which may govern intestinal absorption and biliary excretion. Single nucleotide 
polymorphism of drug metabolizing enzymes and transporters modulates 
pharmacokinetics and toxicological properties of the parent drug and metabolites. It is 
more likely to cause CYP 3A4 mediated clinically relevant drug-drug interaction.  
Rosuvastatin acid, a BCS and BDDCS class III drug is highly soluble and less permeable 
and, therefore, demonstrate selective hepatic uptake. It is one of the most effective statins 
due to its unique characteristics such as superior binding affinity, and tight binding 
interactions at the enzyme active site. It is highly bound to plasma proteins mainly to 
albumin. It undergoes minimal metabolism and hence eliminated unchanged in the feces. 
Moreover, multiple hepatic organic anion-transporting polypeptide (OATP) uptake and 
BCRP efflux transporters significantly contribute to hepatobiliary disposition of 
rosuvastatin. Genetic polymorphisms in these transport proteins may significantly alter 
systemic exposure of rosuvastatin acid. Because of insignificant metabolism, it is less 
likely to cause clinically important metabolic drug-drug interactions.   
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Introduction 
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose 
levels. The epidemic of diabetes has increased because of obesity and lifestyle changes. 
In 2010, diabetes mellitus was ranked as the seventh leading cause of death in the United 
States [1]. Moreover, worldwide the number of people with diabetes is projected to 
increase to 366 million by 2030 in all-age groups [2].  
Diabetes mellitus is the primary risk factor for coronary artery disease and stroke [3], 
which are ranked as the leading causes of death in the United States [4, 5].  An update to 
the guidelines of Adult Treatment Panel III, issued by the National Cholesterol Education 
Program, indicates that a larger number of diabetic patients than non-diabetic individuals 
were administered 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase 
inhibitors (statins) for the treatment of hypercholesterolemia [6].  Several statins 
including simvastatin, atorvastatin acid (ATV), rosuvastatin acid (RST) and pravastatin 
acid are the commonly prescribed lipid-lowering agents.  Atorvastatin calcium (Lipitor
®
, 
Pfizer Pharmaceuticals, NY, USA) is the world’s best selling medication of all time [1].  
A clinical trial conducted in patients with type 2 diabetes mellitus concluded that ATV is 
effective in the primary prevention of serious cardiovascular events including stroke, 
irrespective of low density lipoprotein-cholesterol (LDL-C) level before treatment [7] ; 
therefore, ATV is widely prescribed in the diabetic population [6]. 
Atorvastatin is extensively metabolized by cytochrome P450 (CYP) 3A4/5 and 
biotransformed into pharmacologically active ortho- and para- hydroxylated metabolites 
[8] that remain in equilibrium with their respective pharmacologically inactive lactone 
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forms [9], which have 83-fold higher affinity for CYP3A4 [8, 10]. Although, statins are 
well-tolerated, approximately 7% of patients on statins therapy experience mild or severe 
skeletal muscle complaints. The incidence of statin-associated adverse effects is 
dependent on the dose or plasma concentration of statins.  Moreover, the risk is higher in 
old age, metabolic disorders, renal and hepatic disorders as well as patients receiving 
inhibitors of CYP enzymes and/or transporters [11]. Because of elevated incidence of 
statin-associated rhabdomyolysis, cerivastatin was deliberately withdrawn from the 
United States  market in 2001 [12].  A meta-analysis study conducted by the United 
States FDA, using data from 252,460 patients treated with lipid-lowering agents found in 
average 0.44 incidences of rhabdomyolysis per 10,000 person-years with statin 
monotherapy and the incidence is increased when statins are co-administered with 
fibrates.  Moreover, diabetic patients on statin monotherapy exhibited approximately 2.9 
times higher relative risk of rhabdomyolysis requiring hospitalization [13].   
Hermann et al. [14] showed significantly higher levels of concentration of atorvastatin 
lactone metabolite in patients experiencing statin-associated myopathy.  Moreover, an in 
vitro study, using primary human skeletal muscle cells, showed that atorvastatin lactone 
(ATV-LAC) had a 14-fold higher potency to induce myotoxicity as compared to the acid 
form [15]. The lactone/acid concentration ratio could potentially be used as a specific 
diagnostic tool for statin-induced muscle toxicity [16].  Recently, in vitro study published 
by our group has shown a significant reduction in the expression and activity of CYP3A4 
in human livers from donors with diabetes mellitus [17].  Moreover, CYP3A4 is the main 
enzyme involved in metabolic clearance of ATV-LAC [17]. The oxidative 
biotransformation of ATV-LAC is considered to be the primary pathway for ATV 
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elimination [8]. A previously published clinical study showed significantly lowered 
clearance of ATV-LAC in stable kidney transplant recipients with diabetes mellitus and 
indicated clinical significance of this finding while prescribing ATV treatment in this 
population who have additional co-morbidities and are on multiple medications [17].  
Rosuvastatin acid, a synthetic HMG-CoA inhibitor is also widely prescribed medication 
due to its unique properties including selective liver uptake and increased potency. It 
exhibits minimal metabolism and thus is less likely to cause CYP3A4 mediated metabolic 
drug-drug interactions. However, it is a substrate of multiple hepatic OATP uptake 
transporters and may cause transporter mediated drug-drug interactions with oral 
antidiabetic drugs [18].  
Increased plasma levels of statins and their metabolites may elevate the risk of clinically 
significant side effects especially in a diabetic population receiving concomitant 
medications [17]. Therefore, it is essential to better characterize the pharmacokinetics 
(PK) of the most commonly prescribed statins and the factors that possibly affect PK 
properties as well as clinically significant drug-drug interactions.   
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Atorvastatin calcium (Lipitor
®
) 
1.1. Physicochemical properties of atorvastatin calcium 
Currently, ATV is used as calcium salt of an active acid. Atorvastatin calcium [(3R,5R)-
7-[3-(phenylcarbamoyl)-5-(4-fluorophenyl)-2-isoprotopyl-4-phenyl-1H-pyrrol-1-yl]-3,5-
dihydroxyheptanoic acid, calcium salt], C66H68CaF2N4O10 has a molecular weight of 
558.62 and pKa of 4.46. It is white to off-white crystalline powder; soluble in methanol, 
dimethyl sulfoxide and slightly soluble in water. It is insoluble in aqueous solution of pH 
4 and below and it is very slightly soluble in pH 7.4 phosphate buffer and water [19].   
1.2. Clinical uses 
Atorvastatin acid is a synthetic drug from the most efficient statin class of lipid lowering 
agents and is widely used to treat dyslipidemia and cardiovascular disorders. Atorvastatin 
acid blocks cholesterol biosynthesis by reversible, competitive inhibition of the rate-
limiting enzyme, HMG-CoA reductase. It is used as a monotherapy and/or fixed dose 
combination therapy along with exercise and diet to reduce the risk of heart attacks and 
stroke. It is contraindicated in pregnant and nursing females, and patients with liver 
diseases [20]. 
1.3. Mechanism of action 
Atorvastatin acid is a competitive inhibitor of HMG-CoA, the main enzyme, catalyzing 
the rate limiting step of endogenous cholesterol biosynthesis and thus reduces the 
cholesterol content of the hepatocytes. This results in an up-regulation of LDL-C-
receptors, which subsequently increases the uptake and catabolism of LDL-C and lowers 
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its plasma levels. The pleiotropic effects of ATV include anti-inflammatory actions, 
reduction of platelet aggregation, improvement of endothelial function and 
antiproliferative activity on smooth muscle [21].  
1.4.  Side effects 
Skeletal muscle related problems are the common side effects that develop with statin 
treatment.  Myotoxicity ranging from a mild condition called myalgia (muscle ache or 
weakness without creatine kinase elevation) to rare but potentially fatal rhabdomyolysis 
(severe muscle breakdown with marked creatine kinase elevation [>10 times above the 
upper limit of normal] resulting in hospitalization [11]. Liver injury is another serious 
side effect associated with the use of ATV. Patients are generally monitored especially 
when they experience skeletal muscle or liver related problems. In this situation, to 
minimize the risk of side effects, dose adjustment or discontinuation of therapy is 
initiated by clinicians. The other common side effects of ATV are diarrhea, nausea, runny 
or stuffy nose, mild sore throat, and stomach upset [20]. 
1.5. Pharmacokinetics properties 
A. Absorption 
Oral absorption of a drug reflects the movement of drug from the gastrointestinal tract 
into the blood stream. It is significantly affected by the physicochemical properties of the 
drug and formulation including dissolution rate, stability in the gastrointestinal tract and 
permeability. Moreover, physiological factors including gastric emptying time, peristaltic 
movement and gastric pH also affect the oral bioavailability of drug. Complete 
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absorption of ATV is expected due to its high solubility and permeability at intestinal pH 
(pH=6). 
Upon oral administration, ATV undergoes extensive first pass metabolism through the 
gut wall and liver and exhibits very low absolute bioavailability (14%). The extensive gut 
wall extraction of ATV is the result of intestinal CYP3A4, UDP-glucuronosyltransferase 
(UGT) enzymes and P-glycoprotein (P-gp) efflux transporter interplay [22]. 
Atorvastatin acid reaches maximum plasma concentration (Cmax) of 3.61 µg/L after 10 mg 
of an oral dose and time to Cmax (Tmax) is 1.5 hr. It exhibits the linear PK for both Cmax 
and area under plasma-concentration time curve (AUC) over the dose range of 5-40 mg. 
The net transport of drug across the membrane is governed mainly by intestinal P-gp 
efflux transporter, the active uptake transporter H
+ 
monocarboxylic carrier and to a lesser 
extent by passive diffusion. However, the role of organic anion-transporting polypeptide 
(OATP) uptake transporters for intestinal absorption is not known yet [22]. A secondary 
peak in an individual plasma concentration-time profile indicates enterohepatic 
recirculation of ATV [23].  
B. Distribution 
The volume of distribution of a drug reflects the extent of extravascular tissue binding. It 
is affected most importantly by binding affinity of the drug to plasma proteins, blood 
elements and by permeability into tissue and membrane. The plasma protein binding of 
ATV is >98%, and its volume of distribution is 381L, which is higher than the total 
volume of body water indicating extensive tissue binding [22].  
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C. Metabolism 
Atorvastatin acid undergoes complete metabolism and the liver is the major site for its 
elimination despite the significant first-pass effect through the gut wall. The detailed 
metabolic pathways for phase I and II are shown in Figure I-1 and I-2, respectively. It is 
extensively metabolized through Phase I enzymes primarily by CYP3A4/5 in the 
intestine and liver and it forms pharmacologically active ortho- and para- hydroxylated 
metabolites [8].  The parent drug and its active acid metabolites remain in equilibrium 
with their respective inactive lactone forms [9], which have 83-fold higher affinity for 
CYP3A4 and exhibit higher metabolic clearance [8, 10].  The results of in vitro study 
conducted using human liver microsomes indicated a predominant role of CYP3A4 in the 
biotransformation of ATV-LAC [24].   
The study published by Prueksaritanont et al. demonstrated the role of phase II enzymes 
in the clearance of ATV through glucuronidation as a novel route. The formation of 
ATV-LAC is also attributed to glucuronidation metabolic pathway, which is mediated 
mainly through UGT1A1 and 1A3 enzymes [25, 26].   
Lactones are hydrolyzed either chemically or enzymatically mainly by paraoxonase 
(PON1 and PON3) enzymes and esterases [27, 28]. Lactonization of an acid form is also 
mediated by Coenzyme A-dependent pathway through the formation of acyl-CoA 
thioester [29]. Moreover, glucuronidation and a low pH environment are also responsible 
for lactonization [26].  
Hepatic uptake transporters, OATP1B1 and OATP1B3 play a significant role in the 
active uptake of ATV and its metabolites.  Atorvastatin acid and its metabolites are also 
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substrates of efflux transporters including P-gp and BCRP, which govern their intestinal 
absorption and liver elimination [30].  
D. Elimination  
Biliary route is the major elimination pathway of the parent drug and its metabolites and 
approximately 1% of the administered dose is excreted through renal route.  This 
indicates that the liver is the primary site for ATV metabolism and elimination. The 
clearance of ATV is 625 mL/min in human [22]. 
1.6. Effect of age and gender 
The clinical PK of ATV is affected by age and gender; however, dose adjustment is not 
required. The Cmax and AUC of ATV were 42.5% and 27.3 % higher, respectively in an 
elderly population aged between 66-92 years compared to young individuals (age 19-35 
years). Similarly, Cmax and AUC of ATV were 17.6 % higher and 11.3% lower 
respectively, in women and male subjects. The terminal half-life is 36.2% longer, and 
Tmax is 5.5% shorter in elder participants than young subjects. The terminal half-life and 
Tmax were 19.9% and 39.1 % shorter, respectively in women as compared to men. The 
differences in the PK of ATV could be age-related effects on intestinal and liver 
enzymatic activity [31]. 
1.7. Effect of race 
No difference in the PK of ATV was observed between Asian and Caucasian population, 
therefore modifications of dosing recommendations are not required for either race [32]. 
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1.8. Effect of food 
In a clinical study assessing the influence of food on the rate and extent of ATV 
absorption found that Cmax and AUC of ATV decreased by 47.9 % and 12.7%, 
respectively when administered with food. The Tmax of ATV increased from 2.6 h to 5. 9 
h when administered with food. Moreover, the mean elimination half-life decreased from 
37.5 h to 32 h with food. Food with medium fat content significantly decreased the rate of 
absorption (Tmax) but had a minor effect on the extent of absorption [33].  Therefore, food 
does not appear to affect ATV therapeutic efficacy.  
1.9. Effect of renal and hepatic impairment 
Urinary route is a minor route of excretion and thus renal impairment had no effect on the 
PK of ATV. Moreover, haemodialysis did not have any effect on the PK of ATV.  
However, Cmax and AUC were 5 fold and ≥11 fold greater, respectively in patients with 
Child-Pugh Class A and B liver impairment, respectively. Therefore, dose adjustment is 
not required in renal impairment, but the dosing schedule should be carefully determined 
for patients with liver dysfunctions [34].  
1.10. Effect of time of administration 
The rate and extent of absorption of ATV were lowered when it was administered in the 
evening as compared to the morning administration to patients with 
hypercholesterolemia. No difference was noted for mean elimination half-life between 
times of administration. Moreover, time of administration also had no effect on the 
efficacy of ATV [23]. 
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1.11. Effect of genetic polymorphism 
Genetic polymorphism of various transporters and drug metabolizing enzymes involved 
in the disposition of ATV significantly affects its PK. The effect of single-nucleotide 
polymorphism (SNP) of OATP1B1 (SLCO1B1), P-gp (ABCB1), BCRP (breast cancer 
resistant protein, ABCG2) and UGT1A3 enzyme on the PK of ATV and ATV-LAC are 
summarized in Table I-1. Moreover, a genome-wide association study has provided 
compelling evidence for strong association of myopathy with SNP located within 
SLCO1B1 [35]. In addition, Riedmaier et al. have demonstrated that polymorphisms of 
PON1 and PON3 esterase enzymes are associated with changes in ATV-LAC hydrolysis 
and increased the expression of PON1 mRNA in human liver tissues [28]. 
1.12. Drug-drug interaction 
The U.S. FDA database reviewed by Thompson et al. reported approximately 58% cases 
of rhabdomyolysis related to statins are associated with the concomitant medication 
affecting statin metabolism [11].  The potential of a serious clinical drug interaction is 
highest when concomitant medications are metabolized by the same CYP enzyme [36].  
Metabolism of 60% of marketed medications is dependent on the activity of CYP3A.  
Concomitant drugs that are inhibitors of CYP3A4 or UGT enzymes increase plasma 
levels of ATV and its metabolites therefore may enhance the risk of statin-induced 
rhabdomyolysis [13, 37-40].  Moreover, several cases reported severe statin-related 
rhabdomyolysis with concurrent use of drugs including cyclosporine, colchicine, fusidic 
acid, delavirdine, diltiazem, esomeprazole, clarithromycin, antiretroviral drugs, 
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gemfibrozil and fluconazole that inhibit enzymes or transporter systems, which are 
involved in the disposition of ATV [41-49]. 
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2. Rosuvastatin calcium (Crestor ®) 
2.1.  Physicochemical properties of rosuvastatin calcium 
Rosuvastatin is a synthetic drug and is available as white to off-white crystalline calcium 
salt of an active acid. Chemical formula of rosuvastatin calcium is (E,3R,5S)-7-[4-(4-
fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-
dihydroxyhept-6-enoate), C44H54CaF2N6O12S2. It is sparingly soluble in water, having 
logP and pKa values of 2.52 and 4.44 respectively [50]. The molecular weight of RST is 
481.54. The chemical structure of rosuvastatin calcium is shown in Figure I-3. 
2.2. Clinical uses 
Rosuvastatin calcium (Crestor
®
) is widely used as an adjunct therapy to diet for lowering 
elevated plasma levels of total cholesterol, LDL-C and triglycerides for the treatment of 
various cardiovascular related disorders including primary hyperlipidemia, mixed 
dyslipidemia, hypertriglyceridemia and homozygous familial hypercholesterolemia [51]. 
2.3.  Mechanism of action 
Rosuvastatin acid is relatively hydrophilic and therefore exhibits selective hepatic uptake 
with limited access to non hepatic tissues. It competitively inhibits HMG-CoA reductase 
enzyme, a rate-limiting enzyme of the mevalonate pathway for cholesterol biosynthesis. 
It thereby decreases intracellular levels of cholesterol, which results in increased LDL-C 
receptors in the liver facilitating the plasma clearance of LDL-C. Rosuvastatin acid also 
exerts non-lipid lowering action like vasculoprotective effects possibly by reducing 
inflammation of endothelial cells [52]. 
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2.4. Side effects  
Skeletal muscle-related complaints, nausea, headache, abdominal pain and asthenia are 
the most common adverse effects that develop with RST treatment [51]. 
2.5. Pharmacokinetic properties 
A. Absorption 
Upon oral administration, RST undergoes moderately rapid absorption that is estimated 
to be approximately 50%. The modest absolute bioavailability (approximately 20%) and 
a high hepatic extraction ratio (0.63) suggest significant first pass metabolism [53, 54]. 
After a single 20 mg post-dose, a Cmax of 6.1 ng/mL was measured at approximately 5 h 
(Tmax). The Cmax and AUC are linear over the dosage range of 5 to 80 mg after both single 
and seven daily doses; moreover, it does not accumulate following repeated dosing. It 
also exhibits enterohepatic recirculation suggested by secondary peak in plasma 
concentration time profile [53, 54]. 
B. Distribution 
Rosuvastatin acid is reversibly bound to plasma proteins mainly albumin with a bound 
fraction of 88%. The large mean volume of distribution at steady state (134L) 
demonstrated extensive peripheral tissue distribution primarily in the liver [53].  
C. Metabolism 
Rosuvastatin acid undergoes limited metabolism mainly by CYP2C9 isoenzyme and to a 
lesser extent through CYP2C19 and CYP3A4 [55]. It is biotransformed into its 
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pharmacologically active main metabolite, an N-desmethyl derivative which has seven-
fold lower inhibitory effect on HMG-CoA [54]. A previously published in vitro study has 
shown that upon incubation of RST with human liver microsomes, RST underwent 
significant glucuronidation through UGT1A1 and 1A3 to form acyl glucuronide 
conjugates and lactonization to pharmacologically inactive 5S-lactone (RST-LAC) 
metabolite [55]. The chemical structures of both the metabolites are shown in Figure I-4. 
The average Cmax values for RST-LAC and N-desmethyl rosuvastatin were 12–24% and 
<10% of the parent RST Cmax, respectively [54].  
D. Elimination 
Fecal (approximately 90% of the dose) and renal (approximately 10% of the dose) are the 
major and minor routes of excretion of RST, respectively. Rosuvastatin acid mainly 
excretes unchanged (76.8% of the dose) in feces with elimination half-life of 20 h [54].  
2.6. Effect of age and gender 
The effect of age and gender on the PK of RST was studied in young (18-35 years) and 
elderly (>65 years) healthy volunteers, with an average age of 24 years and 64 years, 
respectively. An average AUC (0-t) was 6% and of Cmax was 12% greater in the young 
subjects as compared to the older subjects. Similarly, the mean of AUC(0-t) was 9% and of 
Cmax was 18%  lower in male as compared to female groups. These minor differences are 
not considered clinically important and therefore no dose adjustment is recommended 
[56]. 
2.7. Effect of race 
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Systemic exposure of RST and the two metabolites were significantly higher in white 
subjects as compared with Chinese, Malay and Asian-Indian living in the same 
environment. The PK differences could be due to genetic polymorphisms of SLCO1B1 
gene resulting in altered transport activity of RST by OATP1B1 hepatic uptake 
transporter [57]. 
2.8. Effect of food 
The extent of absorption of RST is not affected by food; while the rate of absorption is 
decreased by 20%, the efficacy of the drug remains unchanged. Therefore, RST can be 
administered with or without food [58]. 
2.9. Effect of hepatic and renal impairment 
The clinical PK of RST at steady state were similar between patients with mild (Child-
Pugh class A) to moderate (Child-Pugh class B) hepatic impairment and subjects with 
normal hepatic functions. However, severe hepatic impairment may increase plasma 
systemic exposure of RST [59].  The systemic exposure of RST was similar between 
patients with mild-to-moderate renal impairment (creatinine clearance ≥ 30 ml/min/1.73 
m
2
) and healthy volunteers at steady state. Nevertheless, the exposure was three fold 
higher in patients with severe renal impairment (creatinine clearance < 30 ml/min/1.73 
m
2
) as compared to healthy subjects [51]. Rosuvastatin acid plasma concentrations were 
approximately 50% higher in patients undergoing haemodialysis therapy as compared 
with healthy controls [60]. 
2.10. Effect of time of administration 
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The PK and pharmacodynamic properties of RST were not different between the morning 
and evening time of oral administration in healthy volunteers who received a daily dose 
of 10 mg for 14 days [61].  
2.11. Effect of genetic polymorphism 
Various clinical studies conducted in healthy Finish and Korean population have 
described the impact of SNP in OATP1B1 and BCRP transporters on the PK of RST, 
which is summarized in Table I-2. 
2.12. Drug interactions 
Rosuvastatin acid has a limited metabolism and is less likely to interact with other 
clinically used drugs. Administration of azole antifungal drugs including itraconazole 
[62], fluconazole [63] and ketoconazole [64] had no or very small effect on the systemic 
exposure of RST and thus these interactions are not considered clinically relevant. These 
clinical drug interactions studies supported the previous findings regarding limited 
metabolism of RST through CYP2C9, CYP2C19 and CYP3A4. Similar results were 
obtained when RST was administered with the macrolide antibiotic, erythromycin, which 
is a potent CYP3A4 inhibitor and demonstrated the minor role of CYP3A4 in RST 
metabolism [65].  
Upon oral co-administration of RST with HIV protease inhibitors including 
atazanavir/ritonavir or fosamprenavir/ritonavir [66] and liponavir/ritonavir, [67] several 
fold increase of AUC and Cmax may occur following the inhibition of BCRP mediated 
intestinal uptake and/or biliary efflux and OATP1B1 mediated hepatic uptake. A 
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combined therapy of RST and HIV protease inhibitors warrants careful administration. 
Gemfibrozil [68, 69] and cyclosporine [70] significantly increased plasma concentrations 
of RST by inhibiting OATP meditated hepatic uptake. A minimal change in the systemic 
exposure of RST was observed with simultaneous administration of fenofibrate [71], 
rifampicin [72], dalcetrapib [73] and silymarin supplements [74] and therefore these 
interactions are not considered clinically relevant. The herbal medicine baicalin 
decreased AUC of RST due to induction of OATP1B1 mediated hepatic uptake [75]. 
Simultaneous administration of RST with antacid preparation containing aluminum 
hydroxide and magnesium hydroxide reduced systemic exposure of RST by 
approximately 50%, and the effect was decreased upon administration of antacid 2 hrs 
after RST dosing [76]. Rosuvastatin acid can increase anticoagulant activity of warfarin, 
and thus careful monitoring is required upon co-administration of both drugs. The exact 
mechanism of the PD interaction between these two drugs is not known yet [77]. 
Coadministration of ezetimibe with RST significantly reduces LDL-C and triglyceride 
levels in serum however; no significant PK interaction was noticed [78]. 
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Figure I-1. Proposed oxidative metabolic (Phase I) pathway of atorvastatin acid. 
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Figure I-2. Proposed glucuronidation (Phase II) metabolic pathway of atorvastatin acid. 
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Figure I-4. Chemical structures of metabolites of rosuvastatin acid a) N-desmethyl 
rosuvastatin b) Rosuvastatin-5S- lactone. 
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Table I-1.  Major polymorphisms in genes coding drug metabolizing enzymes and transporters affecting the pharmacokinetics 
of atorvastatin acid (ATV) and atorvastatin lactone (ATV-LAC). 
 
 
Gene 
name 
Enzyme or 
transporter 
SNP dbSNP 
ID 
Population Effect Analytes Ref 
ABCB1 P-gp c.1236 C>T 
c.2677 G>T/A 
rs1128503 
rs2032582 
Healthy finish 
volunteers 
AUC:TTT/TTT>CGC/CGC 
t ½: TTT/TTT>CGC/CGC 
ATV [79] 
c.3435C>T rs1045642 Koreans t ½: TTTT>GGCC/GTCT ATV 
ATV-LAC 
[80] 
ABCG2 BCRP c.421C>A rs2231142 Healthy finish 
volunteers 
AUC:AA>(C/C) 
AUC:AA>(C/C and C/A) 
ATV 
ATV-LAC 
[81] 
SLCO1B1 OATP1B1 OATP1B1*5 
(521T>C) 
rs4149056 Healthy white 
volunteers 
AUC:CC>(T/T and T/C) 
AUC:TC>(T/T)  
ATV [82] 
Koreans AUC: *15/*15>*1a/*1a, *1b/*1b , 
*1b/*15,*1a/*15, *1a/*1b 
ATV [80] 
UGT1A3 UGT1A3 UGT1A3*1 
UGT1A3*2 
UGT1A3*3 
UGT1A3*6 
NA Healthy finish 
volunteers 
t1/2:*1/*6< *1/*1,*1/*2,*2/*2,*1/*3 
t1/2:*2/*3< *1/*1,*1/*2,*2/*2 
AUC ratio (L/A):*1/*1<*1/*2,*2/*2 
ATV 
ATV-LAC 
[83] 
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Table I-2. Major polymorphisms of drug metabolizing enzymes and transporters affecting the pharmacokinetics of 
rosuvastatin acid. 
 
 
 
 
Gene 
name 
Enzyme or 
transporter 
SNP dbSNP 
ID 
Population Effect Ref 
ABCG2 BCRP c.421 C>A 
 
rs2231142 
 
Healthy finish 
volunteers 
AUC:AA>(C/C and C/A) 
Cmax :AA>(C/C and C/A) 
 
[81] 
Koreans AUC:  CC< (C/A and A/A) 
C max: CC>(C/A and A/A) 
CL/F: CC>(C/A and A/A) 
[84] 
SLCO1B1 OATP1B1 OATP1B1*5 
(521T>C) 
rs4149056 Healthy white 
volunteers 
AUC:CC>(T/T ) 
Cmax:CC>(T/T) 
[82] 
Koreans AUC: *15/*15,*1a/*15> *1a/*1a 
Cmax: *15/*15,*1a/*15> *1a/*1a 
AUC: *15/*15> *1b/*15 
Cmax:*15/*15> *1b/*15 or *1b/*1b 
[57, 85] 
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Abstract 
The aim of the proposed work was to develop and validate a simple and sensitive assay 
for the analysis of atorvastatin (ATV) acid, ortho- and para-hydroxy-ATV, ATV lactone, 
ortho- and para-hydroxy-ATV lactone in human plasma using liquid chromatography-
tandem mass spectrometry. 
All six analytes and corresponding deuterium (d5) labeled internal standards were 
extracted from 50 µL of human plasma by protein precipitation.  The chromatographic 
separation of analytes was achieved using a Zorbax-SB Phenyl column (2.1 mm × 100 
mm, 3.5 µm).  Mobile phase consisted of a gradient mixture of 0.1% v/v glacial acetic 
acid in 10% v/v methanol in water (solvent A) and 40% v/v methanol in acetonitrile 
(solvent B).  All analytes including ortho- and para-hydroxy metabolites were baseline 
separated within 7.0 min using a flow rate of 0.35 mL/min.  Mass spectrometry detection 
was carried out in positive electrospray ionization mode, with multiple reaction 
monitoring scan. 
The calibration curves for all analytes were linear (R
2 ≥ 0.9975, n=3) over the 
concentration range of 0.05-100 ng/mL and with LLOQ of 0.05 ng/mL.  Mean extraction 
recoveries ranged between 88.6-111%.  Intra- and inter-run mean %accuracy were 
between 85-115% and %imprecision was ≤15%.  Stability studies revealed that ATV acid 
and lactone forms were stable in plasma during bench top (six hours on ice-water slurry), 
at the end of 3 successive freeze and thaw cycles, and at -80 ºC for 3 months.  The 
method was successfully applied in a clinical study to determine levels of ATV and its 
metabolites over 12-hour post dose in patients receiving atorvastatin. 
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Introduction 
According to the American Heart Association and Centers for Disease Control and 
Prevention, cardiovascular diseases are the leading cause of death in the United States 
[1,2].  Hypercholesterolemia is a major risk factor for the progression of atherosclerosis, 
the principal cause of the development of coronary heart diseases.  The 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used 
for the treatment of hypercholesterolemia.  Statins induce a significant reduction in total 
plasma cholesterol concentration by reversible inhibition of the rate limiting enzyme, 
HMG-CoA reductase of the mevalonate pathway, which is responsible for the 
endogenous biosynthesis of cholesterol [3]. 
Worldwide, atorvastatin (ATV) calcium (Lipitor
®
, Pfizer Pharmaceuticals, NY) is the top 
selling prescribed medication [4].  Upon oral administration, the pharmacologically 
active calcium salt of ATV undergoes mainly cytochrome P450 3A4 (CYP3A4) mediated 
oxidative metabolism and forms two active metabolites, ortho-hydroxy-ATV and para-
hydroxy-ATV [5].  The parent drug and its acid hydroxy metabolites are in equilibrium 
with their corresponding inactive lactones forms, ATV lactone, ortho-hydroxy-ATV 
lactone and para-hydroxy-ATV lactone [6].  The metabolism pathway of atorvastatin, as 
described by Kantola et al. is shown in Figure II-1 [7].  Atorvastatin is the only statin 
with active metabolites since 70% of the ATV HMG-CoA reductase inhibition has been 
attributed to its hydroxy acid (ortho and para) metabolites [8]. 
Atorvastatin is clinically administered with a once daily dose of 10 to 80 mg [3].  The 
drug undergoes extensive first-pass metabolism in the gastrointestinal tract and/or liver, 
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with ~14% absolute oral bioavailability after a 10 mg oral dose.  The peak plasma 
concentrations (Cmax) are reached within 1 to 3 hour after oral administration of ATV.  
Food intake decreases ATV area under the concentration-time curve and Cmax by ~25% 
and 9 %, respectively.  Atorvastatin is highly bound to plasma protein (≥98%) with an 
average volume of distribution of 381 L and total clearance of 625 mL/min.  After 40 mg 
oral dose, Cmax (mean±SD) of ATV, ATV lactone, ortho-hydroxy-ATV, ortho-hydroxy-
ATV lactone and para-hydroxy-ATV lactone were 13.4 ± 9.5, 3.8 ± 2.6, 9.8 ± 6.1, 4.5 ± 
6.0 and 1.8 ± 1.0 ng/mL, respectively [7]. 
Although statins are well tolerated, skeletal muscle toxicity is the main adverse effect 
associated with statin treatment that results in decreased adherence to the therapeutic 
regimen [9].  Several hypotheses based on depletion of the products of the mevalonate 
pathway have been proposed to explain the molecular mechanism of statin-related 
myopathy; however, the underlying mechanism for statin-induced myopathy has not been 
fully elucidated [10].  Hermann et al. observed significantly higher levels of ATV 
lactone, para-hydroxy-ATV, ortho-hydroxy-ATV, and para-hydroxy-ATV lactone 
metabolites in patients experiencing ATV-induced myopathy.  The authors suggested 
potential clinical utility of metabolite to parent concentration ratio as a new diagnostic 
marker to assess the risk of ATV-associated myopathy [11].  Moreover, an in vitro study 
using primary human skeletal muscle cells found that ATV lactone has a 14-fold higher 
potency to induce myotoxicity as compared with its acid form further corroborating the 
usefulness of ATV lactone concentration as a marker for statin-induced myopathy [12].  
The plasma levels of para-hydroxy-ATV is almost 10–fold lower as compared with 
ortho-hydroxy-ATV [7]; thus, it is necessary to achieve an adequate LLOQ to be able to 
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quantify the concentration of para metabolites in plasma, especially when ATV is 
administered at low dose. 
To date, several methods have been published for quantification of ATV and its 
metabolites in a biological matrix (plasma or serum), bulk drug, pharmaceuticals 
products, and aqueous samples.  Various techniques employed include an electrochemical 
method [13], high-performance liquid chromatography with ultra violet detection [14-
17], enzyme inhibition [18,19], liquid chromatography-mass spectrometry [20], 
microbore liquid chromatography/electrospray ionization-tandem mass spectrometry 
[21], and liquid chromatography-tandem mass spectrometry [22-30]. 
High-performance liquid chromatography with ultra violet or electrochemical detection 
methods typically have a higher limit of quantification and are more time consuming.  
Gas chromatography meets the required LLOQ for most analytes; however, it needs 
complex derivatization steps.  Enzyme inhibition assays are sensitive and easy to 
implement but are non-specific and do not provide any information on the metabolite 
concentrations.  Undeniably, mass spectrometry has become the method of choice for 
quantification of metabolite concentration in biological matrices due to its superior 
selectivity.  However, few methods [20,25,26] have been reported for simultaneous 
determination of ATV and the five ATV metabolites (ortho- and para-hydroxy-ATV, 
ATV lactone, ortho- and para-hydroxy-ATV lactone).  Moreover, most reported methods 
require time-consuming extraction procedures, and they did not provide the sensitivity 
required to quantify para-hydroxy-ATV, that is present at ~10% of the total 
concentration, after administration of low dose ATV [20,25,26].  Furthermore, most 
methods require 500-1000 µL plasma volume [25,26].  In this manuscript, we describe 
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the development and validation of a highly sensitive method for determination of ATV 
and its five metabolites using 50 µL of plasma. 
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Experimental 
Reagents and chemicals 
ATV calcium hydroxy acid (ortho-hydroxy-ATV and para-hydroxy-ATV) and lactone 
metabolites (ATV lactone, ortho-hydroxy-ATV lactone and para-hydroxy-ATV lactone) 
and corresponding deuterium (d5) labeled internal standards (IS) (d5-ATV, d5-ATV 
lactone, d5-ortho-hydroxy-ATV, d5-para-hydroxy-ATV, d5-ortho-hydroxy-ATV lactone 
and d5-para-hydroxy-ATV lactone) were purchased from Toronto Research Chemicals 
(Toronto, Ontario, Canada).  HPLC grade acetonitrile and glacial acetic acid were 
obtained from Fisher Scientific (Fair Lawn, NJ, USA).  HPLC grade methanol was from 
Pharmco Products Inc. (Brookefield, CT, USA).  A Milli Q50 (Millipore, Bedford, MA, 
USA) water purification system was used to generate HPLC grade water.  Human drug-
free plasma with sodium fluoride/potassium oxalate as an anticoagulant was purchased 
from Bioreclamation Inc (Westbury, NY, USA).  Human plasma from individuals on 
ATV therapy was obtained by venipuncure in sodium heparin, fluoride/potassium oxalate 
or K2EDTA vacutainers (BD, Franklin lakes, NJ, USA) after obtaining informed consent. 
Chromatographic conditions 
The separation of analytes was performed on a Zorbax-SB Phenyl, Rapid Resolution HT 
(2.1 mm × 100 mm) column with 3.5 µm particle size from Agilent Technologies 
(Wilmington, DE, USA), preceded by a 0.5 µm filter (Supelco, Bellefonte, PA).  The 
analytical column was maintained at 40 °C temperature.  Mobile phase, consisting of a 
gradient mixture of 0.1% v/v glacial acetic acid in 10% v/v methanol in water (solvent A) 
and 40% v/v methanol in acetonitrile (solvent B), was used at a flow rate of 0.35 mL/min 
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for separation and rapid elution of analytes from the extracted matrix within 7.0 min.  
During the first 0.3 min of the gradient, %B increased from 10% to 60% where it was 
kept until 0.8 min and then gradually increased to 75% until 4.6 min.  At 4.61 min, %B 
was decreased to 10% and kept to re-equilibrate the column until 7.0 min. 
Mass spectrometric conditions 
The LC-MS/MS system consisted of an Agilent Technologies 1200 series HPLC system 
with binary pumps, autosampler, thermostatted column compartment and micro vacuum 
degasser (Santa Clara, CA) coupled to an API 4000 triple quadrupole mass spectrometer 
(AB Sciex, Toronto, Canada), equipped with Turbo V
TM
 ion source.  Mass spectrometric 
detection and quantitation of all analytes were carried out using multiple reaction 
monitoring (MRM) scan in electrospray positive ion mode.  Q1 and product ion scans 
were obtained by infusing solutions of individual analytes and their respective IS using 
an infusion pump. 
The following MRM transitions were selected: (m/z, Q1→Q3) of ATV (m/z, 
559.2→440.2), d5-ATV (m/z, 564.2→445.2), ATV lactone (m/z, 541.2→448.2), d5-
ATV lactone (m/z, 546.2→453.2), ortho-hydroxy-ATV (m/z, 575.2→440.2), d5-ortho-
hydroxy-ATV (m/z, 580.2→445.2), para-hydroxy-ATV (m/z, 575.2→440.2), d5-para-
hydroxy-ATV (m/z, 580.2→445.2), ortho-hydroxy-ATV lactone (m/z, 557.2→448.2) 
and d5-ortho-hydroxy-ATV lactone (m/z, 562.2→453.2), para-hydroxy-ATV lactone 
(m/z, 557.2→448.2), d5-para-hydroxy-ATV lactone (m/z, 562.2→453.2).  Source 
temperature and gas parameters were optimized after the chromatographic conditions 
were finalized by infusing a solution of para-hydroxy-ATV in T junction with the mobile 
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phase consisting of 70% of solvent B.  All peak areas were obtained using Sciex Analyst 
1.5.1 data processing software. 
Standards/QCs preparation 
Separate stock solutions of ATV (0.4 mg/mL), ortho-hydroxy-ATV (1.0 mg/mL) and 
para-hydroxy-ATV (1.0 mg/mL) were prepared in acetonitrile:water mixture (90:10, 
v/v).  Similarly, 1.0 mg/mL separate stock solutions of ATV lactone, ortho-hydroxy-
ATV lactone and para-hydroxy-ATV lactone were prepared in acetonitrile.  Intermediary 
stock solutions of composite mixtures of acids only and lactones only (100 µg/mL for 
each compound) were prepared in acetonitrile:water mixture (90:10 v/v) and acetonitrile, 
respectively, and were used to spike calibrators and quality control samples (QCs) in 
drug-free human plasma kept on an ice-water slurry. 
Individual deuterated (d5) IS of acid and lactone stock solutions of 1.0 mg/mL were 
prepared in acetonitrile:water (90:10 v/v) and acetonitrile, respectively.  Intermediary 
internal standard solutions containing 50 ng/mL of either acids or lactones were prepared 
in acetonitrile.  All stock and working standard solutions were stored at -20 °C until use.  
Eight calibration standards with concentrations ranging from 0.05 ng/mL to 100 ng/mL 
and quality control samples at four concentration levels (0.05, 0.15, 5.00 and 75.0 ng/mL) 
were prepared in drug-free human plasma by using respective spiking solutions and were 
stored at -80 °C. 
Sample extraction 
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Calibrators, QCs, control blank, double blank, and patient samples were thawed on ice-
water slurry and vortex-mixed thoroughly for 10 seconds.  A 50 μL aliquot of each 
plasma sample was aliquoted into 1.5 mL polypropylene tube; all samples were treated 
with 200 μL of 0.1% acetic acid in acetonitrile (as a protein precipitation reagent) 
containing 0.8 ng/mL of the combined acids and combined lactone IS, except for double 
blank.  All tubes were vortex-mixed for 10 seconds and thereafter all precipitated proteins 
were separated by centrifugation for 15 min at 14,000 g and 4°C temperature.  The 
supernatant was transferred to a fresh glass vial and 10 μL was injected onto LC-MS/MS. 
Validation of the assay 
The validation of the method was performed according to general recommendation 
guidelines for bioanalytical methods by U.S. Food and Drug Administration (FDA) [31]. 
Validation parameters including selectivity, sensitivity, accuracy, precision, recovery and 
stability were determined. 
Stability 
The stability studies aimed to establish the conditions in which the analytes are stable and 
the degree of inter-conversion of acid to lactone or lactone to acid forms.  The first set of 
QC samples contained composite mixture of all six analytes.  In the second set, QC 
samples contained only ATV and its two hydroxy acid metabolites.  The third set 
comprised lactone–only QC samples containing only ATV lactone and its two hydroxy 
metabolites.  All three sets of QC samples were prepared at low level quality control 
(LQC) (0.15 ng/mL) and high level quality control (HQC) (75.0 ng/mL) concentration 
levels.  The following stability studies were carried out: 
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I. Post preparative stability (autosampler stability):  The stability of the analytes in 
processed samples, kept in the autosampler at 4°C, was tested by reinjecting one of 
the three validation runs 24 hours after extraction. 
II. Bench-top stability: Triplicate LQC and HQC kept on ice-water slurry for six hours 
were extracted along with freshly spiked calibrators. 
III. Long-term stability:  Long-term stability at -80 °C was established by analyzing six 
replicates of LQC and HQC for all three sets of QC samples, after two weeks, one 
month and three months. 
IV. Freeze and thaw stability:  Freshly spiked triplicates of LQC and HQC of all three 
sets of QC samples were stored at -80 °C for at least 12 hours and were thawed on ice 
water slurry.  At the end of three successive freeze and thaw cycles, QC samples were 
extracted along with freshly spiked calibrators and QCs. 
Linearity, accuracy and precision 
Eight-point calibration curves were obtained using 0.05, 0.10, 0.50, 2.00, 10.0, 50.0, 90.0 
and 100 ng/mL calibrators.  All calibrators, six replicates of the first set of QC samples at 
four concentration levels, double blank (without IS) and control blank (with IS) were 
tested in three runs to evaluate the intra- and inter-run imprecision and accuracy of the 
method. 
Limit of quantitation 
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Lower limit of quantitation (LLOQ) is defined as the lowest concentration of an analyte, 
which has at least five times higher response (signal-to-noise, S/N=5/1) compared to 
blank response and can be analyzed with an acceptable accuracy and imprecision 
(accuracy within 80- 120% and imprecision ≤ 20%).  Five serial dilutions of plasma 
sample containing 0.200 ng/mL of each analyte were made by mixing equal volumes of 
spiked plasma with blank plasma.  Six replicates of each spiked sample were extracted 
and S/N of peak and %CV of the analyte/IS ratio were calculated.  The sample with S/N 
at least five and %CV below 20% for each analyte was selected as potential LLOQ for 
the validation. 
Selectivity 
Drug-free human plasma samples from six different donors were evaluated for the 
presence of endogenous matrix components that may interfere with quantitation of the 
analytes or the IS.  Area of the peaks eluting at the same retention time as the analytes 
and internal standards of interest, in extracted selectivity samples, were compared with 
those in chromatograms obtained from LLOQ samples. 
Recovery and matrix effect 
Triplicates of LQC and HQC from the first set of QC samples along with blank plasma 
samples were extracted and were used to evaluate recovery and matrix effect 
(enhancement or suppression of ionization).  Solutions with concentrations equivalent to 
100% recovery of the extracted LQC (0.03 ng/mL) and HQC (15 ng/mL) containing all 
analytes and IS were prepared in water: 0.1% acetic acid in acetonitrile, 1:4 (v/v) 
(reference for matrix effect) and in extracted blank plasma (reference for recovery).  In 
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addition, matrix effect was also evaluated using a post-column infusion method.  This test 
was performed by infusing a solution containing 20 ng/mL of analytes and IS prepared in 
solvent B:solvent A (70:30 v/v) at 10 µL/min along with the injections of the blank 
solvent, double blank matrix extract and extracted HQC to identify the region of 
ionization suppression. 
To investigate the potential of interference and matrix effect from co-administered 
medications and their metabolites, specific to transplanted population, a pool plasma 
sample was prepared from samples collected from the three stable kidney transplant 
patients treated with sirolimus (2, 2, or 4 mg/day), mycophenolic acid (2000 mg/day) and 
prednisone (5 mg/day), but not with atorvastatin.  The pool sample was obtained by 
mixing equal volumes of plasma from samples collected at 1, 2, 4, 8 and 12 hours after 
the morning dose of the co-administered medications.  The pooled plasma samples were 
spiked with LQC and six replicates were extracted along with calibration STD, QCs, and 
a non-spiked pool. 
Application of the method in a clinical pharmacokinetic study 
The proposed method was successfully applied to determine the levels of acid and 
lactone forms of ATV and hydroxy metabolites in human plasma samples obtained from 
a pharmacokinetic study conducted to investigate ATV disposition in the stable kidney 
transplant recipients who received ATV. 
 51 
 
Results and discussion 
Sample collection and preparation 
Lactonization of an acid form and hydrolysis of lactone to an open-acid form of ATV is 
mediated through UDP-glucuronosyltransferase (UGTs) [32] and esterases 
(paraoxonases) [33], respectively.  Esterase activity is the most important cause of 
instability of ester-containing drugs in biological matrices.  We tested the effect of 
several anticoagulants on lactone to acid interconversion by comparing different types of 
plasma (sodium heparin, K2EDTA and sodium fluoride/potassium oxalate) and serum.  In 
addition, one blood sample was collected for each anticoagulant and serum from five 
representative patients who were on 10-40 mg daily dose of ATV.  The plasma and serum 
were separated by centrifugation at 1500 g and concentrations of all analytes were 
determined using the validated assay.  Moreover, freshly spiked HQC containing lactone 
only analytes that was freshly prepared in serum or plasma with different anti-coagulants 
were analyzed.  We could not find statistically significant difference (One-way ANOVA, 
p>0.9) between serum and various anticoagulants (Table II-1); however, we preferred to 
use sodium fluoride (esterase inhibitor) plasma to ensure stability of lactone upon long-
term storage [34]. 
Liquid-liquid and solid phase extractions usually involve tedious and time-consuming 
extraction steps such as drying and the addition of pH modifiers, which in this case may 
lead to undesirable acid-lactone interconversion.  A previously reported LC-MS/MS 
assay for ATV and metabolites (27) extensively studied the known stability issues of 
highly unstable lactone and showed that the possible interconversion between lactone and 
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acid forms can be minimized by lowering the working temperature to 4 °C and lowering 
the plasma pH to 4-6.  Non-acidified acetonitrile as a precipitating agent resulted in 
significant interconversion of lactone to acid form during the resident time of the 
extracted samples in an autosampler.  Therefore, 0.1% glacial acetic acid in acetonitrile 
was used to minimize the interconversion of lactone to acid. 
LC-MS/MS detection 
Ortho- and para- analytes have the same precursor ion-product ion transitions.  
Additionally, the acids could potentially undergo in-source fragmentation and, following 
the loss of water, the resulting product would interfere with their respective lactones.  For 
these combined reasons, we sought chromatographic conditions that would assure 
baseline chromatographic separation of the respective analytes.  To achieve this goal, 
various reverse phase analytical columns were tested and the required selectivity, as well 
as the excellent peak shape (in terms of sharpness and symmetry), were achieved using a 
narrow bore Zorbax-SB phenyl column.  Because this column provided excellent peak 
focusing, a high S/N was obtained that enabled us to use a simple protein precipitation 
extraction without performing pre-concentration steps for sample clean up.  Total elution 
of analytes using a gradient mixture of mobile phase resulted in a run time of 7.0 min, 
including the re-equilibration of the column.  The retention times of ATV, ATV lactone, 
ortho-hydroxy-ATV, para-hydroxy-ATV, ortho-hydroxy-ATV lactone and para-
hydroxy-ATV lactone were 3.9, 4.4, 3.8, 3.2, 4.2 and 3.5 min, respectively (Figure II-2). 
The MS was operated using electrospray ionization probe in positive ion mode to obtain 
high signal intensity.  For each analyte, [M+H]+ was the major precursor ion used to 
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obtain the product ion spectra.  The major product ions are formed by the neutral loss of 
the (phenylamino)carbonyl group and phenylamino group, from acid and lactone 
compounds, respectively.  Temperature and gas parameters of the source were optimized 
based on para-hydroxy-ATV, since the plasma concentration of this analyte is typically 
lower than other analytes. 
The compound specific parameters i.e. declustering potential (DP), entrance potential 
(EP), collision cell exit potential (EXP) and collision energy (CE) and similarly, gas 
parameters including curtain gas (CUR=30 psi), gas 1 (GS1=60 psi), gas 2 (GS2=30 psi), 
and collision gas (CAD=10 psi), ionspray voltage (IS=5500 V), and temperature 
(TEM=550 °C), were optimized to achieve maximum signal.  No significant in-source 
inter-conversion was observed from acid to lactone form. 
Method validation 
The analytes were stable in the conditions described above.  The post preparative stability 
assessment proved that extracted samples can be injected after being kept at 4°C for 24 
hours post extraction, the anticipated resident time in autosampler; furthermore, analytes 
were stable after three cycles of freeze and thaw and during bench top stability carried 
out on ice-water slurry.  The data obtained also revealed that the samples were stable in 
the matrix after 3 months storage at -80 °C.  No interference was observed from 
endogenous components with analytes and IS in blank plasma from six different donors, 
demonstrating the specificity of the method. 
The calibration curves obtained from analyte/IS peak area ratios vs. nominal 
concentration were linear using weighted (1/x2) linear regression over the concentration 
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range, with correlation coefficients (R2) ≥ 0.9975.  According to FDA guidelines, the 
accuracy of calibration standards and quality control samples (n>5) should be between 
85-115%, and imprecision below 15%, except at the LLOQ level, for which accuracy 
may be between 80-120% and imprecision below 20%.  For the current assay, the 
measured mean values (n=3) were within 91.6-106% of their nominal values for 
calibrators (Table II-2), 89.2-110% for intra-run QCs (results not presented) and 91.7-
107% for inter-run QCs (Table II-3), which indicates acceptable accuracy of the proposed 
method. 
A lower limit of quantitation of 0.05 ng/mL was achieved for all analytes and a 
chromatogram of an extracted LLOQ is shown in Figure II-2.  The extraction recovery 
for all analytes was within 88.6-111%.  No significant matrix effect was observed for 
each analyte upon calculating the ratio of average area response of reference for recovery 
to reference for the matrix effect at LQC and HQC concentration levels. 
Evaluation of the matrix effect is essential to assure the reliability of quantitative assays 
using HPLC-MS/MS and the integrity of the resulting pharmacokinetics data.  We used 
stable isotope labeled internal standards for each of the analytes, as they compensate 
reasonably well during variations in sample analysis.  However, due to their slightly 
different elution times compared to their respective non-labeled species, deuterated 
internal standards may not always compensate well for ionization enhancement or 
suppression due to coelution of matrix endogenous components, such as phospholipids 
[35].  Phosphatidylcholine and lyso-phosphatidylcholine are major human plasma 
phospholipids that produce matrix effect.  Zhang and colleagues reported the key 
phospholipids in human serum extracts that can cause matrix effects by identifying the 
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precursor ions generating fragment with m/z 184 [36].  Following the same technique, we 
determined the retention time of phospholipids with MRM transitions: Q1 m/z 496, 520, 
522, 524, 544, 758 and 782 and Q3 m/z 184.  We have then adjusted the chromatographic 
conditions to ensure that the analytes do not co-elute with these phospholipids.  To study 
matrix effect, post-column infusion of a solution containing the analytes and their 
respective IS, concomitantly with injecting extracted blank plasma were carried out.  We 
monitored retention times of the major phospholipids as shown in Figure II-3A, and 
found that no significant ion suppression occurred at the retention time of the analytes or 
IS. 
The post-column infusion chromatogram shown in Figure II-3B indicates that ATV and 
metabolites were eluted at retention times different from the retention time of key 
phospholipids.  Post-column infusion of analytes and IS, concomitantly with injecting an 
extracted blank plasma, shows that the signal intensity of each analyte of interest does not 
change in the region of their respective elution period (Figure II- 3C).  The mean of the 
calculated concentrations of six LQC samples prepared in pooled plasma from patients 
treated with an immunosuppressive regimen and who did not receive atorvastatin was 
between 92–97% of the expected nominal concentration.  No interfering peaks were 
eluting at the retention times of the analytes of interest.  This demonstrates that sirolimus, 
mycophenolic acid, prednisone, and their metabolites, do not interfere with the 
quantitation of atorvastatin and its metabolites. 
Application of the method 
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The method was successfully applied to measure the concentration of ATV and its 
metabolites in the stable kidney transplant recipients who received atorvastatin for the 
treatment of hypercholesterolemia.  The study protocol was approved by the Institutional 
Review Board of Rhode Island Hospital, Providence RI, USA.  Written informed consent 
was obtained from all subjects after verbal explanation of the study protocol prior to 
enrolling in the study. 
In Figure II- 4A, ATV and metabolites steady-state 12-hour concentration-time profile, 
obtained from the four kidney transplant recipients is shown.  All patients received a 10 
mg dose of ATV in the morning along with a triple immunosuppressive regimen that 
included oral sirolimus, mycophenolic acid and prednisone.  The concentration-time 
profiles for ATV and metabolites show that the method has an acceptable LLOQ for 
quantitation of all analytes including the para-hydroxy metabolites.  Moreover, in Figure 
II-4B, metabolite to parent ATV concentration ratio obtained from the nine kidney 
transplant recipients treated with 10, 20 and 40 mg of ATV dose is shown.  The 
concentration of ATV and metabolites were measured in nine plasma samples over a 12-
hour post dose period and the average ratio for each metabolite is presented.  As shown in 
Figure II-4B, in our patient population, the concentration of ATV, ortho-hydroxy-ATV-
lactone and para-hydroxy-ATV-lactone were greater than the parent ATV, whereas, the 
concentration of ortho-hydroxy-ATV and para-hydroxy-ATV was lower than the parent 
ATV concentration 
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Conclusion 
We describe a reproducible, reliable, sensitive and simple bioanalytical method.  The 
major advantages of the present method, as compared with previous reports, are low 
LLOQ, 50 µL plasma volume and simple extraction method.  The proposed validated 
bioanalytical technique accomplishes the required selectivity, sensitivity, accuracy, and 
imprecision to be applied to various studies involving pharmacokinetics, drug 
metabolism, clinical pharmacology/toxicology, bioavailability/bioequivalence, and drug-
drug interactions for accurate quantitative analysis of ATV and its five metabolites.  This 
method offers an easy and convenient way to conduct routine clinical monitoring of toxic 
metabolites, therefore, it can be used by toxicologists and clinical chemists who wish to 
implement the metabolite/parent drug ratio as a new diagnostic marker for identifying 
patients at risk of developing ATV-induced myotoxicity. 
 58 
 
Acknowledgements 
The authors gratefully acknowledge the financial support of American Heart Association 
award #0855761D.  Use of an API 4000 mass spectrometer provided as a collaboration 
agreement with AB Sciex is gratefully acknowledged. 
 59 
 
 
 
 
 
 
Adapted from Kantola et al. (1998) 
 
 
Figure II-1.  Proposed metabolism pathway of atorvastatin to atorvastatin lactone, ortho-
hydroxy-atorvastatin, para-hydroxy-atorvastatin, ortho-hydroxy-atorvastatin lactone, and 
para-hydroxy-atorvastatin lactone. 
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Figure II-2.  Chromatograms showing the integrated peaks of atorvastatin acid (A), 
atorvastatin lactone (B), ortho-hydroxy-atorvastatin (C), para-hydroxy-atorvastatin (D), 
ortho-hydroxy- atorvastatin lactone (E), and para-hydroxy-atorvastatin lactone (F) from 
extracted calibration standard at the lower limit of quantitation (0.05 ng/mL). 
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Figure II-3.  Injection of matrix spiked with analyte and IS without post-column infusion 
along with MRM transitions of key phospholipids. Chromatograms showing the peaks of 
analytes and corresponding IS along with key phospholipids (A). Chromatogram 
obtained with post-column infusion shows no matrix effect at the retention times of 
analytes and IS. Arrow indicates region where the signal of compounds infused post-
column is suppressed during the elution of endogenous matrix components (B). 
Chromatogram of a blank sample injected while the analytes and IS are infused post 
column.  Arrow indicates region where the signals of analytes and IS infused post-
column are suppressed during the elution of endogenous matrix components (C). 
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Figure II-4. Plasma concentration (ng/mL) versus time profiles of atorvastatin and 
metabolites, in acid and lactone forms, from the four stable kidney transplant recipients 
who received a 10 mg atorvastatin dose; data are expressed as mean and error bars 
represent standard deviation (A) Metabolite/parent atorvastatin concentration from the 
stable kidney transplant recipients (n=9) on a steady-state dose of 10-40 mg atorvastatin 
(B). 
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Table II-1. Effect of Various Anticoagulants on Interconversion of Atorvastatin (ATV) 
lactones; the first part represents ATV lactone %accuracy and %CV for blank samples of 
serum or plasma with different anti-coagulants freshly spiked with ATV lactones at high 
quality control level.  The second part of the table represents the mean and standard 
deviation of ATV and metabolite concentration from 5 patients at steady-state ATV with 
samples obtained as serum or plasma with different anti-coagulants. 
 
 
 
 
n = 3 
% accuracy=100- [(mean-nominal)/nominal]*100 
%CV calculated as (standard deviation/mean)*100 
 
Analytes added  
   Type of anticoagulants   
 
Sodium 
heparin 
K2EDTA Serum 
Sodium 
fluoride 
ATV lactone 
%Accuracy 
%CV 
98.8 
3.3 
102 
4.3 
101 
3.5 
104 
4.5 
Para-hydroxy-ATV lactone 
%Accuracy 
%CV 
101 
4.1 
102 
3.2 
102 
3.2 
105 
4.8 
Ortho-hydroxy-ATV lactone 
%Accuracy 
%CV 
98.0 
3.5 
101 
3.7 
99.4 
6.2 
102 
5.0 
      
Concentration of analytes 
 in representative patients 
Concentration 
(ng/mL) 
    
ATV 
     
  Mean 2.94 2.51 2.80 2.20 
Std dev 3.7 3.2 3.5 2.7 
ATV lactone 
     
Mean 2.43 2.32 2.38 2.16 
Std dev 2.2 2.1 2.2 2.0 
Para-hydroxy-ATV 
     
Mean 0.33 0.32 0.34 0.22 
Std dev 0.3 0.3 0.3 0.2 
Para-hydroxy-ATV lactone 
     
Mean 0.35 0.34 0.35 0.32 
 Std dev 0.3 0.3 0.3 0.3 
Ortho-hydroxy-ATV 
     
Mean 2.91 2.57 2.78 2.25 
Std dev 4.0 3.5 3.8 2.9 
Ortho-hydroxy-ATV lactone 
     
Mean 4.87 4.46 4.87 4.24 
Std dev 5.5 5.2 5.8 4.7 
  
 
6
4
 
Table II-2. Summary of Standards and Calibration Curve Parameters from Three Individual Runs. 
Analyte  STD 1 STD 2 STD 3 STD 4 STD 5 STD 6 STD 7 STD 8  R
2
 
 STD (ng/mL) 0.05 0.10 0.50 2.00 10.0 50.0 90.0 100   
ATV 
           
%Accuracy 100 100 98.7 97.0 104 98.5 99.0 103  0.9983 
%CV 3.2 7.7 9.6 0.1 0.1 4.1 4.3 6.2    
            
ATV lactone % Accuracy 97.6 104   102 100 98.0 103 93.1 102  0.9975 
 %CV 5.1 8.7 7.5 1.4 2.0 8.2 5.6 6.4   
Para-hydroxy-ATV 
            
% Accuracy 97.7 106 94.2 95.5 104 103 95.8 104  0.9987 
%CV 2.2 3.9 1.2 2.4 3.1 5.2 6.0 4.4   
 
Para-hydroxy-ATV lactone 
            
% Accuracy 100 99.4 103 98.5 102 104 94.4 98.6  0.9981 
 %CV 3.4 8.3 7.5 3.2 2.7 4.5 2.6 0.6   
Ortho-hydroxy-ATV 
            
% Accuracy 98.6 103 97.8 95.0 103 99.5 97.1 105  0.9980 
%CV 1.2 2.3 1.5 4.0 2.1 5.7 4.4 4.1   
Ortho-hydroxy-ATV lactone 
            
% Accuracy 98.2 104 98.3 101 100 105 91.6 102  0.9984 
%CV 4.6 9.1 3.2 0.6 3.2 1.9 1.8 3.0   
 
 
n = 3 (1 replicate for each of the three validation runs) 
% accuracy=100- [(mean-nominal)/nominal]*100 
%CV calculated as (standard deviation/mean)*100 
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Table II-3. Summary of Quality Control Samples from Three Individual Runs. 
 
n = 18 (6 replicates for each validation run). 
% accuracy=100- [(mean-nominal)/nominal]*100 
%CV calculated as (standard deviation/mean)*100 
 
Analyte    QCs    
 QC (ng/mL)   0.05   0.15  5.00  75.0  
ATV 
      
%Accuracy 100 105 97.6 91.7  
%CV 9.2 6.2 4.0 4.6  
ATV lactone 
      
%Accuracy 105 100 99.5 96.4  
%CV 9.4 8.1 4.9 4.4  
Para-hydroxy-ATV 
      
%Accuracy 97.4 107 95.6  94.0  
%CV 7.4 5.5 6.6  3.2  
Para-hydroxy-ATV lactone 
      
%Accuracy 103 98.5 101 97.0  
 %CV 8.6 6.5 4.8 3.8  
Ortho-hydroxy-ATV 
      
%Accuracy 98.1 106 95.8 93.9  
%CV 13 7.9 4.4 4.7  
Ortho-hydroxy-ATV lactone 
      
%Accuracy 98.0 98.2 100 97.4  
%CV 12 7.8 4.5 3.8 
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Abstract 
A simple and sensitive assay was developed and validated for the simultaneous 
quantification of rosuvastatin acid (RST), rosuvastatin-5S-lactone (RST-LAC), and N-
desmethyl rosuvastatin (DM-RST), in buffered human plasma using liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). 
All the three analytes and the corresponding deuterium-labeled internal standards were 
extracted from 50 µL of buffered human plasma by protein precipitation.  The 
chromatographic separation of the analytes was achieved using a Zorbax-SB Phenyl 
column (2.1 mm×100 mm, 3.5 µm).  The mobile phase consisted of a gradient mixture of 
0.1% v/v glacial acetic acid in 10% v/v methanol in water (solvent A) and 40% v/v 
methanol in acetonitrile (solvent B).  All the analytes were baseline-separated within 6.0 
min using a flow rate of 0.35 mL/min.  Mass spectrometry detection was carried out in 
positive electrospray ionization mode. 
The calibration curves for all the analytes were linear (R≥0.9964, n=3) over the 
concentration range of 0.1-100 ng/mL for RST and RST-LAC, and 0.5-100 ng/mL for 
DM-RST.  Mean extraction recoveries ranged within 88.0-106%. Intra- and inter-run 
mean percent accuracy were within 91.8-111% and percent imprecision was ≤15%.  
Stability studies revealed that all the analytes were stable in matrix during bench top (6 h 
on ice-water slurry), at the end of three successive freeze and thaw cycles and at -80 °C 
for 1 month.  The method was successfully applied in a clinical study to determine the 
concentrations of RST and the two metabolites over 12-h post-dose in patients receiving 
rosuvastatin. 
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Introduction 
Rosuvastatin acid (RST) is a synthetic and relatively hydrophilic lipid lowering agent [1].  
It is widely used to treat hypercholesterolemia and to prevent progression of coronary 
artery diseases.  Rosuvastatin decreases the concentration of low-density lipoprotein-
cholesterol by reversible, competitive inhibition of 3-hydroxy-3-methylglutaryl-
coenzyme A, the rate-liming reductase enzyme that is responsible for cholesterol 
biosynthesis [1].  It is one of the most effective and potent statins due to its unique 
characteristics such as selective uptake into hepatocytes, superior binding affinity, and 
tight binding interaction at the enzyme active site [2]. 
Rosuvastatin (Crestor
®
, AstraZeneca, Wilmington, DE, USA) is available as 5-40 mg 
tablets.  It is orally administered as a calcium salt of the active hydroxy acid form with an 
absolute oral bioavailability of ~20%.  Parent RST is biotransformed to two metabolites: 
rosuvastatin-5S-lactone (RST-LAC, inactive metabolite) and N-desmethyl rosuvastatin 
(DM-RST, active metabolite) [3] primarily by cytochrome P450 (CYP) 2C9, and to the 
lesser extent, by CYP 2C19, and CYP 3A4 isoenzymes [1].  Up to 50% of HMG-CoA-
reductase inhibitor activity of RST has been attributed to DM-RST [3].  The chemical 
structures of RST and its two metabolites are shown in Figure III-1.  After a single oral 
dose of RST, 90% of the dose was recovered in feces and 77% of the dose was excreted 
unchanged as the parent drug [3].  After an oral dose of 20 mg, the average peak plasma 
concentrations (Cmax) of RST was ~6 ng/mL [3].  The average Cmax values for RST-LAC 
and DM-RST were 12–24% and <10% of the parent RST Cmax, respectively [3]. 
Statins are generally well tolerated.  However, skeletal muscle toxicity is the major 
adverse effect associated with statin treatment that results in decreased adherence to the 
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therapeutic regimen.  In addition, a few cases of RST-induced fatal rhabdomyolysis have 
been reported to date [4].  Several hypotheses based on depletion of the products of the 
mevalonate pathway have been proposed to explain the molecular mechanism of statin-
related myopathy; though, the underlying mechanism for statin-induced myopathy has 
not been fully elucidated [5].  A clinical pharmacokinetic (PK) study of atorvastatin [6] 
proposed higher concentration of atorvastatin metabolites, as one of the possible 
mechanisms for statin-associated myopathy.  In addition, an in vitro study [7] indicated 
that the lactone forms of statins are more myotoxic as compared to their respective acid 
forms.  No information is currently available on the association between RST metabolite 
concentrations and drug related adverse effects. 
To date, several methods have been reported for the quantification of parent RST.  These 
methods have utilized high-performance liquid chromatography with ultra-violet 
detection (HPLC-UV) [8,9] or liquid chromatography-tandem mass spectrometry (LC-
MS/MS) [10-18] techniques.  The maximum plasma concentration of RST is usually 
below 10 ng/mL [19]; thus, a sensitive analytical method is required for the quantification 
of RST in human plasma.  Previously reported HPLC-UV methods are less sensitive with 
a lower limit of the quantification (LLOQ) in µg/mL levels and also are more time 
consuming [8,9].  Quantification of RST and its metabolites in biological fluids is 
important with respect to understanding either the PK characteristics or 
pharmacological/toxicological properties. Specifically, the quantification of statin lactone 
may prove to have some diagnostic value as a possible marker for the development of 
myopathy.  However, only two methods were previously reported for the quantification 
of DM-RST metabolite in human plasma, including individual estimation of DM-RST 
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[11] and simultaneous estimation of RST and DM-RST [15]. To the best of our 
knowledge, currently no published bioanalytical method has described a fully validated 
LC-MS/MS assay for the quantification of RST-LAC metabolite in human plasma. 
Rosuvastatin lactone is highly unstable and the possible interconversion between lactone 
and acid forms can be minimized by lowering the working temperature to 4 °C and 
plasma pH to 4-6.  Liquid-liquid and solid phase extractions usually involve time-
consuming extraction steps such as drying and the addition of pH modifiers, which in this 
case may lead to undesirable acid-lactone interconversion. Several methods employed 
solid phase extraction for sample purification utilizing expensive automated 
[11,12,15,20] or manual manifold [16].  Plasma samples were concentrated more than 
two times in these methods to achieve adequate LLOQ [11,12,20,16].  Some methods 
have utilized traditional one or multi step liquid-liquid phase extraction for sample clean 
up using solvents such as ethyl-ether [10,18], methyl-tertiary-butyl ether [13] and ethyl 
acetate [17] and typically report low recovery.  Lan et al. used tetrabutyl ammonium 
hydroxide (TAH) for ion pair liquid-liquid extraction to improve lipophilicity of RST; 
however, reported mean recoveries ranged within 47.5-62.2 % [21].  Moreover, addition 
of TAH to plasma may change its relatively neutral pH to a more alkaline pH; this 
condition may favor interconversion between lactone and acid forms in clinical samples.  
Most of the methods require a large sample volume (500 µL-1,700 µL) [10-14,8,21]. 
We report, for the first time, a fully validated LC-MS/MS assay for the simultaneous 
quantification of RST and its two metabolites, RST-LAC and DM-RST in a small volume 
(50 µL) of buffered human plasma. 
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Experimental 
Reagents and chemicals 
RST, RST-LAC, DM-RST and corresponding deuterium labeled internal standards (IS), 
d6-RST, d6-RST-5S-lactone and d6-DM-RST were obtained from Toronto Research 
Chemicals Inc. (North York, ON, Canada).  HPLC-grade acetonitrile and glacial acetic 
acid were purchased from Fisher Scientific (Fair Lawn, NJ, USA).  HPLC-grade 
deionized water was purified with a Milli Q50 (Millipore, Bedford, MA, USA) water 
purification system.  Sodium acetate trihydrate (99%) and methanol d1 (CH3OD) were 
obtained from Sigma-Aldrich (St. Louis, MO, USA).  HPLC-grade methanol was 
purchased from Pharmco Products Inc. (Brookefield, CT, USA).  Drug-free human 
plasma, with heparin as an anticoagulant, was obtained from Bioreclamation Inc. 
(Westbury, NY, USA). 
Chromatographic conditions 
The analytical column was a Zorbax-SB Phenyl, Rapid-Resolution HT (2.1 mm×100 
mm) with 3.5-µm particle size from Agilent Technologies (Wilmington, DE, USA), 
preceded by a 0.5 µm filter (Supelco, Bellefonte, PA).  The column was maintained at 40 
°C.  Mobile phase, consisting of gradient mixture of 0.1% v/v glacial acetic acid in 10% 
v/v methanol in water (solvent A), and 40% v/v methanol in acetonitrile (solvent B), was 
used at a flow rate of 0.35 mL/min for separation and rapid elution of the analytes from 
the extracted matrix within 6.0 min.  The following mobile phase gradient scheme was 
used: 
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Mass spectrometric conditions 
The LC-MS/MS system consisted of an Agilent Technologies 1200 series HPLC system 
comprising of a binary pump, an autosampler, a thermostatted column compartment, and 
a micro-vacuum degasser (Santa Clara, CA).  The LC was coupled to an API 4000™ 
triple quadrupole mass spectrometer (AB Sciex, Toronto, Canada), equipped with Turbo 
V™ source. 
Triple-quadrupole MS/MS detection and the quantification of all the analytes were 
carried out in positive electrospray ionization mode using multiple-reaction monitoring 
(MRM) scan.  Q1 and product ion scans were obtained by infusion of the individual 
analytes and the IS solutions using an infusion pump.  The following MRM transitions 
(m/z, Q1 →Q3) were selected: RST (m/z, 482.2→ 258.2), d6-RST (m/z, 488.2→264.2), 
RST-LAC (m/z, 464.2→270.2), d6-RST-LAC (m/z, 470.2→ 276.2), DM-RST (m/z, 
468.2→258.2), and d6-DM-RST (m/z, 474.2→264.2) for the best sensitivity and 
minimum interference from matrix components.  The compound specific parameters i.e. 
declustering potential (DP), entrance potential (EP), collision cell exit potential (EXP) 
and collision energy (CE) were optimized to achieve maximum signal.  Source 
parameters were set at curtain gas (CUR=20 psi), gas 1 (GS1=45 psi), gas 2 (GS2=20 
psi), and collision gas (CAD=12 psi), ionspray voltage (IS=5500 V), and temperature 
 Total Time (min)  A (%) B (%) 
 0.00  90 10 
 0.30  40 60 
 0.80  40 60 
 4.50  25 75 
 4.51  90 10 
 6.00  90 10 
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(TEM=450 °C) to achieve the optimal signal.  Peak areas were obtained using AB SCIEX 
Analyst® 1.5.1 data processing software. 
Preparation of standards and quality control solutions 
Separate stock solutions of RST (1.00 mg/mL), and DM-RST (1.00 mg/mL) were 
prepared in methanol, while RST-LAC (0.50 mg/mL) was prepared in acetonitrile.  
Lactone forms ester by reaction with alcohols such as methanol. Thus, methanol was 
avoided in the preparation of the stock solution of the lactone compounds [22,23]. 
Intermediary individual stock solutions containing 100 µg/mL concentration of RST, 
DM-RST or RST-LAC were prepared in respective solvents and were used to spike 
calibrators and quality control (QC) samples (QCs) in buffered plasma kept on ice-water 
slurry.  Drug-free heparin human plasma diluted 1:1 with 0.1 M, pH 4.0 sodium acetate 
buffer was used to prepare calibrators and QCs samples. 
Individual stock solutions of 1.0 mg/mL of d6-RST and d6-DM-RST were prepared in 
CH3OD to avoid deuterium-hydrogen exchange.  Stock solution of 1.0 mg/mL of d6-
RST-LAC was prepared in acetonitrile.  An intermediary IS solution containing 1 µg/mL 
of each IS was prepared in CH3OD. 
All stock and working standard solutions were stored at -20 °C until use.  Eight 
calibration standards with concentrations ranging from 0.1 ng/mL to 100 ng/mL for RST 
and RST-LAC and 0.50 ng/mL to 100 ng/mL for DM-RST and QC samples at four 
concentration levels (0.10, 0.50, 7.50, and 76.0 ng/mL for RST and RST-LAC and 0.50, 
2.50, 10.0 and 76.0 ng/mL for DM-RST) were prepared in drug-free buffered human 
plasma by using respective spiking solutions and were stored at -80 °C. 
Sample extraction 
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Calibrators, QCs, zero standard, double blank and buffered patient samples were thawed 
on ice-water slurry and vortex-mixed thoroughly for 10 seconds.  A 50-μL aliquot of each 
buffered plasma sample was aliquoted into 1.5 mL polypropylene tube; all samples were 
treated with 200 μL of 0.1% acetic acid in methanol (as a protein precipitation solvent) 
containing 2.00 ng/mL of d6-RST, 2.00 ng/mL of d6-RST-LAC and 20.0 ng/mL of d6-
DM-RST except double blank.  All tubes were vortex-mixed for 10 seconds and 
thereafter, centrifuged for 15 min at 14000xg and 4 °C.  The supernatant was transferred 
to a clean glass vial and 15 μL was injected onto LC-MS/MS. 
Validation of the assay 
The validation of the method was performed according to general recommendation 
guidelines for bioanalytical methods by the United States Food and Drug Administration 
[24].  Validation parameters including selectivity, sensitivity, accuracy, precision, 
recovery, matrix effect and stability were determined.  The accuracy of calibration 
standards and QC samples (n≥5) should be within 85-115%, and imprecision should not 
exceed 15%, except at the LLOQ level, for which accuracy may be within 80-120% and 
imprecision should not exceed 20%. 
Stability. Stability studies aimed to establish the conditions in which the degree of 
interconversion between acid and lactone was minimal. The first set of QC samples 
contained composite mixture of all the three analytes.  In the second set, QC samples 
contained only RST and N-desmethyl RST.  The third set comprised only RST-LAC.  All 
three sets of QC samples were prepared at low-level quality control (LQC), 0.50 ng/mL 
for RST and RST-LAC and 2.50 ng/mL for DM-RST and high- level quality control 
(HQC), 76.0 ng/mL for all the three analytes concentration levels. 
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1. Post-preparative stability (autosampler stability): The capability of injecting 
processed samples after being kept in the autosampler at 4°C, was tested by 
reinjecting one of the three validation runs 24 h after extraction. 
2. Bench-top stability: Triplicate LQC and HQC kept on ice-water slurry for 6 h were 
extracted along with freshly spiked calibrators. 
3. Long-term stability: It was established for up to 1 month at -80 °C by analyzing six 
replicates of LQC and HQC, after 1 week and 1 month. 
4. Freeze and thaw stability: Freshly spiked triplicates of LQC and HQC were prepared 
and stored at -80 °C for 24 h and were thawed on ice-water slurry.  At the end of three 
successive freeze and thaw cycles, QC samples were extracted along with freshly 
spiked calibrators and QCs samples. 
Linearity, accuracy, and precision.  Eight-point calibration curves were obtained using 
0.10, 0.20, 2.00, 10.0, 25.0, 50.0, 90.0, and 100 ng/mL for RST and RST-LAC and 0.50, 
1.00, 5.00, 15.0, 30.0, 50.0, 90.0 and 100 ng/mL for DM-RST calibrators.  All 
calibrators, six replicates of first set of QC samples at four concentration levels, double 
blank (without the IS), and zero standard (with the IS) were tested in three runs to 
evaluate intra-run and inter-run precision and accuracy of the method. 
Limit of detection and quantification.  LLOQ is defined as the lowest concentration of an 
analyte, which has at least five times higher response (signal-to-noise, S/N=5/1) 
compared with blank response and can be analyzed with an acceptable accuracy and 
imprecision (accuracy within 80-120% and imprecision ≤ 20%).  Five serial dilutions of 
buffered plasma samples containing 0.500 ng/mL of RST and RST-LAC and 2.50 ng/mL 
of DM-RST were made by mixing equal volumes of spiked buffered plasma with 
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buffered blank plasma.  Six replicates of each spiked sample were extracted, and S/N of 
peak and percent CV of the analyte/IS ratio were calculated.  The sample with a S/N of at 
least five and percent CV below 20% for each analyte was selected as potential LLOQ 
for the validation. 
Selectivity.  The presence of endogenous matrix components that may interfere with the 
quantification of the analytes or the IS was evaluated using drug-free human buffered 
plasma containing heparin as anticoagulant (from six donors).  The analytes and the IS 
responses in extracted selectivity samples were compared with the chromatograms 
obtained from LLOQ samples containing all the three analytes. 
Recovery and matrix effect.  Triplicates of LQC and HQC from first set of QC samples 
along with blank buffered plasma samples were extracted and were used to evaluate 
recovery and matrix effect (enhancement or suppression of ionization).  Solutions with 
concentrations equivalent to 100% recovery of extracted LQC (0.5 ng/mL for RST and 
RST-LAC and 2.5 ng/mL for N-desmethyl RST) and HQC (15.2 ng/mL) containing all 
the analytes and the IS were prepared in water / 0.1% acetic acid in methanol, 1:4 (v/v; 
reference for matrix effect) and in extracted blank buffered plasma (reference for 
recovery). 
In addition, matrix effect was also evaluated using a post-column infusion method.  This 
test was performed by infusing a solution containing 20 ng/mL of the analytes and the IS 
prepared in solvent A/solvent B (30:70 v/v) at 10 µL/min along with injections of the 
blank solvent, double blank matrix extract, and extracted HQC to identify the regions of 
ionization suppression.  To investigate the potential interference from co-administered 
medications and their metabolites specific to the kidney transplant population, a pooled 
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buffered plasma sample was prepared from the three kidney transplant patients treated 
with tacrolimus, mycophenolic acid, and prednisone but not with RST.  The pooled 
sample was obtained by mixing equal volumes of plasma (diluted 1:1 with 0.1 M, pH 4.0 
sodium acetate buffer) from samples collected 1, 2, 4, 8, and 12 h after the morning dose 
of the co-administered medications.  The pooled buffered plasma sample was spiked with 
working standard solution of analytes at LQC level, and six replicates were extracted 
along with calibration calibrators, QCs samples, and a non-spiked pool. 
Application of the method in a pharmacokinetic study 
The assay was utilized in a preliminary PK study aiming to study disposition of RST in 
the kidney transplant recipients.  The study protocol was approved by the Institutional 
Review Board of Rhode Island Hospital, Providence, RI, USA.  Written informed 
consent was obtained from all subjects after verbal explanation of the study protocol.  
The blood samples were collected at various time points during a period of 12 h post-
dose from the four kidney transplant recipients treated with 20 mg of a single oral dose of 
Crestor® along with a triple immunosuppressive regimen including oral tablets of 
tacrolimus, mycophenolate mofetil and prednisone as well as several other medications 
including proton pump inhibitors, antidiabetic agents, antibacterial agents, levothyroxin 
and cardiovascular drugs.  Plasma sample was separated from whole blood with heparin 
as an anticoagulant at 1,500xg for 15 minutes and were immediately buffered with an 
equal volume of 0.1 M sodium acetate buffer (pH 4.0). 
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Results and discussion 
Sample preparation, chromatography and MS detection 
Various reverse phase analytical columns were tested.  The required selectivity, as well 
as excellent peak shape (in terms of sharpness and symmetry), were achieved using a 
narrow bore Zorbax-SB phenyl column.  This column exhibited good stability under a 
low pH mobile phase, and capability to decrease run times.  Due to good peak focusing, 
the high S/N ratio obtained using this column enabled us to use a simple protein 
precipitation extraction without performing pre-concentration steps during sample clean 
up. 
Methanol was chosen over acetonitrile as a precipitating agent because it provides 
excellent peak shape and resulted in an optimal signal of the analytes.  Non-acidified 
methanol as a precipitating agent led to significant interconversion of lactone to acid 
form during the resident time of the extracted samples in the autosampler.  Therefore, 
0.1% glacial acetic acid in methanol was used to minimize the interconversion of lactone 
to acid and vice versa.  Rapid elution of the analytes using a gradient mixture of mobile 
phase was obtained within a 6.0 min run time, including the re-equilibration time of the 
column.  The retention times of RST, RST-LAC, and DM-RST were 3.3, 2.8 and 3.8 
min, respectively (Figure III-2). 
The MS/MS detection for RST can be achieved both in positive and negative ion mode, 
as it contains carboxyl and tertiary amine groups.  Few of the published methods [10,15] 
suggested the use of a negative ion mode for the determination of RST to achieve a better 
LLOQ.  We observed high signal intensity when using electrospray in positive ion mode, 
therefore, all analytes and the IS were monitored in positive ion mode.  Rosuvastatin acid 
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gave its precursor ion at m/z 482.2.  The principal product ion for RST was at m/z 258.2, 
with two minor fragments at m/z 300 and m/z 272. The most abundant product ion for 
DM-RST was at m/z 258.2 therefore, m/z 468.2→258.2 was chosen for the MRM 
transition. The structures of major product ions of RST and DM-RST monitored are 
shown in Figure III-1b [11,12]. For RST-LAC, the most intense product ion was at m/z 
270.2 and minor was at m/z 282.2 and thus transition of m/z, 464.2→270.2 was selected.  
The proposed structure of major product ion of RST-LAC monitored is illustrated in 
Figure III-1b. 
Method validation 
The analytes were stable in the conditions described above. The post-preparative stability 
assessment proved the stability of extracted samples at 4°C for 24 h post-extraction, the 
anticipated resident time in the autosampler.  No interconversion of analytes had occurred 
when they were monitored by re-injecting the HQCs spiked with each compound 
individually after 24 h. The analytes were found stable after three cycles of freeze and 
thaw and during bench top stability carried out on ice-water slurry (Table III-1a).  
Stability of all the three analytes was tested in various conditions such as non-buffered 
human plasma and buffered human plasma (human plasma diluted 1:1 with 0.1 M, pH 
4.0 sodium acetate buffer).  Rosuvastatin acid and DM-RST were found stable in both 
kinds of plasma but approximately 25% loss of RST-LAC occurred in non-buffered 
plasma after 1 month storage at -80 °C (Table III-1b).  Interconversion of acid to lactone 
or vice versa was also negligible in the buffered plasma.  For the proposed assay 
validation, plasma was diluted 1:1 with 0.1 M, pH 4.0 sodium acetate buffer.  No 
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interference was observed from endogenous components with the analytes and the IS in 
blank buffered plasma from six different donors, proving the specificity of the method.  
The calibration curves obtained from the analyte/IS peak area ratios vs. nominal 
concentration were linear using weighted (1/x
2
) linear least squares regression over the 
concentration range, with correlation coefficients (R) ≥ 0.9964. The measured mean 
values (n=3) were within 92.4-111% of their nominal values for calibrators (Table III-2), 
88.7-109% for intra-run QCs samples (results not presented), and 91.8-105% for inter-run 
QCs samples (Table III-3), which proves acceptable accuracy of the proposed method. 
A LLOQ of 0.1 ng/mL was achieved for RST and RST-LAC, and 0.5 ng/mL for DM-
RST. Chromatograms of an extracted LLOQ and blank plasma are shown in Figure III-
2a and 2b, respectively.  The mean extraction recoveries for all the analytes were within 
88.0-106%, as shown in Table III-1a.  No significant matrix effect was observed for 
each analyte upon calculating the ratio of average area response of reference for recovery 
to reference for the matrix effect at LQC and HQC concentration levels. 
Matrix effect is defined as the effect of co-eluting matrix components on ionization 
efficiency of the target analyte.  Hence, suppression or enhancement of analyte response 
may have deleterious effects both on sensitivity and on the reproducibility of a particular 
assay.  The integrity of resulting data could be adversely affected by lack of specificity, 
selectivity, accuracy and precision and may not be absolute [25].  Evaluation of the 
matrix effect is essential to insure reliability of quantitative assays using HPLC-MS/MS, 
and the integrity of PK data.  Hence, the matrix effect was thoroughly studied as required 
by the FDA guidelines.  We used the stable isotope labeled IS for each of the analytes, as 
they compensate reasonably well during variations in sample analysis.  However, due to 
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their slightly different elution times compared with their respective non-labeled species, 
the deuterated internal standards IS may not always compensate for ionization 
enhancement or suppression due to co-elution of matrix endogenous components, such as 
phospholipids [26]. Phosphatidylcholine and lyso-phosphatidylcholine are the major 
phospholipids in human plasma causing significant matrix effect.  Zhang et al. reported 
the key phospholipids in human serum extracts that can cause matrix effects by 
identifying the precursor ions generating fragment with m/z 184 [27]. Following the same 
technique, we determined the retention times of phospholipids with MRM transitions: Q1 
m/z 496, 520, 522, 524, 544, 758 and 782 and Q3 m/z 184. We adjusted the 
chromatographic conditions to ensure that the analytes do not co-elute with the 
phospholipids. 
To study the matrix effect, a post-column infusion of a solution containing the analytes 
and the IS, concomitantly injected with extracted blank matrix, was carried out.  We 
monitored retention times of the major phospholipids, and we found that no significant 
ion suppression occurred at the retention times of the each analyte and the IS (data are not 
shown). The post-column infusion chromatogram shown in Figure III-3a indicates that 
RST and metabolites were eluted at retention times different from the retention times of 
key phospholipids. This shows that the signal intensity of each analyte of interest does 
not change in the region of their respective elution period (Figure III-3b).  No significant 
matrix effect was observed for each analyte upon calculating the ratio of average area 
response of reference for recovery to reference for the matrix effect at LQC and HQC 
concentration levels. 
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The mean of the calculated concentrations of six LLQC samples prepared in pooled 
buffered plasma from patients treated with an immunosuppressive regimen and who did 
not receive RST was between 91–96% of the expected nominal concentration.  No 
interfering peaks were eluting at the retention times of the analytes of interest. This 
demonstrates that tacrolimus, mycophenolic acid, prednisone and their metabolites do not 
affect the quantification of RST and its metabolites. 
Application of the method 
The present method was successfully applied in a clinical study for quantitative 
determination of RST and lactone metabolite over 12 h post-dose in the stable kidney 
transplant recipients after receiving a single dose of rosuvastatin. Individual plasma 
concentration-time profiles of RST and RST-LAC (12 h post-dose) are shown in Figure 
III-4a and 4b, respectively. The plasma concentrations for DM-RST are not shown in 
the figure as these concentrations were below the LLOQ for most of the time points. 
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Conclusion 
In summary, we describe a reproducible, reliable, sensitive, and simple bioanalytical 
technique for the simultaneous determination of RST and metabolites in human plasma. 
The major advantages of the present method are the requirement for small plasma volume 
(50 µL) and simple sample preparation. 
The proposed validated bioanalytical technique accomplishes the required LLOQ, 
accuracy, and precision to be applied in various studies involving PK, drug metabolism, 
clinical pharmacology/clinical toxicology, bioavailability/bioequivalence and drug-drug 
interactions for accurate quantitative analysis of RST and its metabolites. 
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Figure III-1a Structures of (i) rosuvastatin acid, RST (ii) N-desmethyl rosuvastatin, DM-RST and (iii) rosuvastatin-5S-
lactone, RST-LAC.  
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Figure III-1b Structures of major product ions (i) rosuvastatin acid, RST and N-desmethyl rosuvastatin, DM-RST and (ii) 
rosuvastatin-5S-lactone, RST-LAC. 
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Figure III-2a Chromatograms showing the integrated peaks of rosuvastatin acid (i), N-desmethyl rosuvastatin (ii), and 
rosuvastatin-5S-lactone (iii) from extracted buffered calibration standard at lower limit of the quantification (0.1 ng/mL for 
rosuvastatin acid and rosuvastatin-5S-lactone and 0.5 ng/mL for N-desmethyl rosuvastatin). 
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Figure III-2b Chromatograms of extracted double blank buffered human plasma (RT represents retention time), rosuvastatin 
acid channel (i), N-desmethyl rosuvastatin channel (ii), and rosuvastatin-5S-lactone channel (iii). 
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Figure III-3a Chromatogram obtained with post-column infusion shows no matrix effect at the retention times of the analytes 
and the IS. Arrow indicates region where the signal of compounds infused post-column is suppressed during the elution of 
endogenous matrix components. 
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Figure III-3b Chromatogram of a blank sample injected while the analytes and the IS are infused post column. Arrow 
indicates region where the signals of the analytes and the IS infused post-column are suppressed during the elution of 
endogenous matrix components. From top to bottom, rosuvastatin-5S-lactone, d6-rosuvastatin acid, d6-rosuvastatin-5S-
lactone, rosuvastatin acid, N-desmethyl rosuvastatin, d6-N-desmethyl rosuvastatin.  
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Figure III-4a Individual plasma concentration-time profiles of rosuvastatin acid of the stable 
kidney transplant recipients (n=4) who received a single oral dose of 20 mg of rosuvastatin. 
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Figure III-4b Individual plasma concentration-time profiles of rosuvastatin-5S-lactone of the 
stable kidney transplant recipients (n=4) who received a single oral dose of 20 mg of 
rosuvastatin. 
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Table III-1a. Results of stability studies and recovery (mean±%CV, n=3). 
Analyte 
Sample 
ID 
Freeze & 
Thaw 
 
Bench 
top 
 
Autosampler 
stability 
 
Recovery 
Rosuvastatin (RST) 
LQC 107±3.8 99.0±12 111±7.0 106±5.5 
HQC 98.7±2.1 105±3.0 107±0.7 88.0±4.1 
Rosuvastatin-5S-
lactone (RST-LAC) 
LQC 101±14 98.3±12 95.6±3.4 98.8±10 
HQC 106±7.4 109±5.6 105±2.9 89.0±3.1 
N-desmethyl 
rosuvastatin (DM-
RST) 
LQC 103±7.4 105±3.6 114±8.1 99.3±1.5 
HQC 106±3.0 108±3.9 107±2.5 90.2±4.5 
 
 
Table III-1b. Stability studies after 1 week and 1 month at -80 °C (mean±%CV, n=3). 
Analyte 
Sample 
ID 
after 1 week at -80 °C after 1 month at -80 °C 
Buffered 
plasma 
Non-
buffered 
plasma 
Buffered 
plasma 
Non-
buffered 
plasma 
Rosuvastatin (RST) 
LQC 94.4±3.7 95.8±12 98.8±5.4 100 ±5.2 
HQC 95.4±5.9 97.6±5.5 103±3.0 93.4±4.5 
Rosuvastatin-5S-
lactone (RST-LAC) 
LQC 99.4±3.1 81.5 ±12 105±1.9 74.8±6.1 
HQC 104 ±12 84.2 ±5.6 95.6±8.9 75.2±3.1 
N-desmethyl 
rosuvastatin (DM-
RST) 
LQC 93.0±1.9 95.9 ±11 108 ±1.6 109±5.6 
HQC 92.7±5.7 95.9 ±5.7 94.6±0.6 92.0±8.9 
 
% accuracy= (mean concentration/nominal concentration) x100 
%CV calculated as (standard deviation/mean) x100 
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Table III-2. Summary of standards and calibration curve parameters from three individual runs. 
Analyte  STD 1 STD 2 STD 3 STD 4 STD 5 STD 6 STD 7 STD 8  R 
Rosuvastatin 
(RST) 
STD (ng/mL) 0.10 0.20 2.00 10.0 25.0 50.0 90.0 100   
%Accuracy 102 96.6 93.0 101 97.3 111 102 97.8  0.9964 
%CV 4.8 10 2.7 5.5 9.7 3.6 2.1 9.6   
Rosuvastatin-5S-
lactone  
(RST-LAC) 
STD (ng/mL) 0.10 0.20 2.00 10.0 25.0 50.0 90.0 100   
%Accuracy 102 96.3 101 102 98.2 101 98.5 102  0.9980 
%CV 0.6 0.9 5.9 3.9 4.6 5.8 1.2 9.6   
N-desmethyl 
rosuvastatin 
(DM-RST) 
STD (ng/mL) 0.50 1.00 5.00 15.0 30.0 50.0 90.0 100   
%Accuracy 100 101 92.4 99.4 100 101 107 99.2  0.9980 
%CV 1.4 1.8 6.2 4.0 4.5 5.2 6.3 5.6   
 
n = 3 (one replicate for each of the three validation runs) 
% accuracy= (mean concentration/nominal concentration) x100 
%CV calculated as (standard deviation/mean) x100 
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Table III-3. Summary of quality control samples from three individual runs. 
 
n = 18 (six replicates for each validation run) 
% accuracy= (mean concentration/nominal concentration) x100 
%CV calculated as (standard deviation/mean) x100 
Analyte   Quality control samples  
Rosuvastatin (RST) 
QC (ng/mL) 0.10 0.50 7.50 76.0  
%Accuracy 96.8 105 97.5 99.0  
%CV 13 11 9.9 6.8  
Rosuvastatin-5S-lactone (RST-LAC) 
QC (ng/mL) 0.10 0.50 7.50 76.0  
%Accuracy 97.0 91.8 93.6 101  
%CV 10 12 8.1 6.3  
N-desmethyl rosuvastatin (DM-RST) 
QC (ng/mL) 0.50 2.50 10.0 76.0  
%Accuracy 102 101 95.3 93.1  
%CV 15 12 9.2 8.2  
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Abstract 
Aim: Atorvastatin calcium (Lipitor®, Pfizer Pharmaceuticals, NY) is an 
antihyperlipidemic agent from the statins class of drugs is the top-selling prescribed 
medication in the prevention and treatment of cardiovascular disorders. The aim of the 
present study was to develop a combined parent-metabolite population pharmacokinetic 
(PK) model of atorvastatin acid (ATV) and to investigate potential associations between 
clinical and demographic covariates on the population PK parameters.  
Subjects and methods: Atorvastatin parent and metabolite plasma concentrations (1-11 
per patient) of one hundred and thirty two, male or female non-transplant (diabetic, n=46; 
non-diabetic, n=53) or the stable kidney transplant recipients (diabetic, n=22; non-
diabetic, n=11) who administered single or multiple oral doses of atorvastatin calcium 
were included in the study. Plasma concentrations of ATV and atorvastatin lactone 
(ATV-LAC) were quantified using previously validated liquid chromatography-tandem 
mass spectrometry assay. A total of 639 concentrations including both an acid (n=322) 
and lactone (n=317) forms of atorvastatin were analyzed by nonlinear mixed-effects 
modeling approach (NONMEM
®
, version 7.2.0) to identify the influence of patients’ 
specific characteristics on PK properties of both the parent drug and its lactone 
metabolite. The first-order conditional estimation with interaction method was used to fit 
the data. The inter-subject variability was assessed using additive, exponential and 
proportional models. Likewise, the residual variability was evaluated using additive, 
exponential, proportional and combined additive-proportional error models. The 
influential covariates affecting pharmacokinetic parameters of both the parent and major 
metabolite were examined thorough PLT Tools (PLTsoft, San Francisco, CA, USA). A 
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stepwise covariate model building approach, forward addition (<3.84, p<0.05, df=1) 
followed by backward elimination (≥7.9, p<0.005) was used. The final model was 
validated using visual predictive check and nonparametric bootstrap analysis (n=1000). 
Results: Pharmacokinetic characteristics of ATV and ATV-LAC were well described 
using a two-compartment model with first-order oral absorption and a one-compartment 
with linear elimination, respectively with some degree of interconversion between the 
two forms.  
The inter-individual and the residual variability of pharmacokinetic parameters for both 
the parent drug and metabolite were modeled using an exponential and proportional error 
model, respectively. The population mean estimates of the final model parameters 
including absorption rate constant (Ka), apparent volume of distribution of ATV in the 
central compartment (V2/F), apparent oral clearance of ATV to ATV-LAC (CL/F),  
apparent volume of distribution of ATV in the peripheral compartment (V3/F), apparent 
inter-compartmental clearance of ATV (Q/F), apparent oral clearance of ATV-LAC to 
ATV (CLM/F), apparent volume of distribution of ATV-LAC in the central compartment 
(VM/F) and apparent inter-compartmental clearance of ATV-LAC (QM/F) were 0.771 h
-1
, 
481 L, 1126 L/h, 5462 L, 343 L/h, 506 L/h, 2349 L and 748 L/h, respectively.  
The goodness-of-fit plots indicated good agreement between observed and individual as 
well as population predicted plasma concentrations of the parent and metabolite. In this 
study, we found renal transplantation, lactate dehydrogenase (LDH) liver enzyme and 
gender as the significant covariates, respectively for clearance and volume of distribution 
of ATV-LAC. Renal transplant recipients had 50% lower metabolite clearance compared 
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to non-transplant patients. The bootstrap analysis and visual predictive check 
demonstrated robustness of the present population pharmacokinetic model. 
 
Conclusion: In summary, a combined parent-metabolite population pharmacokinetic 
model of ATV was developed. The pharmacokinetic analysis indicated significantly 
reduced clearance of lactone metabolite in the stable kidney transplant recipients. Greater 
risk of statin-related skeletal muscle toxicity is possibly because of decreased clearance 
of lactone metabolite. This finding should be taken into account while prescribing ATV 
treatment in the kidney transplant population who have additional co-morbidities and are 
on multiple interacting medications.  
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Introduction  
Chronic kidney disease (CKD) is a major health issue that is common among the adult 
population in the United States. It is an irreversible and progressive disease, and if left 
untreated, chronic renal failure can advance to end stage renal disease. Chronic kidney 
disease is ranked as the eighth leading cause of death in the United States. At present, 
more than 20 million people are suffering from CKD in the United States [1]. Moreover, 
more than 35% of adults with diabetes, another growing global burden of diseases, have 
CKD [1]. 
Patients with CKD are at significantly greater risk of cardiovascular diseases mainly 
because of higher prevalence of diabetes mellitus, oxidative stress [2] and lipid 
abnormalities [3]. Statins [3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase inhibitors] class of lipid lowering drugs are the choice of treatment for 
cardiovascular disorders in patients with or at a risk of CKD due to potential benefits 
attributed to its cardioprotective and nephroprotective properties [4]. Statins block 
cholesterol biosynthesis by reversible and competitive inhibition of the rate limiting 
enzyme, HMG-CoA reductase. A calcium salt of atorvastatin acid (ATV) (Lipitor®, 
Pfizer Pharmaceuticals, NY) is the best-selling statin of all time. It is administered as an 
active acid form, which undergoes extensive first-pass effect after oral administration [5]. 
Atorvastatin acid is extensively metabolized mainly by intestinal and liver cytochrome 
P450 (CYP) 3A4/5 and generates pharmacologically active ortho and para hydroxylated 
metabolites [6]. The parent drug and its active acid metabolites remain in equilibrium 
with their respective inactive lactone forms [7]. Atorvastatin lactone (ATV-LAC) has 83 
fold greater affinity for CYP3A4 and exhibits higher metabolic clearance [6]. The 
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formation of lactone form is attributed to the glucuronidation metabolic pathway, which 
is mediated through UDP-glucuronosyltransferases (UGT) 1A1 and predominantly 
through 1A3 [8]. The enzymatic interconversion between acid and lactone forms is 
governed by esterases, paraoxonase (PON), UGT1A1 and 1A3 enzymes [8, 9]. 
Organic anion-transporting polypeptide (OATP) uptake transporters, OATP1B1 and 
OATP1B3, play a major role in the hepatic uptake of ATV and its metabolites [5]. 
Atorvastatin acid and its metabolites are also substrates of efflux transporters including P-
glycoprotein (P-gp) [10] and breast cancer resistant protein (BCRP), which govern their 
intestinal absorption and liver elimination [11]. 
Statins are well tolerated; however, statin-related minor or severe skeletal muscle toxicity 
is the common adverse effect associated with statin therapy [12]. Several factors such as 
concomitant medications, metabolic disorders and hepatic or renal function aggravate the 
risk of statin-induced muscle complaints [13]. Hermann and colleagues [14], revealed 
significantly higher levels of ATV-LAC metabolite in patients experiencing statin-
associated myopathy. Moreover, an in vitro study, using primary human skeletal muscle 
cells showed that ATV-LAC had a 14-fold higher potency to induce myotoxicity as 
compared to its acid form [15]. Additionally, a previous study has indicated lactone/acid 
ratio measurement as a specific diagnostic tool for statin-induced muscle toxicity [16]. 
Genetic propensity of an individual is a likely factor in the altered pharmacokinetics (PK) 
that may result in statin-associated myopathy [13]. Genetic polymorphism associated 
with OATP1B1 and OATP1B3 (SLCO1B1 and SLCO1B3), P-gp (ABCB1), BCRP 
(ABCG2), bile salt export pump (ABCB11) and drug metabolizing enzymes (CYP and 
UGT) significantly affect ATV PK [17]. The extent of ATV-LAC formation is 
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significantly associated with UGT1A genetic polymorphisms that affect UGT1A3 
expression [18] while the reverse reaction, ATV-LAC hydrolysis is influenced by PON1 
and PON3 gene polymorphism [19]. 
Occurrences of severe rhabdomyolysis have been reported in patients with renal 
transplant because of concomitant use of statins with immunosuppressants and other 
medications [20-26] and associated co-morbidities. It is essential to investigate and 
interpret patients’ demographic characteristics, genetic polymorphism as well as 
physiological and pathological characteristics that significantly alter pharmacokinetic 
properties of parent drug and its major metabolite in the kidney transplant recipients who 
require lifetime treatment with several concomitant drugs including immunosuppressants 
and who are at greater risk of developing adverse effects. Assessment of such factors will 
allow clinicians to select the right dose of ATV for optimum therapy.  
The objective of this study was to develop a combined population PK model of ATV and 
ATV-LAC metabolite to allow the evaluation of chronic diseases, genetic polymorphisms 
as well as other patient specific characteristics.  
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Materials and methods 
 
Study design 
The open-label study was conducted in the kidney transplant and non-transplant 
recipients with and without diabetes mellitus at several study locations. The study 
protocol was approved by the Institutional Review Board of Rhode Island Hospital, 
Providence, RI, University of Rhode Island, Kingston, RI and South County Hospital, 
Wakefield, RI. The study procedures were explained verbally to the study participants, 
and thereafter their signed informed consent was obtained. All participants underwent 
normal physical examination on the day of the study and medical histories were 
documented for all study subjects. Except ten participants all were on steady state 
treatment with ATV in 5-80 mg dose range. 
 
Patient population 
The study population contained non-transplant (diabetic, n=46; non-diabetic, n=53) and 
the stable kidney transplant (diabetic, n=22; non-diabetic, n=11) recipients. Male (n=77) 
and female (n=55) participants over 18 years of age were included in the study. The 
subjects with congestive heart failure as defined by the New York heart association 
(NYHA) grades III and IV, liver dysfunction, pregnancy, undergoing active bacterial, 
fungal or viral infections, receiving CYP3A4/5 inhibitors or inducers were excluded from 
the study. The subjects with the kidney transplant were on a triple immunosuppressive 
drug regimen comprised of tacrolimus or sirolimus oral tablets, prednisone and 
mycophenolic acid either from mycophenolate mofetil (Cellcept™, Roche, Nutley, NJ) or 
mycophenolate sodium (Myfortic, Novartis, East Hanover, NJ). 
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Pharmacokinetic study 
Blood samples (6 mL) were collected at various time points over 24 h post-dose. The 
blood was collected by venipuncture in Vacutainer
®
 tube containing fluoride/potassium 
oxalate anticoagulant (Becton Dickinson, Franklin Lakes, NJ, USA). Plasma was 
separated by centrifugation at 1500xg and stored at -80°C until analysis. In addition to 
the PK study, additional blood samples were drawn to genotype each subject in EDTA 
Vacutainer
® 
tube
 
(Becton Dickinson, Franklin Lakes, NJ, USA) tube and stored in -80 °C 
until DNA extraction. 
 
Quantitative analysis of ATV and ATV-LAC in plasma 
Plasma levels of ATV and ATV-LAC were determined using a validated liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method [27]. Briefly, both the 
analytes and their corresponding deuterium (d5) labeled internal standards were extracted 
from 50 µL of human plasma using 200 µL of 0.1% v/v glacial acetic acid in acetonitrile 
as protein precipitating solvent. The chromatographic separation of analytes was 
achieved within 7.0 min using a Zorbax-SB Phenyl column (2.1 mm × 100 mm, 3.5 µm) 
with a flow rate of 0.35 mL/min. The mobile phase consisted of a gradient mixture of 
0.1% v/v glacial acetic acid in 10% v/v methanol in water (solvent A) and 40% v/v 
methanol in acetonitrile (solvent B). Mass spectrometry detection was carried out in 
positive electrospray ionization mode, with multiple reaction monitoring scan. The 
calibration curves for both analytes were linear (R
2 ≥ 0.9975, n=3) over the concentration 
range of 0.05-100 ng/mL.  
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Genetic polymorphism study 
Genomic DNA was extracted according to the procedure described in the manual using 
QIAGEN kit (QIAamp DNA Blood Mini Kit; Qiagen, Hilden, Germany). The subjects 
were genotyped for the following single nucleotide polymorphism (SNP):  
CYP3A4 In6 C>T (rs35599367), 
CYP3A5*3 219-237A>G (rs776746),  
ABCB1 1236C>T (rs1128503), 2677G>T, A (rs2032582), 3435C>T (rs1045642), 
ABCB11 1331C>T (rs2287622),  
ABCC2 -24C>T (rs717620), 1249G>A (rs2273697), 3972C>T (rs3740066),  
ABCG2 421C>A (rs2231142),  
SLCO1B1 388A>G (rs2306283), 521C>T (rs4149056), 
SLCO1B3 334T>G (rs4149117), 699G>A (rs7311358), 767G>C (rs60140950), 
PON1 -108T>C (rs705379), -832G>A (rs854571), -1741G>A (rs757158) and  
PON3 63C>T (rs13226149)  
by allelic discrimination with a TaqMan Drug Metabolism Genotyping Assay on an 
Applied Biosystems 7300 Real-Time PCR (Applied Biosystems, Foster City, CA). 
CYP3A4*1B -285A>G  (rs2740574) and UGT1A3*2  31T>C (rs3821242) and 140T>C 
(rs6431625) were genotyped by polymerase chain reaction amplification and the 
subsequent direct sequencing using Applied Biosystems 3130xl Genetic Analyzer 
(Applied Biosystems, Foster, CA) as described previously [28, 29]. 
 
Population PK analysis 
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Population pharmacokinetic analysis of plasma concentration-time profiles of ATV and 
its major metabolite, ATV-LAC were performed through nonlinear mixed effects 
modeling tool using NONMEM
®
 (version 7.2.0, ICON Development Solutions, Ellicott 
City, MD, USA) as described previously with modifications [30, 31]. A graphical user 
interface, PLT Tools (PLTsoft, San Francisco, CA, USA) was used to facilitate 
NONMEM analysis.  
To account differences in the molecular weight of ATV and metabolite, the 
concentrations of ATV-LAC were expressed as equivalent of the parent (the 
concentration of the metabolite was multiplied by the ratio of the molecular weights of 
ATV and ATV-LAC metabolite). Total of 639 concentrations (1-11 per patient) were 
included in the population PK analysis. 
The basic PK model of parent drug without covariates was developed by evaluating 
various PK models including one-, two- and three- compartment as well as different 
estimation methods including the first-order (FO), the first-order conditional estimation 
(FOCE) and the FOCE with interaction (FOCE-INTER). The inter-subject variability was 
assessed using additive, exponential and proportional models. Likewise, the residual 
variability was evaluated using additive, exponential, proportional and combined 
additive-proportional error models. 
The correct PK model was selected according to the following criteria:  (i) a minimum 
value of the objective function; (ii) a low estimate of between- and within-subject 
variability; (iii) physiological plausibility of the estimates; (iv) goodness-of-fit and (v) 
normal distribution of weighted residuals. 
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After the development of the base model for ATV, a combined parent-metabolite model 
was developed by incorporating lactone concentrations based on the previously described 
mechanism [6]. The mixed effects were determined from a combined model. The 
influential covariates affecting the PK parameters of parent and metabolite were 
examined through PLT Tools. Potential covariates were added one at a time and 
reduction in the objective function value, and between-subject variability along with 
improvement in the fit were recorded. The effect of continuous covariates including age, 
body weight, glycosylated haemoglobin (HbA1c), glucose, total bilirubin, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), 
lactate dehydrogenase (LDH), g-glutamyl transferase (GGT), cholesterol, high-density 
lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, serum 
creatinine, total protein and serum albumin on the PK parameter was modeled using a 
power model scaled to median covariate value of the population. On the other hand, the 
effects of categorical covariates including the presence diabetes mellitus status or renal 
transplant as well as gender, ethnicity, concomitant use of prednisone, mycophenolic 
acid, sirolimus, tacrolimus and genetic polymorphism were modeled using a proportional 
model. 
Forward stepwise addition of significant covariates was performed until no longer the 
objective function value was reduced (<3.84, p<0.05, df=1). These covariates were then 
incorporated in the base model to form the full model. Removal of each covariate from 
the full model was carried out in backward elimination method, and increase in the 
objective function value was examined. The covariate that increased the objective 
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function value by 7.9 or more (p<0.005) upon removal from the full model was retained 
in the model.  
The validation of the final model was performed to assess its stability and predictive 
performance using nonparametric bootstrap analysis and visual predictive check (VPC). 
Visual predictive check is based on model-simulated data predictions including random 
effects, which visually examine the distribution of observed plasma concentration-time 
data and predictions at each sampling time. The ﬁnal model and parameter estimates were 
used to simulate the data for 1000 virtual patients for VPC. A 95% prediction interval and 
median of the simulated concentrations were plotted along with observed plasma 
concentration–time data within 2.5th and 97.5th percentiles of the simulated model-
simulated data.  For bootstrap analysis, new datasets (n=1000) of the same size as the 
original dataset were generated by sampling random subjects with replacement from the 
original dataset and each of them was fitted using the final model. Median and 95% 
confidence interval of each PK parameter were calculated from bootstrap analysis.  
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Results 
A total of 639 concentrations including both atorvastatin acid (n=322) and lactone 
metabolite (n=317) from 132 patients were available for the population PK modeling. 
The detailed demographic information of study participants is listed in Table IV-1. The 
mean oral dose of steady state treatment of ATV was 24.5±19.0 mg. Moreover, a single 
40 mg oral dose of Lipitor was administered to the ten kidney transplant recipients.   
Initially, a base model for ATV was determined, thereafter ATV-LAC metabolite was 
added, and a combined parent-metabolite model was explored. Pharmacokinetic 
characteristics were best described using a two-compartment model with first-order oral 
absorption for ATV while a one-compartment with linear elimination was used for ATV-
LAC as described previously [30, 31]. A schematic diagram representing the structural 
PK model for a combined parent drug and major metabolite used to model plasma 
concentration time profiles of ATV and ATV-LAC is illustrated in Figure IV-1. The 
model was developed based on the mechanism described by Jacobson et al. [6] with some 
interconversion of lactone to an acid form. However, for simplicity, no other complex 
pathways of elimination of ATV were incorporated in the model. 
Subroutines ADVAN13 TRANS1, FOCE-INTER and double-precision model were 
selected as they helped to meet the selection criteria described in the method section. The 
interindividual and the residual variability of the PK parameters for both the parent drug 
and metabolite were modeled using an exponential and proportional error model, 
respectively.  
Significant covariates for V2/F, CL/F, Q/F, CLM/F and VM/F obtained after performing 
univariate analysis are listed in Table IV-II.  Forward step wise addition of significant 
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covariates resulted in the full model incorporating status of the kidney transplant and 
LDH for CLM/F, and gender for VM/F. The final model obtained after performing 
backward elimination included the same covariates as obtained in the full model. The 
mean estimates of model parameters such as absorption rate constant (Ka), apparent 
volume of distribution of ATV in the central compartment (V2/F), apparent oral clearance 
of ATV to ATV-LAC (CL/F),  apparent volume of distribution of ATV in the peripheral 
compartment (V3/F), apparent inter-compartmental clearance of ATV (Q/F), apparent 
total oral clearance of ATV-LAC (CLM/F), apparent volume of distribution of ATV-LAC 
in the central compartment (VM/F), apparent inter-compartmental clearance of ATV-LAC 
to ATV (QM/F) including bootstrap median and 95% confidence intervals of the final 
model are shown in Table IV-III.  The final model for the typical values of various 
pharmacokinetic parameters is shown below: 
Ka = θ1 
V2 = θ2 
CL = θ3 
V3 = θ4 
Q = θ5 
CLM = θ6 × θ9 TRAT −1 ×  
LDH
167.5
 
θ11
 
VM = θ7 × θ10 GEND −1  
QM = θ8 
 
The goodness-of-fit plots of the final model for ATV and ATV-LAC are presented in 
Figure IV-2 and IV-3, respectively. It can be depicted from the goodness-of-fit plots that 
all the points are close to the line of unity indicating good agreement between observed 
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and individual as well as population predicted plasma concentrations of parent and 
metabolite. The model is successful to describe the observed PK data.  No specific trend 
was observed in the plot of conditional weighted residuals with interaction (CWRESI) 
versus time after a dose of ATV or population predicted concentrations for both parent 
and metabolite. The CWRESI are randomly distributed with a mean of close to zero and 
most of them lay within ±2 units of the null ordinate of perfect agreement. The results of 
VPC evaluation contained simulated (n=1000) concentration-time profiles for both ATV 
and ATV-LAC at steady state and after a single dose are presented in Figure IV-4.  The 
prediction interval (2.5
th
 and 97.5
th
 percentiles) incorporated most of the concentrations 
of both an acid and lactone forms of ATV and indicated that the final model provided an 
adequate fit to observed data. 
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Discussion 
In this study, we found renal transplantation, LDH and gender as the significant 
covariates for clearance and volume of distribution of lactone metabolite, respectively.  
The assessment of demographic and clinical characteristics of patients indicated the 
status of transplant as the most statistical significant covariate for CLM, and it decreased 
between subject variability from 72% to 52%. Moreover, gender and LDH level 
influences VM/F and CLM/F, which reduced inter-patient variability from 78% to 53% and 
72% to and 59%, respectively.  
The effect of kidney transplant covariate was examined as a dichotomous variable (non-
transplant=1 transplant=2). According to our study finding, the clearance of ATV-LAC is 
significantly decreased in patients with the kidney transplant. Nevertheless, an earlier  
published population PK study [30] reported a decrease in clearance of ATV-LAC 
metabolite in patients with diabetes mellitus. The study population only contained the 
stable kidney transplant recipients with or without diabetes mellitus. Lack of non-
transplant subjects limited its ability to assess transplant as a covariate. The present study 
included of the stable kidney transplant (n=33) and non transplant (n=99) recipients.  
Several different mechanisms could be proposed for lower metabolite clearance in 
transplant patients including oxidative stress, pro-inflammatory cytokines and elevated 
parathyroid hormone levels. Previous studies have reported coexistence of an 
inflammatory condition with elevated oxidative stress in the stable kidney transplant 
recipients [32-35]. Moreover, elevated parathyroid hormone levels remain in a significant 
number of renal transplant recipients after transplantation due to persistent secondary 
hyperparathyroidism [36-38].   
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A few in vitro studies have demonstrated down regulation of CYP3A4, the main 
metabolizing enzyme of ATV-LAC metabolite,  by various cytokines such as interleukin 
IL-1β, IL-6, [39] interferon-γ, and hepatocyte growth factor [40]. Furthermore, oxidative 
stress reduces CYP3A activity, and the more likely mechanism involves P450 
metabolism of fatty acid hydroperoxides  [41] and activation of nuclear factor-κB leading 
to subsequent protein denaturation [42]. A previous in vitro and rat studies described the 
role of parathyroid hormone in the down regulation of CYP enzyme family [43]. 
Furthermore, transplant patients receive multiple interacting medications other than 
immunosuppressive therapy such azole antifungals, amiodarone, macrolide antibiotics, 
nefazodone, HIV protease inhibitors, mibefradil, digoxin, verapamil, nicotinic acid, 
warfarin, and diltiazem. Concomitant use of these medications may affect the metabolism 
and clearance of statins. Several cases of severe rhabdomyolysis have been reported in 
the kidney transplant recipients secondary to concurrent use of statin with 
immunosuppressant and other medications [20-22, 24-26].  
The LDH level was also a significant covariate for the clearance of ATV-LAC. Likewise, 
prior published studies also found LDH and AST liver enzyme levels as significant 
covariates for the clearance of an acid and lactone forms of ATV, respectively [30, 31]. 
Atorvastatin acid undergoes significant first-pass effect and therefore altered liver 
functions may affect its oral bioavailability. As LDH level increases, the clearance of 
metabolite decreased exponentially, which suggests that patients with liver disorders may 
have greater systemic exposure of lactone metabolite. Infections and hepatic disorders are 
the common complications in the kidney transplant recipients attributed to impaired 
resistance because of immunosuppressive treatment [44, 45]. Furthermore, few studies 
 123 
 
have indicated elevated levels of liver enzymes in the kidney transplant recipients with 
mycophenolate mofetil therapy [46, 47].  
Significantly higher plasma levels of ATV-LAC metabolite in patients experiencing 
statin-related myopathy were observed previously [14].  Moreover, ATV-LAC had a 14-
fold higher potency to induce myotoxicity as compared to an acid form [15].  These 
previous results indicate that patients with reduced clearance of ATV-LAC are more 
likely to experience ATV related muscle side effects such as myopathy. This finding 
warrants careful treatment of ATV in the kidney transplant population. 
The population PK analysis showed significantly higher volume of distribution of 
metabolite in male as compared to female.  The variability in the volume of distribution 
of several drugs between females and males is attributed to several factors including 
plasma volume, plasma proteins and tissue binding, fat proportion, body weight, organ 
blood flow, body composition and body mass index. Atorvastatin acid is a highly protein-
bound drug; more than 98% binds to plasma proteins [5]. Moreover, main plasma 
proteins that bind to drugs in human plasma are altered by sex hormone and therefore 
protein binding is affected by gender differences resulting in variability in volume of 
distribution of drugs [48].  
Genetic polymorphisms of various transporters and drug metabolizing enzymes (listed in 
the method section) involved in the disposition of ATV, which significantly affects its PK 
were evaluated.  Single nucleotide polymorphism of PON1 and 3 enzymes were the only 
significant covariates found for the clearance of ATV-LAC in univariate search. 
Riedmaier et al. have demonstrated that polymorphisms of PON1 -108T>C and PON3, 
63C>T esterases are associated with changes in ATV-LAC hydrolysis and increased 
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expression of PON1 mRNA in human liver tissues [19]. Furthermore, SLCO1B1, 
521T>C and ABCB11, 1331C>T were significant covariates for the clearance of parent 
drug. However, statistical significance was not obtained for these covariates during 
multivariate analysis. Additional studies with diverse and large population are necessary 
to thoroughly assess the effects of SNP on the PK of both an acid and lactone forms of 
ATV.  
The current study has several limitations: (a) Because of lack of a diverse population, 
probably it was not possible to thoroughly evaluate the effect of genetic polymorphism, 
age and ethnicity on the PK properties of ATV and metabolite; (b) We did not determine 
whether the transplant patients included in this study were affected by non-alcoholic 
steatohepatitis due to lack of noninvasive method; (c) Sparse sampling limited the ability 
of the model to accurately predict absorption phase of ATV; (d) absolute bioavailability 
of ATV was not determined due to unavailability of intravenous data.   
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Conclusion 
In summary, a combined parent-metabolite population pharmacokinetic model of ATV 
was developed. The pharmacokinetic analysis reported 50% reduction in clearance of 
ATV-LAC in the kidney transplant recipients. This finding should be taken into account 
while prescribing ATV treatment in the kidney transplant population. However, a further 
study to investigate pharmacokinetic of ATV over a 24 h dosing interval in a large 
number of the kidney transplant and non-transplant patients is required to confirm this 
finding. 
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Figure IV-1. Schematic diagram of the proposed structural combined parent-metabolite 
pharmacokinetic model for orally administered ATV and its major metabolite, ATV-
LAC. A two-compartment model with first-order oral absorption and one-compartment 
with linear elimination was used to describe the PK of ATV and ATV-LAC, respectively 
with some interconversion between two forms. Elimination of ATV-LAC only from the 
central compartment was assumed and no other pathways of elimination of ATV were 
accounted. Ka = absorption rate constant; V2/F = apparent volume of distribution of the 
parent drug in the central compartment; CL/F = apparent oral clearance of the parent drug 
to the metabolite; V3/F = apparent volume of distribution of the parent drug in the 
peripheral compartment; Q/F = apparent inter-compartmental clearance of the parent 
drug; CLM/F = apparent total oral clearance of the metabolite; VM/F = apparent volume of 
distribution of the metabolite in the central compartment; QM/F = apparent inter-
compartmental clearance of the metabolite to the parent drug. 
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Figure IV-2. The goodness-of-fit plots of the final model for atorvastatin acid: (a) OBS vs PRED (b) OBS vs IPRED (c) 
CWRESI vs PRED (d) CWRESI vs time post-dose at steady state. (e) CWRESI vs time after single dose. OBS = observed 
concentrations of atorvastatin acid; PRED = population predicted concentrations of atorvastatin acid; IPRED = individual 
predicted concentrations of atorvastatin acid; CWRESI = conditional weighted residuals with interaction. Logarithmic scale 
was used for clarity. 
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Figure IV-3 The goodness-of-fit plots of the final model for atorvastatin lactone: (a) OBS vs PRED (b) OBS vs IPRED (c) 
CWRESI vs PRED (d) CWRESI vs time post-dose at steady state. (e) CWRESI vs time after single dose. OBS = observed 
concentrations of atorvastatin lactone; PRED = population predicted concentrations of atorvastatin lactone; IPRED = 
individual predicted concentrations of atorvastatin lactone; CWRESI = conditional weighted residuals with interaction. 
Logarithmic scale was used for clarity. 
  
 
1
3
0
 
     
0.01
0.1
1
10
100
1000
143 148 153 158 163 168
C
o
n
c
e
n
ta
rt
io
n
 (
n
g
/m
L
)
Time (hr)
a
                             
0.01
0.1
1
10
100
0 2 4 6 8 10 12
C
o
n
c
e
n
tr
a
ti
o
n
 (
n
g
/m
L
)
Time (hr)
b
 
     
0.01
0.1
1
10
100
143 148 153 158 163 168
C
o
n
c
e
n
ta
rt
io
n
 (
n
g
/m
L
)
Time (hr)
c
                            
0.01
0.1
1
10
100
0 2 4 6 8 10 12
C
o
n
ce
n
tr
at
io
n
 (
n
g/
m
L)
Time (hr)
d
 
 
 
Figure IV-4. The plots of the visual predictive checks for the final model from the simulated data for plasma concentrations of 
(a) atorvastatin acid at steady state (b) atorvastatin acid after single dose (c) atorvastatin lactone at steady state (d) atorvastatin 
lactone after single dose. Observed concentrations (○) compared to the 97.5th (upper dashed line), 50th (middle solid line) and 
2.5
th
 (lower dashed line) percentiles of the 1000 simulated datasets. Logarithmic scale was used for clarity. 
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 Table IV-1. Characteristics of the patients included in the NONMEM analysis.
 Mean Median Range 
Demographics    
Gender [male/female] 77/55   
Age [years] 56.44 58 19-77 
Ethnicity [Caucasian/Hispanic/African American/others] 120/2/6/4   
Diabetes [non-diabetic/diabetic] 64/68   
Weight [kg] 90.1 88.6 45-145 
Transplantation [non-transplant/transplant] 99/33   
Time post transplant [months] 56.15 47 3-140 
Atorvastatin acid dose in mg  20 25.7 5-80 
Prednisone dose [mg/day] 5.85 5 2.5-30 
Mycophenolic acid dose [mg/day] 1000 1000 1000-2000 
Tacrolimus dose [mg/day] 2.16 2 0.5-5 
Sirolimus dose [mg/day] 1.79 2 1-3 
    
Clinical    
Albumin [g/dl] 4.31 4.30 4-5 
Protein, total [mg/dl] 6.87 6.90 6-8 
Cholesterol, total [mg/dl] 169.5 168 73-285 
High-density lipoproteins cholesterol [mg/dl] 53.2 50.5 17-147 
Low-density lipoproteins  cholesterol [mg/dl] 85.8 87.2 11-182 
Triglycerides [mg/dl] 167.2 135.5 44-811 
Creatinine [mg/dl] 1.13 1.04 1-3 
Creatinine kinase [IU/l] 135.9 92.5 16-3118 
Glucose [mg/dl] 132.6 113 65-601 
Hemoglobin A1c [%] 6.34 5.8         5-12 
Lactate  dehydrogenase  [IU/l] 173 167.5         81-324 
Aspartate aminotransferase [IU/l] 24.9 23.5          12-93 
Alkaline phosphatase [IU/l] 77.80 74 32-184 
Alanine aminotransferase [IU/l] 24.31 22           6-85 
Gamma-glutamyl transferase [IU/l] 37.29 24.5         6-492 
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Table IV-2. Significant covariates for the univariate and multivariate analyses. 
 
 
CLM/F, apparent total oral clearance of ATV-LAC; V2/F, apparent volume of distribution 
of ATV in the central compartment; CL/F, apparent oral clearance of ATV to ATV-LAC; 
VM/F, apparent volume of distribution of ATV-LAC in the central compartment; Q/F, 
apparent inter-compartmental clearance of ATV, PON, paraoxonase; SLCO1B1, gene 
encoding organic anion-transporting polypeptide; ABCB11, gene encoding breast cancer 
resistant protein
 Δ Minimum objective 
 function value 
P values 
Univariate analysis   
Effect of transplant status on CLM/F -41.4 <0.001 
Effect of lactate dehydrogenase on CLM/F -36.2 <0.001 
Effect of dose of tacrolimus on CLM/F -18.5 <0.001 
Effect of PON3, 63C>T on CLM/F -9.0 <0.005 
Effect of PON1 -108T>C on CLM/F -7.5 <0.01 
Effect of dose of sirolimus on CLM/F -7.2 <0.01 
Effect of alanine aminotransferase  on CLM/F -7.2 <0.01 
   
Effect of cholesterol on V2/F -19.2 <0.001 
Effect of status of transplant on V2/F -14.5 <0.001 
Effect of gender on V2/F -11.4 <0.001 
Effect of triglycerides on V2/F -11.3 <0.001 
Effect of ethnicity on V2 /F -11.0 <0.001 
   
Effect of dose of sirolimus on CL/F -12.7 <0.001 
Effect of SLCO1B1,521T>C on CL/F -11.0 <0.001 
Effect of status of transplant on CL/F -10.8 <0.005 
Effect of g-glutamyl transferase on CL/F -9.1 <0.005 
Effect of dose of tacrolimus on CL/F -8.9 <0.005 
Effect of ABCB11,1331C>T on  CL/F -6.8 <0.01 
Effect of hemoglobin A1C on  CL/F -5.3 <0.01 
   
Effect of gender on VM/F -13.7 <0.001 
   
Effect of total bilirubin on Q/F -14.5 <0.001 
Effect of total protein on Q/F -7.4 <0.01 
   
Multivariate analysis   
Effect of transplant status on CLM/F +30.0 <0.001 
Effect of gender on VM /F +19.4 <0.001 
Effect of lactate dehydrogenase on CLM/F +8.9 <0.005 
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Table IV-3. The parameter estimates for the atorvastatin and metabolite population 
models and the results of bootstrap validation of the final model. 
 
 
CLM/F, apparent total oral clearance of ATV-LAC; V2/F, apparent volume of distribution 
of ATV in the central compartment; CL/F, apparent oral clearance of ATV to ATV-LAC; 
VM/F, apparent volume of distribution of ATV-LAC in the central compartment; Q/F, 
apparent inter-compartmental clearance of ATV
Model parameter (units) Estimate Bootstrap median  
(95% CI) 
   
ka (hr
-1
) 0.771 0.762 (0.489, 1.02) 
V2/F (L) 481 456 (159, 1020) 
CL/F (L/hr) 1126 1120 (723, 1550) 
V3/F (L) 5462 5220 (1990, 9410) 
Q/F (L/hr) 343 341 (164,682) 
CLM/F (L/hr) 506 499 (401, 597) 
VM/F (L) 2349 2280 (1100, 4070) 
QM/F (L/hr) 748 754(407, 1171) 
Effect of lactate dehydrogenase on 
CLM/F 
0.479 0.496 (0.356, 0.689) 
Effect of gender on VM/F 0.327 0.337 (0.140, 0.691) 
Effect of transplant on CLM/F -0.944 -0.979 (-1.66, -0.352) 
   
Random effects   
Inter-individual variance (2)   
2 V2/F 2.99 2.90 (0.544, 1.99) 
2 CL/F 0.340 0.332 (0.580, 0.934) 
2 Q/F 1.41 1.42 (0.105, 0.971) 
2 CLM//F 0.531 0.520 (0.978, 2.17) 
2 VM/F 0.712 0.677 (0.813, 1.38) 
   
Intra-individual variability (σ2)   
Atorvastatin acid (ng/mL) 0.373 0.373 (1.79, 2.12) 
Atorvastatin lactone (ng/mL) 0.287 0.283 (1.73, 1.98) 
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ABSTRACT 
Aim: To develop a whole-body physiologically-based pharmacokinetic model to 
predict oral pharmacokinetics of atorvastatin acid as well as rosuvastatin acid with 
their respective metabolites in the stable kidney transplant patients with diabetes 
mellitus using in silico and experimentally measured input parameters. 
Subjects and methods: A clinical study was conducted in the stable kidney transplant 
recipients with diabetes mellitus to obtain plasma concentration-time profiles of the 
parent drug and its metabolites. The kinetic parameters of metabolic clearance of 
atorvastatin acid previously determined using human liver microsomal fractions 
obtained from donors with diabetes mellitus were integrated in the model. In vitro 
dissolution studies of both statins were carried out in different pH media to assess pH 
dependent release profile.  Simulations were implemented using the built-in Advanced 
Compartmental Absorption and Transit (ACAT) model and Population Estimates for 
Age-Related (PEAR
TM
) physiology in GastroPlus
TM
 software package (Simulations 
Plus, Inc., Lancaster, CA, USA). The essential input parameters to construct 
physiologically-based pharmacokinetic model of statins were measured 
experimentally, in silico predicted and/or obtained from the literature.  
Results:   
The simulated plasma concentration-time profiles of both statins and their metabolites 
were in a good correlation with mean plasma concentrations observed in study 
patients. Berezhkovskiy algorithm utilized to determine tissue distribution of 
perfusion-limited tissues as it successfully estimated observed high volume of 
distribution for both statins. Parameter sensitivity analysis revealed that systemic 
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exposure of both statins is most sensitive to change in intestinal transit time. The 
stochastic simulation performed using virtual trial feature of the software showed that 
the observed mean plasma concentration-time curves of both statins lie between 90% 
confidence interval, maximal and minimal simulated concentrations of ten virtual 
patients. 
Conclusion: A whole-body physiologically-based pharmacokinetic model was 
constructed to simulate systemic exposure of orally administered atorvastatin acid and 
rosuvastatin acid with their metabolites in stable kidney transplant patients with 
diabetes mellitus. This study also demonstrated that disease specific in vitro metabolic 
clearance data are superior for an appropriate prediction of systemic exposure of the 
drug that undergoes extensive metabolism, which might have changed due to altered 
activity of drug metabolizing enzymes in specific disease state. 
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INTRODUCTION 
The 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) are 
widely prescribed medication for treatment of hypercholesterolemia. Statins effectively 
decrease elevated levels of low-density lipoproteins and total cholesterol and hence the 
mortality rate has been drastically reduced in all over the world thereby, it remains the 
drug of choice to prevent coronary heart diseases.
1
 Several lipid-lowering agents from 
statins class including, fluvastatin, atorvastatin, pravastatin, rosuvastatin, lovastatin, 
simvastatin pitavastatin are commercially available. Atorvastatin acid (ATV) is the 
largest-selling prescribed medication while rosuvastatin acid (RST) is the most 
efficacious among all statins.
2
 
 An active acid form of atorvastatin undergoes extensive first-pass metabolism after an 
oral administration (10-80 mg/day). The drug is highly bound to plasma protein 
(>98%) with an absolute oral bioavailability of 14%.
1
 It is extensively metabolized 
mainly by intestinal and liver cytochrome P450 (CYP) 3A4 enzyme and forms 
pharmacologically active ortho- and para-hydroxylated (o-OH-ATV and p-OH-ATV) 
metabolites.
3
 The parent drug and its hydroxy acid metabolites remain in equilibrium 
with their respective pharmacologically inactive lactone forms (ATV-LAC, o-OH-
ATV-LAC and p-OH-ATV-LAC),
4
 which have 83-fold higher affinity for CYP3A4 
and exhibit higher metabolic clearance.
3, 5
 Thus, it has been postulated that the 
elimination of the parent drug occurs primarily via hydroxylation of ATV-LAC rather 
than hydroxylation of the parent drug.
3
 Moreover, previous study reported nearly equal 
systemic exposure of lactone metabolite as compared to an acid form.
6
 The formation 
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of lactone is attributed to glucuronidation via UDP-glucuronosyltransferase (UGT)1A1 
and 1A3,
7
 low pH environment
4
 and intermediate product of coenzyme A-dependent 
pathway.
8
 On the other hand, lactones are hydrolyzed either chemically or 
enzymatically
9
 mainly by paraoxonase 1 and 3 and esterases.
10-12
 The results of in vitro 
study from our group indicated a predominant role of CYP3A4 in the 
biotransformation of ATV-LAC,
5
 which is in consistent with previous findings.
3
 The 
parent drug and its metabolites mainly excreted into the bile and approximately 1% of 
the administered dose is excreted through renal route.
1
 
Rosuvastatin acid has a modest absolute bioavailability (approximately 20%). It is 
reversibly bound to 88% of plasma protein and also exhibits limited metabolism. 
Rosuvastatin acid mainly excreted unchanged (76.8% of the dose) in feces.
13
 It is 
primarily metabolized by isoenzyme CYP2C9 and to the minor extent through 
CYP2C19 and CYP3A4,
14
 thereby it generates pharmacologically active principal 
metabolite, N-desmethyl derivative.
13
 Furthermore, the formation of an inactive 5S-
lactone metabolite of rosuvastatin acid (RST-LAC) occurs via the glucuronidation 
pathway.
14
 Fecal (approximately 90% of the dose) and renal (approximately 10% of 
the dose) are the major and minor route of excretion of RST, respectively.
13
  
Hepatic uptake transporter, organic anion-transporting polypeptide (OATP) 1B1, plays 
a major role in an active uptake of ATV and its metabolites.
15, 16
Atorvastatin acid and 
its metabolites are also substrates for efflux transporters including P-glycoprotein (P-
gp),
17, 18
 and breast cancer resistant protein (BCRP),
19
 which govern their intestinal 
absorption and hepatic elimination. Similarly, RST is transported into the liver by 
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multiple uptake transporters including OATP1A2, OATP2B1, OATP1B3, 
OATP1B1.
20, 21
 It is also a substrate of various efflux transporters such as BCRP, P-gp, 
and MRP2 that mediate its intestinal and biliary excretion.
19, 21, 22
  
Statins are well tolerated by most patients although skeletal muscle-related toxicity is 
the most common reported side effect that develops after commencing statin therapy. 
Myotoxicity is ranging from a mild condition called myalgia to rare but potentially 
fatal rhabdomyolysis usually requiring hospitalization. Because of elevated incidence 
of statin-associated rhabdomyolysis, cerivastatin was voluntarily withdrawn from the 
United States market in 2001.
23
 A meta analysis study conducted by the United States 
FDA including 130, 865 patients indicated three times higher incidence of fatal 
rhabdomyolysis in diabetic patients.
24
 Significantly higher plasma level of ATV-LAC 
was found in atorvastatin-treated patients experiencing myopathy.
25
 Moreover, an in 
vitro study conducted using human skeletal muscle cell culture exposed to an acid and 
lactone forms of statin showed that lactone form is more toxic to muscle cells than an 
acid form.
26
 Furthermore, Skottheim et al. suggested that the lactone/acid 
concentration ratio can potentially be utilized as a specific diagnostic tool to determine 
patients at higher risk of developing statin-induced skeletal muscle toxicity.
27
 Recently, 
we published both in vivo and in vitro studies that assessed the effect of diabetes 
mellitus on the biotransformation of ATV.
5
 We found 3.56 times reduced clearance of 
ATV-LAC metabolite in the stable kidney transplant recipients with diabetes mellitus
5
 
because of down regulation of CYP3A4, the main metabolizing enzyme of ATV-LAC 
in this population.
28
 It is essential to construct physiologically-based pharmacokinetic 
(PBPK) models for statins to simulate its distribution in the liver and skeletal muscle to 
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estimate their pharmacological and toxicological effects in patients with diabetes 
mellitus. 
Recently, in silico prediction by advanced computation technology has been widely 
preferred for drug discovery and development to reduce the time and investment of 
research by decreasing the need of extensive experimental work. Mechanistic 
modeling tools integrate various information about the drug including estimated in 
silico physicochemical and biopharmaceutical properties, experimentally measured in 
vitro drug metabolism kinetic parameters and intestinal permeability to predict fraction 
absorbed, oral bioavailability, intestinal and hepatic extraction. Several software 
packages are available for mechanistic simulation including GastroPlus
TM
, SimCYP, 
PKSim and IDEA.  
GastroPlus
TM
 is a mechanistically based simulation software program design for the 
prediction of advanced absorption, physiologically-based pharmacokinetics/dynamics, 
in vivo and in vitro extrapolation and drug-drug interactions. GastroPlus
TM
 software 
uses the Advanced Compartmental Absorption and Transit (ACAT)  model,
29
 which is 
the modified version of previously elucidated the original Compartmental Absorption 
and Transit (CAT) model
30-32
 to incorporate a whole-body related various 
physiological parameters to each interconnected  hypothetical compartment. The 
ACAT model comprised of total eighteen compartments including nine enterocytes 
and nine gastrointestinal compartments. The gastrointestinal compartment starts from 
stomach; followed by six small intestinal compartments, caecum and colon. Each 
compartment defines several events including disintegration, dissolution, release, 
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precipitation, luminal degradation, absorption/desorption, gut wall metabolism, uptake 
of the drug, which are repeated in each compartment as it travels through different 
segments of the gastrointestinal tract. Furthermore, physiological values of 
gastrointestinal pH, mean transit times, permeability, fluid volume, dimension, bile salt 
and pore size are incorporated in each compartment. The inter-compartmental transit of 
the drug is illustrated by integrated series of linear and nonlinear differential equations. 
To perform each simulation, the drug specific input parameters including pH 
dependent solubility, logP, pKa, particle size, dose, in vitro kinetic data of enzymatic 
biotransformation and transport mechanisms were fed into the software. 
The aim of the study was to build PBPK models for ATV and RST to predict plasma 
concentration-time profiles and tissue distribution of the parent drug and its 
metabolites in the stable kidney transplant subjects with diabetes mellitus using 
physiological and drug-related parameters. 
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MATERIALS AND METHODS 
Study design 
The open-label crossover pharmacokinetic study of ATV and RST was carried out in 
the diabetic stable kidney transplant recipients. The study protocol was approved by 
the Institutional Review Board of Rhode Island Hospital (Providence RI, USA). The 
procedures of the study were explained verbally to the study subjects, and thereafter 
their signed informed consent was obtained.  
Patient population 
The ten stable kidney transplant male (n=7) or female (n=3) subjects with documented 
diabetes mellitus (type 1 or 2) were recruited. The study participants comprised of 
mainly Caucasian population with 51 years of mean age and 90.39 Kg mean body 
weight. The patients were receiving a triple immunosuppressant regimen consisting of 
mycophenolic acid either from mycophenolate mofetil (Cellcept™, Roche, Nutley, NJ) 
or mycophenolate sodium (Myfortic, Novartis, East Hanover, NJ), tacrolimus and 
prednisone. Patients with severe clinical gastroparesis, liver diseases, pregnancy, 
abdominal surgery (within past 3 months), and history of inflammatory bowel disease 
were excluded from the study. Moreover, patients taking concomitant medications, 
which may alter gastric pH and gastrointestinal motility, were not recruited in the 
study. 
Pharmacokinetic study 
Study subjects were notified to stop their statin medication at least 3 days prior the 
study. Moreover, they were instructed to fast the night before the study day. The 
participants were subjected to routine physical examination including height, weight 
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and blood pressure measurement on each day of the study. Thereafter, patients 
administered a single 20 mg oral dose of rosuvastatin calcium (Crestor®, AstraZeneca 
Pharmaceuticals LP, DE, USA) along with their routine medications including 
immunosuppressant regimens. All patients were served two standardized diabetic meal 
at the end of 6 h and 10 h after administration of statin medications including morning 
low fat breakfast bar. Blood samples were collected in vacutainer tubes containing 
lithium heparin as an anticoagulant at various time points (0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 
10 and 12 h) post-dose. The blood samples were centrifuged immediately at 1400xg 
and plasma samples were diluted 1:1 with 0.1 M, pH 4.0 sodium acetate.
33
 The study 
samples were stored at −80°C until analysis. The similar study procedures were 
followed by the same participants after administering a single 40 mg oral dose of 
atorvastatin calcium (Lipitor
®
, Pfizer Inc, NY, USA) after at least two weeks. For 12 h 
post-dose pharmacokinetics study of ATV, blood samples were collected in vacutainer 
tubes containing fluoride/potassium oxalate as an anticoagulant.
33
 The blood samples 
were immediately centrifuged at 1400xg and plasma samples were stored at −80°C 
until analysis. 
Quantitative analysis of ATV, RST and their metabolites in human plasma 
Plasma levels of ATV and its metabolites (ATV-LAC, o-OH-ATV and o-OH-ATV-
LAC) were determined using previously validated liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) assay.
33
 Briefly, the analytes and corresponding deuterium 
(d5) labeled internal standards were extracted from 50 µL of human plasma using 200 
µL of 0.1% v/v glacial acetic acid in acetonitrile as protein precipitating solvent.  The 
chromatographic separation of the analytes was achieved using a Zorbax-SB Phenyl 
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column (2.1 mm × 100 mm, 3.5 µm) within 7.0 min using a flow rate of 0.35 mL/min.  
Mobile phase consisting of a gradient mixture of 0.1% v/v glacial acetic acid in 10% 
v/v methanol in water (solvent A) and 40% v/v methanol in acetonitrile (solvent B).  
Mass spectrometry detection was carried out in positive electrospray ionization mode, 
with multiple reaction monitoring scan.  Calibration curves for all the analytes over the 
concentration range of 0.05-100 ng/mL were used.
33
 Likewise, quantitative 
determination of RST and its metabolite, RST-LAC in human plasma was carried out 
using a previously reported validated LC-MS/MS assay.
34
 In brief, all the analytes and 
the corresponding deuterium-labeled (d6) internal standards were extracted from 50 μL 
of buffered human plasma by protein precipitation. The analytes were 
chromatographically separated using a Zorbax-SB Phenyl column (2.1 mm×100 mm, 
3.5 μm). The mobile phase comprised of a gradient mixture of 0.1% v/v glacial acetic 
acid in 10% v/v methanol in water (solvent A) and 40% v/v methanol in acetonitrile 
(solvent B). The analytes were separated at baseline within 6.0 min using a flow rate of 
0.35 mL/min. Mass spectrometry detection was carried out in positive electrospray 
ionization mode. Calibration curves for both the analytes were linear (R≥0.9964, n=3) 
over the concentration range of 0.1–100 ng/mL for RST and RST-LAC. Mean 
extraction recoveries ranged within 88.0–106%. Intra- and inter-run mean percent 
accuracy were within 91.8–111%, and percent imprecision was ≤15%. Stability studies 
revealed that all the analytes were stable in matrix during bench-top (6 h on ice–water 
slurry), at the end of three successive freeze and thaw cycles and during storage at 
−80°C for 1 month. 
In vitro dissolution study 
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In vitro dissolution studies of ATV and RST were carried out using USP apparatus II-
paddle type, LID-8D dissolution tester (Vanguard Pharmaceutical Machinery, Inc., 
Spring, TX, USA). A single tablet dosage form of 40 mg of ATV and 20 mg of RST 
per dissolution bath was used for dissolution experiments. The dissolution study was 
performed using 0.1 M hydrochloric acid (1.2 pH) and 0.05 M ammonium acetate 
buffer with 3, 4.5, 6.8 and 8 pHs as dissolution media. The pH of each dissolution 
media was adjusted using glacial acetic acid or ammonium hydroxide. The dissolution 
of ATV was carried out at 75 rpm speed, and samples were collected at 5, 10, 15, 30, 
45, 60, 90, 120, 150, 180, 210 and 240 min. Similarly, dissolution of RST was carried 
out at 50 rpm speed and samples were collected at 10, 20, 30, 45, 60, 90 120, 150, 180, 
210 and 240 min. The volume of dissolution medium was 900 mL, and it was replaced 
with fresh buffer equilibrated at 37 °C after each sampling. All dissolution experiments 
were carried out in triplicates. The collected samples were immediately kept on dry ice 
to minimize interconversion between acid and lactone forms and were analyzed using 
HPLC-UV assay with slight modification of the methods described by Macwan et al.
33, 
34
 
Physiologically-based pharmacokinetic (PBPK) model structures 
Computer hardware and the software 
The simulations for disposition and absorption were performed using GastroPlus
TM
 
version 8.0.0002 simulation software (Simulations Plus, Inc., CA, USA) on a Dell 
laptop computer with Intel core i3 CPU M350 (2.27 GHz).  
A whole-body disposition 
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A whole-body PBPK modeling approach was utilized through the ACAT model in 
PBPK
TM
 module of the software. A separate whole-body PBPK models were built for 
the disposition of the parent drug and each metabolite, and these were coupled via 
gut/hepatic metabolism and/or transport, allowing simultaneous simulations of both the 
parent drug and its metabolites. Built-in age, body weight, height, and gender-
dependent Population Estimates for Age-Related physiology
TM 
(PEAR) module was 
used to generate human physiology for 51 years (mean age of study subjects) old an 
American male patient with body weight of 90.4 kg (mean weight of study subjects) 
based on the study population. The PEAR is generated based on data from the National 
and Nutrition Examination Survey.
35
 The volume, weight and rate of blood perfusion 
of each body tissue were computed from default balance model. 
Prediction of disposition parameters of ATV 
Intestinal permeability 
Experimentally measured human jejunal permeability of many drugs using in vivo 
perfusion methods is very limited. Computer based in silico prediction based on 
chemical structure of the drug is widely preferred. The permeability of the drug 
changes as it transit through different regions of the gastrointestinal tract due to 
alteration of several parameters including regional pH, surface area, ionization, density 
of villi and microvilli. Built-in optimized logD model scales regional permeability 
based on these parameters. Furthermore, regional gastrointestinal absorption of the 
drug is determined by human in silico effective jejunal permeability (S+Peff) and the 
concentration gradient at the apical membrane of the enterocytes. Integrated 
ADMET
TM 
predictor module of GastroPlus
TM
 computed human S+Peff based on built-
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in quantitative structure-property relationship model. Apparent jejunal permeability of 
ATV was studied by rat infusion technique
36
 and the calculated human effective 
jejunal permeability (Peff) value was equivalent to estimate of ADMET
TM 
predictor.  
CYP3A4, UGT1A1/3, OATP1B1 and P-gp kinetic constants 
Atorvastatin acid is predominantly metabolized in the liver and gut mainly by CYP3A4 
enzyme. Recently, we determined enzymatic metabolism kinetics of an acid and 
lactone forms of atorvastatin using human liver microsomal fractions (HLMs) obtained 
from donors with and without diabetes mellitus.
5
 Briefly, microsomal fractions were 
prepared as illustrated previously 
28
 from human livers obtained from donors with and 
without diabetes mellitus (Xenotech LLC, Lenexa, KA, USA) and were stored at 
−80°C until analysis. Several concentrations of an acid and lactone forms of 
atorvastatin were incubated with prepared HLMs. At the end of incubation, ice-cold 
acetonitrile containing an internal standard was added to cease the reaction. The 
samples were centrifuged, and the supernatant was injected onto an analytical column. 
The quantitative determination of ATV and its five metabolites were performed using 
previously described LC-MS/MS assay with slight modifications.
33
 Enzyme kinetic 
parameters (Km and Vmax) of ATV and ATV-LAC were calculated using GraphPad 
Prism (GraphPad Software, San Diego, CA, USA).  
For the simulations, in vitro average Km (5.21 µM) and the sum of Vmax values (2593.7 
pmol/min/mg microsomal protein) were used as input parameters for the formation of 
CYP3A4 mediated para- and ortho-hydroxylated acid metabolites that obtained upon 
incubation of ATV with HLMs from livers of diabetes donors.
5
 Moreover, from 
available literature data, an average Km of 14 µM
7, 37
 and fitted Vmax values for the 
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formation of ATV-LAC metabolite mediated mainly through UGT1A3 and UGT1A1 
enzymes were integrated in the model to account for glucuronidation mediated 
metabolism of ATV.  The enzyme kinetic parameters of CYP3A4 and UGT1A1 were 
applied to both the gut and liver while UGT1A3 was only applied to liver tissue due to 
negligible expression in the intestine.
38
 All in vitro Vmax values were scaled to in vivo 
Vmax based on either GastroPlus
TM 
 built-in or literature based absolute quantification 
data of each enzyme. To incorporate OATP1B1 mediated hepatic uptake clearance of 
ATV, an average of 0.85 µM and 5.225 pmol/min/mg
39, 40
 of in vitro Km and Vmax, 
respectively were fed into the model. The fitted Vmax and average Km of 112.5 µM
17, 18
 
were applied only to canalicular membrane of liver for P-gp efflux transporter. To run 
simulations, liver was considered a permeability-limited tissue, on the other hand, the 
rest of the body tissues were perfusion-limited.  
Volume of distribution  
PBPK
TM
 plus module of GastroPlus
TM
 was utilized to determine tissue:plasma partition 
coefficients (Kps) of perfusion-limited tissues (non-hepatic tissues) using 
Berezhkovskiy’s algorithm,41 which calculated Kps based on free concentrations of the 
drug in plasma/tissue as well as the volume fractions of lipids including phospholipids 
and neutral lipids, and body water. However, the partition of the drug between blood 
and interstitial space for permeability-limited liver was determined using Poulin and 
Theil method (extracellular)
42, 43
 that calculated Kps based on hematocrit and the 
fraction unbound in plasma as well as in tissues.  
Systemic clearance 
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Atorvastatin acid is significantly metabolized in both the gut and liver mainly by 
CYP3A4 enzyme. Furthermore, it is a substrate of hepatic OATP1B1 uptake 
transporter that can modulate clearance of the drug, which is eliminated extensively by 
hepatic metabolism; therefore, hepatic elimination plays a major role in overall 
clearance of ATV. In the present study, as mentioned previously, CYP3A4 mediated in 
vitro metabolism of ATV in HLMs obtained from livers of diabetes donors’ were 
interpolated to the model to illustrate metabolic clearance of ATV and the formation of 
the two hydroxylated metabolites. The kinetic parameters were converted to per mg 
protein using a conversion factor of 0.37 nmol total CYP/mg protein.
44
  
Scaling of in vitro metabolic clearance data to in vivo clearance was based on 
measured amount of microsomal protein per gm liver and average liver size. The in 
vitro Vmax values were scaled to in vivo by considering 111 pmol of CYP3A4/mg 
microsomal protein,
45
 17.3 pmol of UGT1A3/mg microsomal protein,
46
 33.2 pmol of 
UGT1A1/mg microsomal protein,
46
 38 mg of microsomal protein/gm of liver tissue
47
 
and 1400 gm of average weight of liver.
48
All the values were corrected for non specific 
binding to microsomes by in vitro unbound faction of 40.5%
49
 for accurate prediction 
of metabolic clearance.  
Prediction of in vivo dissolution rate  
Actual in vivo solubility could be different from in vitro aqueous buffer solubility 
because of presence of bile salt and lipids in the intestinal fluids. Biorelevant solubility 
was determined to account for altered solubility with changes in bile salt 
concentrations in different regions of intestine. The most accurate prediction of 
absorption of the lipophilic drugs can be made by measuring biorelevant solubility in 
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biologically relevant gastrointestinal media such fasted state simulated intestinal fluid 
(FaSSIF), fed state simulated intestinal fluid (FeSSIF) and fasted state simulated 
gastric fluid (FaSSGF). An equilibrium solubility of ATV measured in FaSSIF was 0.3 
mg/mL,
50
 and it was used to run simulations along with in silico solubility of 0.0011 
mg/mL and 0.69 mg/mL in simulated gastric fluid (SGF) and FeSSIF dissolution 
medium, respectively due to unavailability of experimentally measured values. We 
utilized default Johnson dissolution model in GastroPlus
TM
 to predict dissolution rate.  
Gastrointestinal absorption model 
The default human fed physiology and optimized logD model SA/V 6.1 in the ACAT 
model of the software was selected to calculate the changes in the rate of passive 
absorption from gut lumen to enterocytes of dissolved drug as it transit through the 
gastrointestinal tract. The default properties of individual gut compartment such as pH, 
transit time, volume, length, radii, bile salt concentration, surface area enhancement 
factors, and radius of pores between two adjacent cells were implicated in the model. 
The ACAT model parameters are listed in Table V-1. Liver blood flow rate was 
increased to 120 L/h for fed condition.
51
 
The absorption rate coefficient of the drug in each segment of the gastrointestinal tract 
was determined based on human S+Peff. The relative distribution of CYP3A4 and P-gp 
in nine compartments of the gastrointestinal tract in the ACAT model was explained 
previously.
44
 The quantitative expression of UGT1A1 in different segments of the 
gastrointestinal tract was assumed based on available limited information.
38
 
Prediction of disposition parameters ATV major metabolites  
ATV-LAC 
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The pH dependent distribution coefficients for tissue partition were calculated based 
on experimentally measured logD7.0 of 4.2 previously reported by Ishigami et al.
52
 
Other properties such as pKa, fup (fraction unbound in plasma), blood/plasma 
concentration ratio and human Peff estimated by ADMET
TM 
were interpolated to the 
model. Our recent work demonstrated metabolic clearance of ATV-LAC and the 
formation of o- and p-OH-ATV-LAC metabolites by using HLMs obtained from livers 
of donors with diabetes mellitus.
5
 An average Km of 6.0 µM
5
 and fitted Vmax were 
utilized to simulate concentration-time profile of o-OH-ATV-LAC. An in vitro Km 
value was corrected for unbound fraction using default Austin factor. 
o-OH-ATV  
In silico estimates of ADMET
TM
 predictor were implicated in the model due to 
unavailability of experimental data. Previous work identified glucuronide metabolite of 
o-OH-ATV in bile of rat and dog.
53
 Furthermore, to reflect low permeability of 
glucuronide metabolite, human S+Peff was decreased from 1.12 x 10
4
 to 0.8 x 10
4
 cm/s. 
Moreover, like ATV, o-OH-ATV metabolite is also a substrate of hepatic OATP1B1 
uptake and intestinal P-gp efflux transporter.
54
 Fitted Km and Vmax constants for 
OATP1B1 and P-gp were applied to basolateral side of liver and apical side of gut, 
respectively due to lack of data.  
o-OH-ATV-LAC  
Due to deficiency of experimentally measured input parameters, in silico estimates by 
ADMET
TM
 predictor were included for mechanistic modeling of o-OH-ATV-LAC. 
Unlike, o-OH-ATV further metabolic clearance of o-OH-ATV-LAC was not reported 
in the literature. To simulate limited absorption of o-OH-ATV-LAC, fitted Km and 
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Vmax parameters for P-gp efflux transporter at apical side of gut were included. An 
active hepatic uptake of o-OH-ATV-LAC was not considered due to relative more 
lipophilicity than an acid form. 
Prediction of disposition parameters of RST 
Intestinal permeability 
Similar to ATV, human S+Peff determined by ADMET
TM 
predictor module was 
incorporated to run all simulations for prediction of RST oral absorption and 
pharmacokinetics.  
UGT1A1, UGT1A3, OATP and BCRP pharmacokinetic constants 
Rosuvastatin acid exhibit minimal hepatic metabolism, however, to simulate 
concentration-time curve of lactone metabolite that forms via glucuronidation, enzyme 
kinetic constants for UGT1A1 (applied to the liver and gut) and 1A3 (only applied to 
liver) available in literature were integrated in the model
14
. The significant contribution 
of hepatobiliary transport in disposition of RST mediated by several sinusoidal hepatic 
OATP uptake transporters and BCRP canalicular efflux transporter were incorporated 
in mechanistic modeling. The simulations utilized an average Km (4.93 µM) and the 
sum of Vmax (12.3 pmol/min/mg) of OATP2B1, OATP1A2 and OATP1B3 reported by 
Ho et al.
20
 Liver was considered a permeability-limited tissue. Similarly, for BCRP 
efflux transporter, Vmax of 304 pmol/min/mg and an average Km value of 0.473 µM
22, 55
 
obtained from the literature
21
 were added to canalicular membrane of liver tissue. To 
simulate limited intestinal absorption, an average Km of 0.473 µM
22, 55
 for BCRP efflux 
transporter was fed to gut tissues along with fitted Vmax. 
Volume of distribution  
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Mechanistic tissue composition equations defined by Berezhkovskiy
41
 were selected 
for calculation of Kps from blood into cells for perfusion rate limited tissues because it 
provided better estimate of observed high volume of distribution as compared to 
Rodgers and Rowland method.
56, 57
 
Berezhkovskiy assumed homogenous distribution of the drug into tissue and plasma. It 
calculated tissue-plasma partition coefficient based on experimentally measured or in 
silico predicted compound specific biopharmaceutical properties mainly pKa, logP, 
fup, blood/plasma concentration ratio and species-specific tissue composition. The 
partition of the drug between blood and interstitial space for permeability-limited liver 
tissue was estimated using Poulin and Theil method (extracellular).
42, 43
 
Systemic clearance 
Limited metabolic clearance of RST through lactonization mediated by 
glucuronidation pathway involving mainly UGT1A1 and 1A3
14
 enzymes was 
integrated in the ACAT model for gut and PBPK tissues to estimate its overall 
clearance. As mentioned in the previous section, in vitro enzyme kinetic constants 
were scaled to in vivo by assuming 17.3 pmol of UGT1A3/mg microsomal protein,
46
 
33.2 pmol of UGT1A1/mg microsomal protein,
46
 38 mg of microsomal protein/gm of 
liver tissue
47
 and 1400 gm of average weight of liver.
48
 Similarly, in vitro data for 
multiple OATP transporters mediated active uptake clearance were applied to 
permeability-limited liver tissue.
20
 The value was scaled to in vivo assuming 85 mg 
membrane protein/gm liver.
58
 The relative regional distribution of BCRP efflux 
transporter at the apical side of gut was studied earlier by Englund et al.
59
 Renal 
clearance was estimated from fup and glomerular filtration rate.  
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Prediction of in vivo dissolution rate  
Experimentally measured in vitro dissolution release vs time profile was incorporated 
and default Johnson dissolution model was employed. In silico estimates of solubility 
in SGF, FaSSIF and FeSSIF dissolution medium were used for mechanistic modeling 
due to lack of data.  
The physiologically-based ACAT model of the human gastrointestinal tract 
Because of cross over study design, the same subjects received 20 mg of Crestor
®
; 
therefore, human fed physiological model was selected as described in the prior section 
of atorvastatin acid. The ACAT physiological model parameters employed in the 
simulation of RST and RST-LAC are showed in Table V-2. 
Gastrointestinal absorption model 
In silico human Peff was chosen for PBPK model building of RST. Lactonization of 
RST is mediated by UGT1A1 enzyme in both the gut and liver. The relative expression 
of UGT1A1 in each compartment of the gastrointestinal tract in the ACAT model was 
determined based on prior information.
38
 Furthermore, intestinal absorption at apical 
side that is governed by BCRP efflux transporter was included by feeding its 
expression levels throughout the gastrointestinal tract
59
 along with kinetic constants.  
Prediction of disposition parameters RST metabolite 
RST-LAC 
Because of unavailability of human Peff and other biopharmaceutical properties such as 
pKa, fup, blood/plasma concentration ratio and reference solubility, estimates of 
ADMET
TM 
predictor module were used to perform simulations. The logD7.4 of 1.2 was 
reported previously.
60
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Virtual trial simulations 
The population simulator mode in GastroPlus
TM
 permits the user to evaluate the 
combined effects of inter-individual variability in population physiology and the 
predicted disposition parameters along with formulation/compound specific properties 
using a whole-body PBPK model linked with Monte Carlo simulation. A stochastic 
simulation generates variability in each variable by random sampling of each variable 
parameter from predefined distribution for each simulation. The trial was performed 
for ten virtual patients, which is equal to the number of patients participated in our 
clinical study. The virtual trial studies were conducted using GastroPlus
TM
 standard 
physiological conditions and compound-specific characteristics, which were sampled 
randomly from log-normal distributions via Monte Carlo method. Moreover, 
predefined coefficient variations that randomly created based on their mean values in 
GastroPlus
TM
 were used in simulations. 
Parameter sensitivity analysis  
Parameter sensitivity analysis feature of GastroPlus
TM
 was utilized to assess the 
sensitivity of predicted disposition parameters to key input elements. The key input 
parameters, which are likely to affect plasma concentration-time curve based on 
available literature information were separately varied over a broad range of values to 
conduct parameter sensitivity analysis.  
Sensitivity of pharmacokinetic parameters of ATV including maximum plasma 
concentration (Cmax), time to reach Cmax (Tmax) and area under the plasma 
concentration-time curve (AUC) were assessed with changes in transit time of the 
stomach and small intestine, stomach pH, kinetic parameters of CYP3A4 and 
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OATP1B1. Similarly, using PBPK model of RST, the effect of variations in input 
parameters including transit time of the stomach and small intestine, stomach pH, Km 
and Vmax of BCRP and OATP1B1 on simulated pharmacokinetic parameters was 
evaluated. 
Unit converter 
Metabolism and transporter module in GastroPlus
TM
 comprises a convenient unit 
converter. Built-in unit converter is a conversion tool for simple unit conversion that 
converts units of all Km (mg/L) and Vmax (mg/s/mg-enzyme) values obtained from the 
literature to get suitable units of inputs for simulations in GastroPlus
TM
. 
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RESULTS 
PBPK modeling of ATV and its three metabolites 
GastroPlus
TM
 default PBPK
TM
 module along with in vitro clearance data was used to 
describe oral absorption and pharmacokinetics of ATV and its three metabolites. 
In silico or experimentally measured physiochemical/biopharmaceutical 
properties  
Intestinal permeability 
The ADMET
TM
 predictor estimated value of intestinal permeability based on chemical 
structure of the compound predicted the disposition parameters of ATV.  
pKa, blood/plasma concentration ratio, fup and logD   
Several biopharmaceutical properties of the drug including blood/plasma concentration 
ratio, fup and logD strongly influence hepatic bioavailability and thus hepatic 
clearance.  
Blood/plasma concentration ratio of 0.25 for ATV reported in the literature was 
selected for the modeling.
61
 Atorvastatin acid is highly bound to plasma protein. The 
plasma unbound fraction of 2% was reported by Lennarnas et al.
1
 The pKa value of 4.6 
was obtained from Pfizer (in house data). The logD7 of 1.53 previously measured by 
Ishigami et al.
52
 was utilized in the simulations. For mechanistic modeling of all three 
metabolites, in silico estimates of physiochemical properties were utilized due to lack 
of experimentally measured values. The key physicochemical and biopharmaceutical 
parameters are presented in Table V-3.   
PBPK Modeling  
Prediction of systemic clearance 
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Previously our group demonstrated in vitro metabolism of an acid and lactone forms of 
ATV using HLMS. The clinical observations were collected from patients with 
diabetes mellitus; therefore, model building was performed using metabolic intrinsic 
clearance values of diabetes livers reported by Dostalek et al.
5
 These in vitro values 
were scaled to calculate in vivo Km and Vmax except for in vitro Vmax of ATV-LAC as 
explained in detail in the method section. An attempt was made to assess the effect of 
metabolic intrinsic clearance data of ATV for non diabetic livers
5
 on its disposition. As 
expected, the model under-predicted the observed plasma concentration-time profile. 
Transporter mediated an active uptake clearance is the rate-limiting step for overall 
hepatic elimination of ATV;
62
 therefore, permeability-limited liver was selected in the 
proposed model to predict overall hepatic clearance. Metabolic and uptake clearance 
pathways for overall elimination of ATV incorporated in the model successfully 
described the observed clinical plasma concentration-time profile of the parent drug 
following oral dosing within 20% error (Table V-5) together with three metabolites 
depicted from Figure V-1a and Figure V-1b.  
Prediction of volume of distribution 
Initially Rodgers and Rowland equations
56, 57
 were assessed for Kps calculation of 
perfusion-limited tissues. However, the estimated volume of distribution of ATV was 
very low as compared to observed; therefore, Berezhkovskiy algorithm was utilized to 
calculate Kps to determine tissue distribution of perfusion-limited tissues as it 
adequately predicted observed large volume of distribution of ATV. The estimated 
volume of distribution determined based on in silico Kps, tissue volumes and blood 
perfusion successfully explained extensive peripheral tissue binding of ATV.
1
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In vitro dissolution study and prediction of in vivo solubility 
Atorvastatin acid was completely dissolved in dissolution medium with high pH such 
as ≥6.8 as shown in Figure V-2a. The dissolution studies performed at low pHs 
including 1.2 and 3 indicated poor dissolution along with the formation of lactone form 
(Figure V-2b), which was in accordance with results shown by Kearny et al.
4
 The 
formation of ATV-LAC was higher at very low pH, 1.2 as compared to pH 3 and its 
absence at higher pH reflected instability in basic medium (Figure V-2c). The 
systemic exposure of ATV was under-predicted when measured in vitro dissolution vs 
time data was integrated in dissolution model could be because of significant 
differences between its aqueous and biorelevant solubility. 
Gastrointestinal absorption model 
A whole-body PBPK simulation approach in GastroPlus
TM
 allowed determining the 
relative contribution of different gastrointestinal regions to the overall absorption of 
the drug. In silico simulated compartmental absorption of ATV in the human 
gastrointestinal tract following an oral administration of 40 mg tablet resulted in total 
fraction of dose absorption of 99.6%. The predicted highest absorption (58.1%) of 
ATV occurred in jejunum followed by duodenum (17.7%) and ileum (13.6%) of total 
fraction of dose absorbed. 
Virtual trial simulations 
Simulations after an oral dosing of 40 mg of ATV in ten virtual patients were 
compared with mean observed plasma concentration-time curve. The result of virtual 
trial simulations is presented in Figure V-3. The figure shows mean plasma 
concentrations vs time profile of ten virtual patients along with observed 
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concentrations. Moreover, green shaded area represents 90% confidence interval of the 
simulated data around the mean of the predictive values. The solid blue, dashed, and 
dotted lines show individual simulated results that include 100, 95, 90, 75, 50, 25, and 
10% of the range of simulated data. The observed mean plasma concentration-time 
curve lay between 90% of confidence interval, maximal and minimal virtual patients 
and was adequately well illustrated by the generated concentration-time curves of 
virtual population.  
Parameter sensitivity analysis  
The results of parameter sensitivity analysis indicated that AUC and Cmax parameters 
relatively slight sensitive to in vitro transporter kinetic parameters contrary, insensitive 
to in vitro enzymatic clearance data. The parameter sensitivity analysis identified that 
AUC and Cmax parameters were the most sensitive to changes in small intestinal transit 
time and stomach pH, respectively.  
PBPK modeling of rosuvastatin acid and its lactone metabolite 
GastroPlus
TM
 default PBPK
TM
 module in combination with the drug-related properties 
and in vitro clearance data was employed to predict oral pharmacokinetics of RST and 
its lactone metabolite. 
In silico estimated or experimentally measured physiochemical and/or 
biopharmaceutical properties  
Intestinal permeability 
The human Peff of RST and RST-LAC, estimated by ADMET Predictor
TM
 module of 
GastroPlus
TM
 based on quantitative structure–property relationship was 0.74 x 10-4 and 
1.09 x 10
-4
 cm/s, respectively.  
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pKa, blood/plasma concentration ratio, fup and logD   
Rosuvastatin acid is a hydrophilic statin and logD7.4 of -0.33
60
 was used for simulation 
to reflect its poor membrane permeability. The fup (9.4%) and blood/plasma 
concentration ratio (0.56) reported by Jones et al. were incorporated in the model.
63
 
The key physicochemical and biopharmaceutical parameters for simulations are 
included in Table V-4. 
PBPK Modeling  
Prediction of systemic clearance 
The recent in vitro study published by Jones et al. measured hepatic metabolic and 
uptake clearance of various OATP substrates including RST using HLMs and 
sandwich culture human hepatocytes, respectively.
63
 According to study results, no 
measurable CYP enzyme mediated metabolism in HLMs was found for RST, was in 
agreement with observations of previous work
64
 indicating its insignificant 
metabolism. Furthermore, study reported by Prueksaritanont et al. demonstrated 
glucuronidation metabolism of RST and the subsequent formation of lactone 
metabolite mainly by UGT1A1 and UGT1A3 enzymes.
14
  Moreover, carrier-mediated 
uptake clearance by several hepatic OATP transporters is the major clearance pathway 
for RST.
65
 An average Km and the sum of Vmax for multiple OATP transporters 
including OATP1A2, 2B1 and 1B3 reported by Ho et al.
20
 were chosen to determine 
overall hepatic uptake clearance. These in vitro values were scaled as explained in 
detail in the method section to calculate in vivo Km and Vmax to determine overall 
systemic clearance. There was a good agreement between model predicted and 
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clinically observed mean plasma concentration-time profile (within 1.5 fold) of RST 
following an oral dosing (Figure V-4 and Table V-5). 
Prediction of volume of distribution 
Rodgers and Rowland equations were assessed for Kps calculation of perfusion-limited 
tissues in the beginning. However, the predicted volume of distribution of RST was 
very low than the observed value; therefore, Berezhkovskiy algorithm was utilized to 
calculate Kps to determine tissue distribution of perfusion-limited tissues as it well 
described the observed large volume of distribution of RST. The estimated volume of 
distribution calculated based on in silico Kps, tissue volumes and blood perfusion 
adequately explains extensive peripheral tissue binding of RST.
1
  
In vitro dissolution study and prediction of in vivo solubility 
Rosuvastatin acid is a biopharmaceutics classification system (BCS) and 
biopharmaceutical drug disposition classification system (BDDCS) class III drug with 
high solubility and low permeability. It was completely dissolved in dissolution 
medium of all pH ranges as shown in Figure V-5a and b. The minor formation of 
lactone form occurred at pH 1.2 as shown in Figure V-5c. 
Default Johnson dissolution model, which represents the Nernst-Bruner dissolution 
equation along with in vitro release input used to compute RST dissolution rate.  
Gastrointestinal absorption model 
The PBPK module of GastroPlus
TM
 permits to assess the relative contribution of 
various regions of the gastrointestinal tract to the absorption of the drug. In silico 
simulated human gastrointestinal compartmental absorption of RST following an oral 
administration of 20 mg tablet predicted maximum absorption of total fraction of 
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absorbed dose in jejunum followed by ileum and duodenum regions of the small 
intestine (data are not presented). 
Virtual trial simulations 
Like ATV, simulated plasma concentration-time profiles followed by administration of 
an oral dose of 20 mg of RST in virtual subjects were compared with observed plasma 
concentration-time profile as described above. The observed plasma concentration-
time curve lay between 90% of confidence interval, maximal and minimal virtual 
patients (Figure V-6). The observed plasma concentration-time graph matches 
adequately by the created concentration-time curves of virtual population.  
Parameter sensitivity analysis  
The result of parameter sensitivity analysis indicated that AUC and Cmax 
pharmacokinetics parameters were the most sensitive to changes in small intestinal 
transit time. Moreover, they are less likely to be affected by changes in stomach pH 
and are not sensitive to change in stomach transit time, kinetic parameters of BCRP 
and OATP1B1 transporters (data are not shown).  
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DISCUSSION 
The objective of the study was to develop a whole-body PBPK model that 
mechanistically characterized observed plasma concentration-time courses of two 
widely prescribed statins, which disposition governs by various complex phenomenon 
including gut-liver first-pass effect and/or biliary secretions and active hepatic uptake. 
A whole-body PBPK modeling of both statins were performed using GastroPlus
TM
 
software through single simulation mode by required input parameters, which were 
experimentally measured, in silico estimated and/or obtained from the available 
literature. The present mechanistic model accurately described the observed 
concentrations in spite of the complex mechanism governing the absorption and 
elimination especially in case of ATV.  
Atorvastatin acid, a BCS and BDDCS class II
50
 drug, is highly soluble and permeable 
and therefore, complete absorption was predicted.
1
 Atorvastatin acid, a hydroxy acid 
form with an acidic pKa of 4.6 showed significant pH dependent Caco-2 permeability 
with highest permeability at low apical pH. The pH in the proximal portion of the 
small intestine is low as compared to the distal end; therefore, the region specific rate 
of absorption of ATV estimated from in silico simulations was higher in the duodenum 
and jejunum as compared to ileum and caecum. Jejunum being the highest absorption 
site as compared to duodenum could be because of large surface area due to the 
presence of more villi and microvilli. Unlike ATV, both hydrophilicity and BCRP 
intestinal efflux transporters played a significant role in limiting intestinal 
absorption of RST at apical side of intestinal lumen. 
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Atorvastatin acid is metabolized mainly by CYP3A4 and UGT1A1/3 in both the gut 
and liver. The lactone form of atorvastatin is more lipid soluble as compared to an acid 
form based on their reported differences in logD7.0.
52
 The major mechanism governing 
hepatic distribution of an acid and lactone forms of atorvastatin were an active uptake 
and passive diffusion, respectively, which is in accordance with their distribution 
coefficient at physiological pH.
66
 Relative importance of hepatic OATP influx 
transporters for an active uptake of ATV was demonstrated. The results indicated 
hepatic uptake process as rate-limiting step for its hepatic clearance.
62
 Moreover, in 
vitro studies that characterized metabolic clearance
5
 and hepatic transport
39, 40, 66
 
indicated an active hepatic uptake as a rate-determining step in overall hepatic 
elimination; therefore, a permeability-limited liver model was selected to elucidate 
hepatic disposition of ATV. Mechanistic modeling of ATV integrating only in vitro 
metabolic clearance data resulted in significant under-prediction of oral clearance, 
which is accordance with previous study.
67
 The proposed whole-body PBPK model 
adequately predicted observed data considering the significant active hepatic uptake 
clearance. A previously reported PBPK model indicated permeability-limited hepatic 
disposition of various statins such as simvastatin
68
 pravastatin,
69
 which is in 
accordance with our observation. Moreover, an appropriate selection of available 
literature data for metabolic and uptake clearance allowed the model to predict 
observed plasma concentration-time profile satisfactorily without the need of 
additional scaling factors. 
The overall hepatic intrinsic clearance of permeability-limited liver can be expressed 
by the following equation based on a clearance concept
70
 : 
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CLint, overall = PSu, influx ×
CLint, met
PSu, efflux + CLint, met
 
 
Where, 
CLint, overall= overall hepatic clearance 
PSu,influx= membrane permeability–surface area products of free drugs across the 
basolateral membrane for the influx process 
PSu,efflux= membrane permeability–surface area products of free drugs across the 
basolateral membrane for the efflux process 
CLint, met= Intrinsic metabolic clearance 
When PSu,efflux is significantly greater than CLint, met, and transfer of the drug from in 
and out of cells are similar then overall hepatic clearance is determined by CLint, met. 
Moreover, overall clearance predominantly driven by an active uptake clearance, when 
CLint, met is considerably more than PSu,efflux and therefore, an alteration of metabolic 
clearance might not have any significant impact on overall systemic exposure.  
A clinical study observed similar plasma levels of an acid and lactone forms of 
atorvastatin.
6
 In vitro studies indicated metabolic clearance of lactone metabolite 
mainly through CYP3A4 as one of the major mechanisms for elimination of ATV.
3, 5
 
Furthermore, our group revealed a significant reduction (3.56 times) in clearance of 
ATV-LAC in the stable kidney transplant recipients with diabetes mellitus and 
thereafter, observed significantly increased plasma levels of ATV-LAC due to down 
regulation of primary metabolizing enzyme, CYP3A4. As a result, an in vitro enzyme 
kinetic study conducted by Dostalek et al. revealed statistically significant reduction in 
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clearance of hydroxylated metabolites for both an acid and lactone forms of ATV in 
HLMs of donors with diabetes.
5
  
For mechanistic modeling of ATV, observed plasma concentrations were obtained 
from the kidney transplant subjects with diabetes mellitus. To reflect significantly 
reduced clearance of an acid and lactone forms of ATV in diabetes study participants, 
in vitro data obtained from HLMs of donors with diabetes mellitus was selected. 
Besides our group, to the best of our knowledge, only a single in vitro study 
determined enzyme kinetic parameters for metabolic clearance of lactone form 
together with an acid form of atorvastatin. However, the detail characteristics of liver 
tissues were not defined.
3
 The model under-predicted the observed concentration-time 
curve of ATV when enzyme kinetic data for metabolic clearance of an acid form 
obtained from HLMs of donors without diabetes mellitus were integrated (data are not 
shown). Moreover, the optimized Vmax value was significantly lower than 
experimentally measured in vitro value. The possible reasons could be : 1) the 
simulated concentrations in the cytoplasm of hepatocytes could be different from 
concentrations in HLMs; 2) contribution of isoform of CYP enzymes was not 
considered
71
; 3) substantial differences in activities of enzymes in non physiological 
media
72
; 4) incorrect presumption of a rapid equilibrium between blood and 
hepatocytes
73
; 5) inter-individual differences between in vivo and in vitro livers 
attributed to inherent variability.
74
  
We demonstrated that metabolic clearance data generated from HLMs of donors from 
patients with diabetes mellitus was superior for the prediction of concentration-time 
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graph of ATV in this population. Atorvastatin acid is also significantly metabolized to 
ortho- and para-hydroxylated glucuronides.
53
 Ortho-hydroxy atorvastatin acid 
undergoes significant glucuronidation and excreted into bile of rat and dog.
53
 It is 
believed that ortho-hydroxy glucuronidated metabolite pumped back out into the 
intestinal lumen and may exhibit enterohepatic recirculation.
53
 They are believed to be 
a substrate of hepatic OATP uptake transporter because of its relatively low 
lipophilicity. The P-gp efflux transporter at intestinal apical side was applied to reflect 
limited intestinal absorption of observed levels of o-OH-ATV metabolite.
54
 Similarly, 
restricted intestinal absorption of o-OH-ATV-LAC was predicted by considering 
efflux by P-gp at intestinal apical side. 
Metabolic clearance is insignificant for elimination of RST. However, predicted 
biotransformation in lactone metabolite via UGT pathways was consistent with our 
clinical observations. Like ATV, various studies indicated dominant contribution of 
multiple hepatic OATP uptake transporters in hepatic elimination of RST.
16, 20, 21, 75, 76
 
Moreover, a canalicular efflux transporter, BCRP, efficiently facilitates its biliary 
excretion.
19, 22, 55
 A permeability-limited liver model was chosen to determine overall 
hepatobiliary disposition of RST. The model over-predicted observed plasma 
concentrations when BCRP mediated intestinal transport was not incorporated. This 
observation suggested significant contribution of BCRP transporters in intestinal 
absorption. 
Parameter sensitivity analysis revealed that small intestinal transit time and gastric pH 
can significantly affect the AUC and Cmax of the ATV, respectively. Delayed small 
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intestinal transit time and significant intragastric pH differences in patients with 
diabetes have been reported previously.
77, 78
 These physiological changes may result in 
higher systemic exposure of ATV that can increase the risk of muscle toxicity in 
diabetes population.
79
  
Similar to ATV, parameter sensitivity analysis was performed to understand the effect 
of various input parameters on AUC and Cmax of RST. The analysis showed that 
systemic exposure is the most sensitive to changes in small intestinal transit time. 
Delayed small intestinal transit time may have considerable implication on therapeutic 
and toxicological properties of RST in population with diabetes mellitus. On the other 
hand, previous study reported that changes in hepatic uptake activities markedly affect 
plasma concentration-time course of pravastatin in rat
80
 and human.
69
 The PBPK 
model of pravastatin, a hydrophilic statin resembles RST was constructed using ten 
virtual healthy volunteers.
69
 However, the present PBPK modeling was performed in 
transplant patients with diabetes mellitus and was capable to capture influential 
gastrointestinal parameters that might have changed in disease conditions and can 
affect systemic exposure of statins.  
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CONCLUSION 
In summary, a mechanistic modeling approach was used to predict oral 
pharmacokinetics of ATV and RST with their respective metabolites using a blend of 
input parameters obtained from in silico, in vivo and in vitro measurements without the 
need for scaling factors. The present PBPK model of ATV that integrated in vitro 
enzyme kinetic data generated using HLMs from donors with diabetes was superior for 
the prediction of plasma concentration-time curve of ATV in patients with diabetes 
mellitus. In vitro kinetic parameters obtained from tissues of donors with specific 
disease that may alter the activity of drug enzyme metabolizing enzyme and 
transporters as a result influence the pharmacokinetics may be superior for accurate 
prediction of absorption and metabolism in specific population.  
The present work demonstrated the ability of the ACAT model within GastroPlus
TM
 to 
simulate observed plasma concentration-time profiles of statins for, which intestinal-
hepatic metabolism and/or various influx-efflux transporters play a prominent role in 
their disposition. This work demonstrated the mechanistic and model-driven 
application of in vitro uptake and efflux kinetic data for predicting transporter 
mediated disposition of statins. A generic whole-body PBPK based modeling approach 
can advance the reasonable predictions of the parent drug with their metabolites in 
particular population. 
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Figure V-1a. Simulated and observed human oral mean plasma concentration-time 
profiles for atorvastatin acid and atorvastatin lactone metabolite 
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Figure V-1b. Simulated and observed human oral mean plasma concentration-time 
profiles for an acid and lactone from of ortho-hydroxy atorvastatin metabolites 
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Figure V-2 (a) Mean (n=3) dissolution profiles of atorvastatin acid in different pH 
media. (b) Mean (n=3) concentrations of an acid form of atorvastatin in dissolution 
media with pH 1.2, 3, 4.5, 6.8 and 8 (c) Mean (n=3) concentrations of lactone form of 
atorvastatin in dissolution media with pH 1.2 and 3  
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Figure V-3. Virtual trial simulation for ten subjects following a 40 mg oral dose of 
atorvastatin acid. Solid line shows the mean of simulated concentrations of ten 
subjects. Square with error bar represents the clinical observations. The green 
highlighted area represents 90% confidence interval of simulated concentrations data. 
The solid blue, dashed, and dotted lines represent individual simulated results that 
incorporate 100, 95, 90, 75, 50, 25, and 10% of the range of simulated data. 
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Figure V-4. Simulated and observed human oral mean plasma concentration-time 
profiles for rosuvastatin acid and its lactone metabolite. 
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Figure V-5. (a) Mean (n=3) dissolution profiles of rosuvastatin acid in different pH 
media. (b) Mean (n=3) concentrations of an acid form of rosuvastatin in dissolution 
media with pH 1.2, 3, 4.5, 6.8 and 8 (c) Mean (n=3) concentrations of lactone form of 
rosuvastatin in dissolution media with pH 1.2  
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Figure V-6. Virtual trial simulation for ten subjects following a 20 mg oral dose of 
rosuvastatin. Solid line shows the mean of simulated concentrations of ten subjects. 
Square with error bar represents the clinical observations. The green highlighted area 
represents 90% confidence interval of simulated concentrations data around mean. The 
solid blue, dashed, and dotted lines represent individual simulated results that 
incorporate 100, 95, 90, 75, 50, 25, and 10% of the range of simulated data. 
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Table V-1. The ACAT physiological model compartment parameters of default fed human physiology used in simulations of 
atorvastatin acid and three metabolites in GastroPlus
TM 
. 
 
Compartment ASF 
(cm
-1
) 
pH Transit 
time 
(h) 
Volume 
(mL) 
Length 
(cm) 
Radius 
(cm) 
P-gp 
expression 
CYP3A4 
expression 
UGT1A1 
expression 
Stomach 0.0 4.9 1.00 1000 30 10 0.0 0.0 0.0 
Duodenum 2.774 5.4 0.26 48.25 15 1.60 0.538 2.09E-3 6.3E-4 
Jejunam1 2.760 5.4 0.95 175.3 62 1.50 0.645 3.26E-3 1.0E-3 
Jejunam2 2.675 6.0 0.76 139.9 62 1.34 0.723 3.26E-3 1.0E-3 
Ileaum 1 2.583 6.6 0.59 108.5 62 1.18 0.770 1.03E-3 3.2E-4 
Ileaum 2 2.534 6.9 0.43 79.48 62 1.01 0.838 1.03E-3 3.2E-4 
Ileaum 3 2.435 7.4 0.31 56.29 62 0.85 0.908 1.03E-3 3.2E-4 
Ceacum 1.160 6.4 4.50 52.92 13.75 3.50 1.000 3.1E-4 2.0E-4 
Ascending colon 1.508 6.8 13.5 56.98 29.02 2.50 1.000 3.1E-4 2.0E-4 
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Table V-2.  ACAT physiological model compartment parameters of default fed human physiology used in simulations of 
rosuvastatin acid and lactone metabolite in GastroPlus
TM 
. 
 
Compartment ASF 
(cm
-1
) 
pH Transit time 
(h) 
Volume 
(mL) 
Length 
(cm) 
Radius 
(cm) 
BCRP 
expression 
UGT1A1 
expression 
Stomach 0.0 4.9 1.00 1000 30 10 0.0 0.0 
Duodenum 2.778 5.4 0.26 48.25 15 1.60 0.60 6.3E-4 
Jejunam1 2.763 5.4 0.95 175.3 62 1.50 0.60 1.0E-3 
Jejunam2 2.674 6.0 0.76 139.9 62 1.34 0.60 1.0E-3 
Ileaum 1 2.584 6.6 0.59 108.5 62 1.18 1 3.2E-4 
Ileaum 2 2.540 6.9 0.43 79.48 62 1.01 1 3.2E-4 
Ileaum 3 2.456 7.4 0.31 56.29 62 0.85 1 3.2E-4 
Ceacum 0.164 6.4 4.50 52.92 13.75 3.50 0.40 2.0E-4 
Ascending colon 0.232 6.8 13.5 56.98 29.02 2.50 0.40 2.0E-4 
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Table V-3. Summary of key
 
biopharmaceutical properties and in vitro data of atorvastatin acid (ATV), atorvastatin lactone 
(ATV-LAC), ortho-hydroxy atorvastatin acid (O-OH-ATV) and ortho-hydroxy atorvastatin lactone (O-OH-ATV-LAC).
Parameter ATV ATV-LAC O-OH-ATV O-OH-ATV-LAC 
 Value Source Value Source Value Source Value Source 
Molecular weight 558.65 a 540.64 a 574.65 a 556.64 a 
logP/logD7.4 1.53@pH 7 
52
 4.2@pH 7 
52
 4.42 a 5.22 a 
pKa acid 11.36/4.6 a/* 11.16 a 10.97/9.14/4.7 a 10.83/9.02 a 
Fraction unbound in plasma (%) 2 
1
 2.71 a 0.93 a 4.51 a 
Blood/plasma concentration ratio 0.25 
61
 0.66 a 0.54 a 0.65 a 
Human Peff (X10
-4
 cm/s) 1.11 a 1.48 a 0.8 b 1.48 a 
Reference solubility (mg/mL) @ pH  0.021@2.1 
4
 4.4X10
-3
@7 a 0.17@4.17 a 9.84X10
-3
@6.8 a 
Dose (mg) 40 NA NA a NA a NA a 
Mean particle radius (µM) 25 a 25 a 25 a 25 a 
Mean precipitation time (s) 900 a 900 a 900 a 900 a 
Diffusion coefficient (X10
-4
 cm/s) 0.51 a 0.53 a 0.51 a 0.53 a 
CYP3A4 Km (µM) 1.179 
5
 0.604 
5
 NA NA NA NA 
CYP3A4 Vmax: gut/PBPK 
[(mg/s)/(mg/s-mg enzyme)] 
1.699/3.8x10
-3 
 
5
 0.069/10
-5
 
 
5
 NA NA NA NA 
UGT1A1 Km (µM) 3.168 
7, 37
 NA NA 3.057 b NA NA 
UGT1A1 Vmax: gut/PBPK 
[(mg/s)/(mg/s-mg enzyme)] 
2/0.07 b NA NA 0.1/0.007 b NA NA 
UGT1A3 Km (µM) 3.168 
7, 37
 NA NA 3.057 b NA NA 
UGT1A3 Vmax: PBPK 
 (mg/s-mg enzyme) 
0.007 b NA NA 0.07 b NA NA 
OATP1B1 Km (µM) 0.0095 
39, 40
 NA NA 1.535 b NA NA 
OATP1B1 Vmax : PBPK 
 [(mg/s)/(mg/s-mg transporter)] 
0.584x10
-5
 
39, 40
 NA NA 0.012  b NA NA 
P-gp Km (µM)  1.257 
17
 NA NA 25.03 b 20.03 b 
P-gp Vmax: gut or PBPK 
 [(mg/s)/(mg/s-mg transporter )] 
0.0005  
(PBPK) 
b NA NA 0.3  
(Gut) 
b 0.02  
(Gut) 
b 
a=Estimated by ADMET Predictor
TM
 
b=Fitted value 
NA=not applicable 
*= Data obtained from Pfizer Inc 
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Table V-4. Summary of key
 
biopharmaceutical properties and in vitro data of rosuvastatin acid and rosuvastatin lactone used 
in the PBPK simulations. 
 
 
Parameter Rosuvastatin  acid Rosuvastatin  lactone 
 Value  Source Value  Source 
Molecular weight 481.55 a 463.53 a 
logP/logD7.4 -0.33@ pH 7.4 
63
 1.2@7.4 
60
 
pKa acid or base 4.2/1.7
*
/-3.17
*
 
63
/a/a 1.31
#
/-3.33
#
 a 
Fraction unbound in plasma (%) 9.4 
63
 9.13 a 
Blood/plasma concentration ratio 0.56 
63
 0.76 a 
Human Peff (X10
-4
 cm/s) 0.74 a 1.09 a 
Reference solubility (mg/mL) @ pH  0.79@3.72 a 0.12@7 a 
Dose (mg) 20 NA 20 NA 
Mean particle radius (µM) 25 a 25 a 
Mean precipitation time (s) 900 a 900 a 
Diffusion coefficient (X10
-4
 cm/s) 0.57 a 1.2 a 
UGT1A1 Km (µM) 11.72 
14
 NA NA 
UGT1A1 Vmax: gut/PBPK [(mg/s)/(mg/s-mg enzyme)] 0.07077/0.00092 
14
 NA NA 
UGT1A3 Km (µM) 11.72 
14
 NA NA 
UGT1A3 Vmax: PBPK (mg/s-mg enzyme) 0.00023 
14
 NA NA 
BCRP Km (µM) 0.471 
22, 55
 NA NA 
BCRP Vmax: gut/PBPK [(mg/s)/(mg/s-mg transporter)] 0.007/0.000293 
21
 NA NA 
OATP Km (µM) 2.942 
20
 NA NA 
OATP Vmax: PBPK (mg/s-mg transporter) 7.13X10
-5
 
20
 NA NA 
 
*  and 
# 
= Base pKa estimated by ADMET Predictor
TM
 
a = Estimated by ADMET Predictor
TM 
NA= not applicable 
    
  
 
1
8
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Table V-5. Summary of observed and predicted pharmacokinetic parameters of atorvastatin acid and rosuvastatin acid 
following an oral administration. 
 
 
 
 
 
 
 
 
          PPE=Percentage prediction error: [| (Predicted-Observed)/ Observed|]*100
Parameter Atorvastatin  acid Rosuvastatin  acid 
 Observed  Predicted   PPE (%) Observed  Predicted   PPE (%) 
Mean Cmax (ng/mL) 17.88 14.74 17.6 6.26 6.28 0.30 
Mean Tmax (h) 2 1.72 14.0 6 3.96 34.0 
Mean AUC0-t  (ng/mL.h) 103.58 103.32 0.30 55.07 57.90 5.10 
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